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Hazardous air pollutants (HAP’s) are assumed to act without threshold meaning any level of 
exposure can theoretically initiate the carcinogenic process. With approximately 57,000 new 
cancer diagnoses and 25,900 deaths predicted in Ontario in 2006, the implications of lifetime low 
dose cumulative exposure to HAP’s in the etiology of cancer is unknown, yet may be significant. 
As such, this burden of disease (BoD) model was designed to provide a comprehensive 
assessment of the current and future BoD attributable to long term cumulative exposure to six 
carcinogenic HAP’s in two highly exposed regions of Ontario, using a summary measure of 
population health, disability-adjusted life years (DALY’s). Results indicated a total of 32,074 
DALY’s were lost in Toronto and Southwestern Ontario (SWO) from six cancer sites in 2001, 
with the largest burden from cancers of the lung, followed by lymphomas, then leukemia. 
Approximately 0.58% of the burden (187 DALY’s) was attributable to current HAP exposures, 
with the largest health impacts associated with exposure to nickel refinery dusts in SWO (8.91 
DALY’s) and benzene in Toronto (46.30 DALY’s). The model predicted 0.3% of the exposure 
attributable BoD (96 DALY’s) could be avoided in the future if ambient exposures were reduced 
to a feasible distribution. If ambient exposures were further reduced to levels expected if there 
were no anthropogenic releases, the model predicts 147 DALY’s could be avoided, such that 
only 0.12% of the total BoD would be attributable to natural sources of  HAP’s. Results of the 
sensitivity analysis support the notion of the DALY as a robust measure to estimate exposure 
attributable health impacts, as the incorporation of alternative value choices had negligible 
impact on the relative importance of cancer sites, or exposures to the total BoD. Results of the 
model can be used by decision makers to inform public health policy regarding abatement 
priorities of HAP’s in Ontario, on the basis associated health impacts. 
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In developed societies that have undergone epidemiologic and demographic transitions, 
the contribution of the environment to the burden of disease (BoD) is an important public health 
concern. Economic prosperity following these transitions has resulted in industrialization, 
urbanization, and an aging population dominated by chronic disease (Melse & de Hollander, 
2001; Smith & Ezzati, 2005).  
The environment operates as a distal risk factor affecting virtually all diseases through 
complex pathways that are not always understood (Smith & Ezzati, 2005). Genetic, social, and 
economic factors interact with environmental risks, creating disparities in exposure among 
subgroups of the population (Kay et al, 2000; Kreuter et al, 2004; Melse & de Hollander, 2001). 
For example, neighbourhoods within the vicinity of industrial facilities, with elevated levels of 
toxics releases, are more likely to be of low income, poorer general health status, and have 
greater social distress and distrust of industry, compared to communities in rural or distant areas 
(Luginaah et al, 2002; Melse & de Hollander, 2001). 
Recently in Ontario there has also been increased reliance on fossil fuels to meet 
increasing energy and transportation demands. Although the national average annual 
concentrations of hazardous air pollutants (HAP’s) are generally below Health Canada’s 
“acceptable risk” values, the National Air Pollution Surveillance (NAPS) system has consistently 
reported elevated concentrations within the vicinity of industrial and urban locations, reflecting 
concentrated point source emissions, traffic congestion, and population densities. 
Despite inequalities in exposure to environmental air toxics, chronic toxicity studies in 
animal models and epidemiological studies in occupationally exposed workers have causally 
associated many HAP’s with various types of cancers (IARC, 2007).  Furthermore, since the 
1 
concentration-response function for carcinogenic substances in the environment is assumed to 
act linear without threshold (McColl, Hicks et al, 2000), it is theoretically possible that any level 
of exposure can initiate the carcinogenic process. 
Since the 1980’s the total number of individuals either being diagnosed or dying from 
cancer in Ontario has been on the rise. Over the past 12 years, the number of deaths and 
diagnoses has increased by 20-25% (CCDPC-PHAC, 2006). For example, in 1992 there were 
42,886 incidence and 20,109 fatal cases (CCDPC-PHAC, 2006), compared to a best prediction 
of 57,200 new diagnoses and 25,900 deaths in Ontario in 2006 (Canadian Cancer Society, 2006), 
with less then 1% occurring in persons under 20 years. With an aging population structure, the 
statistics imply an increased risk of cancer in older ages may result from a lifetime of low dose 
cumulative exposure to risk factors such as ambient air toxics. 
Previous studies have estimated between 1.5-4% of the total BoD in the Organization for 
Economic Co-operation and Development regions can be attributable to environmental factors 
(Melse & de Hollander, 2001). Historically, developed countries of the OECD have been held 
responsible for 80% of toxic pollutant emissions (CPHA, 1996). However, with recent economic 
and industrial advances in developing countries, such as China and India with populations in the 
billions, the potential global health burden associated with air toxics is in its infancy.  
With uncertainty in current scientific knowledge regarding the contribution of HAP’s to 
the BoD, this regional level assessment can provide valuable information on a potentially 
significant environmental health issue (Kay et al, 2000; Mathers et al, 2001). A better 
understanding of health impacts associated with long term exposure to ambient air toxics can aid 
in informed decision making and efficient policy development to reduce the exposure associated 
BoD, while supporting sustainable development and environmental protection. 
2 
2. BACKGROUND 
2.1. Ambient Air Toxics1
With increased industrialization and urbanization, anthropogenic release of toxics into the 
ambient environment has been recognized as hazardous to human health (Burnett et al, 2000; 
Cohen et al, 2005; Campbell et al, 2004). Environmental health indicators, which quantify health 
impacts associated with environmental hazards, have increasingly been used by decision makers 
to inform discussion concerning control and mitigation policies (Cohen et al, 2005). 
A decision making model to assess human health risks and to develop priorities for 
reductions in oil refinery emissions was produced by the Network for Risk Assessment and 
Management (NERAM) in 2003 (McColl, Hicks et al, 2003). The prototype HEIDI model 
(Health Effects Indicators Decision Index) was originally developed for the Canadian Council of 
Ministers of the Environment (CCME) to support the National Frameworks for Petroleum 
Refinery Emission Reductions (NFPRER). Fourteen substances have since been included in the 
updated HEIDI II; assumptions and uncertainties of the model are described elsewhere (McColl, 
Hicks et al, 2003). Of the 14 substances included in the model, six have been classified as 
carcinogenic by the International Agency for Research on Cancer (IARC) and will be briefly 
reviewed2. Table 2.1 outlines the physical and chemical properties of acetaldehyde, 








                                                 
1 The term ambient air toxics is synchronously used with the term hazardous air pollutants (HAP’s) 
2 BaP/PAH was excluded because of known confounding relationship with environmental tobacco smoke (ETS) 
3 
 
Table 2.1: Physical and Chemical Properties of Six Carcinogenic Ambient Air Toxics 
Chemical Identity: Benzene1 1,3-Butadiene1 Ethylene Oxide1
CAS Registry  71-43-2 106-99-0 75-21-8 
Synonyms Anuleen, benzeen, 
benzole, benzol, coal 
naphtha, cyclohexatriene, 







Ethylene oxide oxirane, 
dihdydro oxirene, 
dimethylene oxide, 




Clear, colorless liquid Colorless gas Colorless gas 
Molecular Weight 78.11g/mol 54.09 g/mol 44.05g/mol 
Molecular Formula C6H6 C4H6 C2H4O 
Boiling Point 80.1 degrees Celsius -4.4 degrees Celsius 11 degrees Celsius 
Melting Point 5.5 degrees Celsius -108.9 degrees Celsius -111 degrees Celsius 
Density 0.8787 0.6211g/ml 0.8824 




Solubility Log Ko/w 2.13 
Log Ko/c 1.8 – 1.9 
Log o/c 1.99 
Log Ko/c 2.46 
Log Ko/w -0.22 
Log Ko/c 0.342 
Conversion  1ppm = 3.24 mg/m3 1ppm = 2.21mg/m3 1ppm = 1.83mg/m3
 
Chemical Identity: Acetaldehyde2 Formaldehyde1 Nickel (compounds)3
CAS Registry  75-07-0 50-00-0 NA-11 










sulfidic, soluble nickel 
Physical 
Description 
Colorless liquid with 
fruity odor at room 
temperature 
Colorless gas  
Molecular Weight 44.05 g/mol 30.03 g/mol  
Molecular Formula CH3CHO CH2O  
Boiling Point 20.2-20.8 degrees Celsius -21 degrees Celsius  
Melting Point -123.5- -121 d. Celsius -92 degrees Celsius  
Density 0.788 g/ml 0.815 g/ml  
Vapor Pressure 98.642 to 134.08 kPa 3,883 mmHg  
Odor Recognition 
Threshold 
0.21ppm 0.5-1.0ppm  
Solubility Log Ko/w 0.45 
Log Ko/c 0.063 
Log Ko/w 0.350 
Log Ko/c 1.567 
 
Conversion Factor 1ppm = 1.83mg/m3 1ppm = 1.23mg/m3  
1ATSDR (Agency for Toxic Substances and Disease Registry) toxicological profile-physical and chemical 
properties 
2Priority substance list profile 




Acetaldehyde is released with the incomplete combustion of gasoline, diesel fuels, 
biomass combustion, and from industrial emissions (Health Canada, 2000). Preliminary data 
from the National Pollution Release Inventory (NPRI) reports 275.13 tonnes of acetaldehyde 
were emitted from industrial point sources in Ontario in 2005. Furthermore, stationary sources of 
acetaldehyde include emissions from wood burning stoves, fireplaces, furnaces, waste 
incinerators, coffee bean roasting and environmental tobacco smoke (ETS) (Health Canada, 
2000). However, the largest contribution of acetaldehyde to ambient air concentrations (56%) 
likely results from secondary formation from precursor volatile organic compound (VOC’s) 
oxidations (CARB, 1987; Health Canada, 2000). With an overall half-life of less then 10 hours 
(Health Canada, 2000), long range transport is unlikely, and acetaldehyde is not persistent nor 
bioaccumulative (Health Canada, 2000) 
 
2.1.2. Formaldehyde 
Similar to acetaldehyde, formaldehyde is released during anthropogenic activities, yet the 
largest contribution in ambient air results from secondary formation in the atmosphere (Health 
Canada, 2001). In urban areas during air pollution episodes, secondary formation can account for 
70-90% of the urban ambient concentration (ATSDR, 1999; Health Canada, 2001). 
Formaldehyde reacts with hydroxyl radicals with a half-life pending atmospheric conditions, 
generally around 10 days (ATSDR, 1999). Despite large ambient concentrations from secondary 
production, the NPRI reports industrial point sources released 901.76 tonnes of formaldehyde in 




Compared to emissions from anthropogenic sources, benzene is found at low 
concentrations naturally in the environment, released from bush fires, crude oil seeps, and plant 
volatiles (ATSDR, 2005; Health Canada, 1993). Preliminary data from the NPRI reports 405.80 
tonnes of benzene were emitted from industrial sources in Ontario in 2005, yet the largest 
contribution of benzene to ambient air has historically resulted from on and off road vehicle 
emissions, accounting for approximately 76% of benzene release (Health Canada, 1993), prior to 
the implementation of new Canada-wide standards for benzene content in gasoline.3 Benzene is 
degraded by photo-oxidation, with a short half-life limiting long range transport (ATSDR, 2005).  
 
2.1.4. 1,3-Butadiene 
1,3-butadiene, hereafter referred to as 1,3-BD,  is released during petrochemical 
production, use, and transport, from vehicle exhaust, and naturally during biomass combustion 
(ATSDR, 1992; Health Canada, 2000). Upon release, 1,3-BD undergoes rapid photo-oxidation 
with hydroxyl radicals (Health Canada, 2000). The NPRI reports 41.76 tonnes of 1,3-BD were 
emitted from industrial point sources in Ontario in 2005. The highest environmental mean 
concentration in Ontario (28µg/m3) has been recorded by the National Air Pollution Surveillance 
program (NAPS) 1km distance from a point source of 1,3-BD production (Health Canada, 2000). 
 
2.1.5. Ethylene Oxide 
Ethylene oxide, hereafter referred to as ETO, is released during herbicide fumigation, 
hospital equipment sterilization, vehicle exhaust, and ETS, with negligible contributions from 
                                                 
3 The new CEPA vehicle emission reduction regulations for benzene content in gasoline has reduced the average 
benzene content in gasoline from 1.6% in 1995 to 0.7% in 1999. Such regulations have been followed by a reduction 
in annual mean ambient benzene concentrations in Canada by approximately 45% (Environment Canada, 2001) 
6 
natural releases (ATSDR, 1990; Health Canada, 2001). ETO is degraded by radical formation 
and hydrolysis, with an estimated atmospheric half-life of 69-149 days (ATSDR, 1990). 
Although the NPRI (2005) reports smaller quantities of emissions from industrial point sources 
in Ontario (13.59 tonnes) compared to other air toxics, exposure to ETO may occur in areas of 
petrochemical production of dense vehicle traffic from the oxidation of ethylene. 
 
2.1.6. Nickel (Refinery Dusts) 
Nickel exists naturally in the earth’s crust generally bound in insoluble complexes with 
large diameter, not posing a human health hazard. However nickel refinery dusts, which include 
inorganic nickel compounds: oxidic, sulfidic, and soluble nickel, are able to penetrate the lungs 
and are hazardous to human health (Health Canada, 1994). Release of inorganic nickel into the 
ambient air occurs during primary bas metal production (mining, smelting, refining), fossil fuel 
combustion, alloy production, and scrap reprocessing. The NPRI reports 164.92 tonnes of nickel 
refinery dusts were emitted into the ambient air in Ontario in 2005.  
 
2.2. Summary Measures of Population Health 
Exposure to environmental hazards has been shown to lead to premature death (Campbell 
et al, 2004; de Hollander et al, 1999; Krewski et al, 2000) and also to suboptimal quality of life 
(Luginaah et al, 2002; Melse & de Hollander, 2001). Summary measures of population health 
(SMPH) combine information on morbidity and mortality in an aggregate estimate of population 
health status, incorporating implicit and explicit social values (Kay et al, 2000; Mathers et al, 
2001; Melse & de Hollander, 2001; Murray & Lopez, 1997; Murray & Lopez, 2000; Pruss-Usten 
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et al, 2003; Smith & Ezzati, 2005). Time lived in less then perfect health is combined with time 
lost due to premature death. SMPH are used to: 
• Aggregate individual data to produce population health statistics 
• Enable comparisons of health conditions between two or more populations, or the same 
population over time 
• Quantify inequalities among subgroups in the population 
• Ensure disabilities receive appropriate and balanced public health policy attention 
• Provide baseline data to aid in priority setting, policy, health planning and research 
• Inform policy and decision making regarding the magnitude of health impacts associated 
with selected risk factors  
• Examine intervention benefits through cost effectiveness analysis 
 
SMPH are divided into two broad classes: health expectancies and health gaps (Figure 2.1) 
(Mathers et al, 2001; Murray & Lopez, 2000; Smith & Ezzati, 2005).  
         
        (adapted from Smith & Ezzati, 2005) 
 
Figure 2.1 Hypothetical Survivorship Curve. The line above ‘B’ depicts the proportion of people alive at each age 
and the line below ‘B’ depicts the proportion alive with optimal health. Thus, Area A is represents time lived with 
optimal health, Area B represents time lived in suboptimal health, and Area C represents time lost to due mortality. 
Life expectancy = A + B  
     
8 
Health expectancies extend the concept of life expectancy, providing a measure of the 
average time a person can expect to live in a health state, given by A + f(B) (Figure 2.1), where  
f( ) is a function of time lived in less then perfect health with condition B, weighted from 
0(suboptimal) to 1(optimal) (Mathers et al, 2001; Murray & Lopez, 1997; Smith & Ezzati, 2005). 
International attempts to measure the BoD using health expectancy measures have generally 
been plagued by discrepant conceptual understandings, methodologies, and interpretations of the 
measures (Murray & Lopez, 1997). Examples of health expectancy measures include: disability-
free life expectancy, active life expectancy, disability-adjusted life expectancy, and quality-
adjusted life years (Mathers et al, 2001; Murray & Lopez, 2000).  
Health gaps extend to concept of potential years of life lost (PYLL), to measure the 
difference between the actual health status and an ideal normative goal for a population, given by 
C + g(B), (Figure 2.1), where g( ) is a function that weights time lived in state B from 0(perfect 
health) to 1(death) (Mathers et al, 2001; Smith & Ezzati, 2005). The most well known measure 
of a health gap is the disability adjusted life year (DALY).  
DALY’s measure years of life lost due to mortality and years of life lost due to disability 
in a single estimate with explicit and transparent value choices and assumptions (Mathers et al, 
2001; Melse & de Hollander, 2001). The DALY was originally developed by Murray & Lopez in 
the early 1990’s to generate informed debate regarding the global burden of disease. 
 
2.3. History of the Global Burden of Disease Study 
The Global Burden of Disease (GBD) project was initiated by the World Bank in 
collaboration with the World Health Organization (WHO) in 1992 to establish comprehensive, 
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consistent, and unbiased estimates of global ill-health (Mathers et al, 2003; Murray & Lopez, 
1997; Ezzati et al, 2006).  
Cause of death and disability have been analyzed by 14 epidemiologic sub-regions in 
three broad disease classes (i) communicable, maternal, and perinatal, (ii) non-communicable, 
and (iii) injuries (Mathers et al, 2001; Murray & Lopez, 1997; Smith & Ezzati, 2005)4. Methods 
used to quantify the global BoD have been widely published (Ezzati et al, 2002; Ezzati et al, 
2003; Mathers et al, 2003; Murray & Lopez, 1997; Murray & Lopez, 2000; RIVM, 2001; Smith 
& Ezzati, 2005; WHO, 2001).  
Since the first study was published in 1996 (Murray & Lopez, 1997), there have been 
numerous publications on the original 1990 data, incorporating new data sources, with internally 
consistent estimates of incidence, prevalence, severity, case-fatality, duration and mortality for 
over 150 causes of death and disability, analyzed by sex and eight age groups, for 226 countries 
and territories (Ezzati et al, 2002; Ezzati et al, 2003; Murray & Lopez, 1997; Murray & Lopez, 
1998; Lopez et al, 2006; Smith & Ezzati, 2005).  
Furthermore, the Comparative Risk Assessment (CRA) module of the GBD analyzed the 
contribution of 26 important risk factors to population health (five environmental)5 through a 
unified framework that enabled comparison of risk factors with various levels of causality (distal, 
proximal, environmental, physiological) (Mathers et al, 2001; Ezzati et al, 2003; Ezzati et al, 
2003; Ezzati et al, 2006).  
                                                 
4 Group 1 causes are divided into infectious, parasitic causes, respiratory infections, maternal causes, parinatal 
disorders, and nutritional deficiencies. Group 2 causes are divided into 14 categories of non-communicable disease. 
Group 3 is divided into intentional and non intention injuries  (Murray & Lopez, 97) 
5 For environmental risk factors, the attributable burden of disease was calculated for (i) unsafe water, sanitation, 
hygiene, (ii) urban outdoor air pollution, (iii) indoor smoke from solid fuels, (iv) lead, and (v) global climate change 
(Ezzati et al, 2003) 
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Results of the GBD study indicated a total of 10% of global disease could be attributed to 
the environmental risks considered in the analysis (Pruss-Usten & Corvalan, 2006). In 
established marked economy (EME) regions, urban outdoor air pollution (the closest proxy to 
HAP’s in the GBD study) contributed to 0.5% of the total BoD. Although a smaller determinant 
of health in the GBD study compared to independent behavioural risk factors such as tobacco use 
(11.7%) and alcohol abuse (10.3%), the contribution of environmental risk factors to disease has 
varied among other BoD studies, from 1.5-4% in high income OECD countries (Melse & de 
Hollander, 2001), to 5-12% in the Netherlands (de Hollander et al, 1999), to 25-33% globally 
(Smith et al, 1999). Inconsistencies in environmental BoD estimates reflect methodological and 
conceptual discrepancies at a global level concerning the definition of ‘environmental risks’, the 
causal linkage between environmental and health, and exposure and disease data collection 
procedures (Ezzati et al, 2003; Kay et al, 2000; Pruss-Usten et al, 2003). As such, the next 
section will describe standardized methods that have been proposed to causally attribute health 
impacts to environmental risk factors such as hazardous air pollutants. 
 
2.4. Environmentally Attributable Burden of Disease 
2.4.1. Causal Attribution 
Traditionally, there have been two methods used to describe the causal attribution of 
environmental risk factors to the BoD: categorical attribution and counterfactual analysis (Ezzati 
et al, 2003; Ezzati et al, 2006; Kay et al, 2000; McMichael et al, 2001; Murray et al, 2003; Melse 
& de Hollander, 2001).  
Categorical attributes death to a single cause of a group of causes based on a defined set 
of criteria (Ezzati et al, 2002; Kay et al, 2000; Mathers et al, 2001; Pruss-Usten, 2003), and thus 
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overlooks the multi-causal nature of many chronic diseases for which the environment usually 
operates distally in the causal chain. 
Counterfactual analysis assesses the contribution of one or more risk factors to disease by 
comparing the current disease burden with the burden predicted under a hypothetical alternative 
scenario. Four ‘hypothetical’ exposure scenarios have been described in the literature (Kay et al, 
2000; Murray & Lopez, 1999; Mathers et al, 2001; Murray et al, 2003; Pruss-Usten et al, 2003), 
the (i) theoretical minimum risk, (ii) plausible minimum risk, (iii) feasible minimum risk, and 
(iv) cost-effective risk.  
The theoretical minimum risk corresponds with an exposure distribution of lowest 
possible risk ceteris paribus ie: zero exposure, whether or not attainable. The plausible minimum 
risk corresponds with an exposure distribution that is imaginable in the population. The feasible 
minimum risk corresponds to risk encountered with an exposure distribution that has been 
achieved in a population. Finally the cost-effective risk would consider the cost of reducing 
exposure when selecting an appropriate alternative scenario for the purposes of policy 
implementation. 
Causal attribution of risk factors for disease can theoretically be done using either 
categorical attribution or counterfactual analysis. However, the CRA group of the GBD using 
counterfactual analysis and a theoretical minimum risk distribution of exposure consistently 
across risk factors, to estimate the reduction in disease if exposure to a risk factor were reduced 
to a counterfactual distribution6 (Ezzati et al, 2003). 
 
 
                                                 
6 For outdoor air pollution in the GBD study, the reference distribution of exposure for particulate matter was the 
World Health Organization Air Quality Guidelines 
12 
2.4.2. Attributable Fraction 
Attributable risk describes the extent to which a risk factor causes disease. The most 
common measure of attributable risk is the population attributable fraction (PAF), which 
represents the magnitude of the current disease burden that would not have occurred in the 
absence of exposure (Hennekens & Buring, 1987; Melse & de Hollander, 2001; Murray et al, 
2003; Steenland & Armstrong, 2006). 
The PAF, also described as a population attributable risk (PAR), excess rate, or etiologic 
fraction, considers the population prevalence of exposure and the magnitude of the relative risk 
(RR) in an ‘exposed’ group compared to an ‘unexposed’ group (Husted, 2005). 
Alternatively, the contribution of a risk factor to the burden of disease can be estimated 
by a population impact fraction (PIF), which compares the disease burden observed with the 
current exposure distribution in a population with that expected assuming an alternative 
hypothetical distribution, a counterfactual (Ezzati et al, 2003; Mathers et al, 2001). Similar to the 
PAF, the PIF considers the magnitude of the relative risk and the population distribution of 
exposure, with both equations described as follows, 
 











' i  PAF =   Pi (RRi – 1) (Equation 1) 






i              Pi (RRi – 1) + 1 
       where:  
PIF = population impact fraction 
       PAF = population attributable fraction 
RRi = relative risk for disease i  
       P i = prevalence of exposure i 






3. TECHNICAL DESCRIPTION OF THE MODEL 
3.1. Model Development and Conception Process 
Evidence from environmental burden of disease (EBD) studies can provide detailed 
information on exposure associated health impacts, facilitate reliable and internally consistent 
data collection, and support the continuous development of harmonized methodologies, tools, 
and modelling techniques for population health impact assessments (Mathers et al, 2001; 
McMichael et al, 2001; Kay et al, 2000; Pruss et al, 2001; Pruss-Usten et al, 2003).  
This model was envisioned to enable a novel analysis of the contribution of ambient air 
toxics to the burden of disease (BoD) in two suspected high risk geographic regions in Ontario, 
using descriptive epidemiological disease data and predicative risk assessment approaches. The 
model is designed to assess public health impacts associated with exposure in three stages: 
• Quantification of the total burden of morbidity and mortality for selected diseases  
• Determination of the magnitude of the BoD attributable to current hazardous air pollutant 
(HAP) exposures 
• Quantification of the magnitude of the BoD that could be reduced with mitigated HAP 
exposures 
 
Although exposure to ambient air pollution has been associated with a plethora of health 
effects, through three different routes of exposure (dermal, ingestion, inhalation) (de Hollander et 
al, 1999; Melse & de Hollander, 2001) the assessment is limited to quantifying carcinogenic 
outcomes from inhalation exposure to selected air toxics, under the assumption that each exerts 
independent and additive effects. 
Many additional assumptions and simplifications were required to quantify and 
characterize exposure associated health impacts in the model. When specific disease and 
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environmental data was unavailable to model, the best alternative estimates are substituted in 
place; uncertainties and justification of simplifying assumptions are provided transparently to aid 
in informed decision making and policy in Ontario regarding abatement priorities for HAP’s on 
the basis of the magnitude of associated health impacts. 
The model is structured in a user-friendly MS Excel Workbook, version 2003. As 
modelling is an iterative process and accuracy is dependant upon the quality of the data (Pruss-
Usten et al, 2003), the model can continuously be updated with recent epidemiological and risk 
data in the future to ensure complete, reliable, and comprehensive analyses of the BoD and 
exposure associated risk.  
 
3.2. Model Overview 
3.2.1. Graphic Description of the Model: 
Broadly, the analysis involves modelling exposure associated health impacts in two 
phases (i) the DALY model, and (ii) the Risk model as depicted in Figure 3.1 
 
Figure 3.1 Graphical representation of the Model, Phase One and Phase Two  
Mortality (counts) 
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The first phase quantifies health impacts associated with selected disease endpoints as 
‘risk factor-independent’ DALY’s. Recall that DALY’s are a time based SMPH that enables 
quantification of disease specific estimates of morbidity and mortality in an aggregate estimate 
of population health. The DALY model methodology has been adapted from the WHO GBD 
project (Murray & Lopez), and relies largely upon epidemiological methods. 
The second phase incorporates risk assessment approaches to quantify exposure 
attributable health impacts in terms of DALY’s derived by an attributable fraction. The exposure 
attributable BoD is modelled under an exposure based approach, using current knowledge of 
exposure and risk to predict current and future disease burdens (Pruss-Usten et al, 2003). 
 
3.2.2. Selection of Exposures, Diseases, and the Reference Year of Analysis 
The purpose of the model is to quantify the current and future burden of premature 
mortality and morbidity by age and sex, based on exposure estimates and dose response 
modelling, for six ambient air toxics in two high risk regions of Ontario, Toronto and the 
Chemical Valley of Southwestern Ontario (S.W.O). 
Six carcinogenic air toxics were selected on the basis of their inclusion in the updated 
HEIDII II model, demonstrating evidence of disease causality and potential hazard, and 
availability of exposure and disease data. The air toxics selected for analysis have been described 
in detail in section 2.1 and include: acetaldehyde, formaldehyde, benzene, 1,3-butadiene (1,3-
BD), ethylene oxide (ETO), and nickel refinery dusts 
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In accordance with Section 64 of the Canadian Environmental Protection Act, 1999, the 
aforementioned air toxics are considered “CEPA Toxic”7 (CEPA, 1999). Furthermore, 
toxicological and epidemiological studies have provided evidence of a causal linkage between 
inhalation exposures and carcinogenic outcomes in humans following high dose inhalation 
exposures in animal models and occupational exposures in human populations. The carcinogenic 
potential of acetaldehyde, formaldehyde, benzene, 1,3-BD, ETO, and nickel refinery dusts has 
thus been evaluated by the International Agency for Research on Cancer (IARC). 
The International Agency for Research on Cancer (IARC) consists of an interdisciplinary 
group of expert scientists who evaluate the weight of evidence for substance carcinogenicity 
following standardized protocols. Cancers associated with inhalation exposure to acetaldehyde, 
formaldehyde, benzene, 1,3-BD, ETO, and nickel refinery dusts are selected on the basis of 
IARC risk evaluations, and are listed in Table 3.1. 
Table 3.1.Cancer Associations with Exposure to HAP’s on the Basis of IARC and Health Canada 
Risk Evaluations 
Air Toxic Associated Cancer(s) Reference ICD-9 codes IARC Class  
Acetaldehyde Oral Cavity & Pharynx 
Esophagus 
Ear, Nasal, & Larynx 
Woutersen et al, 1986 
Health Canada PSL 
140-150, 160-161 2B Possible 
Human 
Carcinogen 
Formaldehyde Oral Cavity & Pharyx 
Ear, Nasal, & Larynx 
Monticello et al, 1996 
Health Canada PSL 





Delzell et al, 1995 
Health Canada PSL 





Rinsky et al, 1987 
Health Canada PSL 







Snellings et al, 1984 
Health Canada PSL 





Ear, Nasal, & Larynx 
Lung, Bronchus, & 
Trachea 
Doll et al, 1990 
Health Canada PSL 
160-161, 162-165 1 Known 
Human 
Carcinogen 
                                                 
7 substances enter the environment in amounts that have been or may have an immediate or long term effect on the 
environment or human health 
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Cancer endpoints are classified to three digit code in accordance with the International 
Classification of Disease, 9th Version (ICD9) (Appendix A). The ICD represents a global 
standard for disease diagnosis, standardizing the management of epidemiological data for the 
purpose of disease surveillance. 
In the model, cancer endpoints are grouped at the organ level, under a presumed common 
mechanism (Mathers et al, 2001; Smith et al, 1999) thus include (i) oral cavity & pharynx, (ii) 
esophagus, (iii) middle ear, nasal, & larynx, (iv) lung, bronchus, & trachea, (v) lymphomas & 
multiple myeloma, and (vi) leukemia’s.  
Population data and epidemiologic indicators of disease (ie: incidence, mortality, 
duration, etc) are modelled for the reference year of 2001. The year 2001 was selected for 
analysis as having the most complete and reliable dataset. With stability in the population 
structure in recent years (Statistics Canada, 2001) it is reasonable to assume 2001 data is 
representative of the current population (Campbell et al, 2004). 
The next section (section 3.3) will provide an overview of the technical requirements to 
model the BoD for the selected site-specific cancers, in terms of DALY’s. The following section 
(section 3.4) will discuss methodology to assess the magnitude of the BoD that is attributable to 
the air toxics under analyses. Detailed descriptions of specific data sources, estimates, and 







3.3. Public Health Impacts: Disability-Adjusted Life Years (DALY’s) 
Public health impacts are most often characterized by measures of mortality, life 
expectancy, potential years of life lost (PYLL), and quality-adjusted life years (QALY’s); 
however with increases in life expectancy and chronic disease in the Ontario population, such 
measures fail to provide a complete and comprehensive picture of population health (Melse & de 
Hollander, 2001; Thomas & Hrudey, 1997) 
The DALY represents a time based measure of quantity and quality of life. DALY’s 
quantify years of life lost due to premature mortality (YLL) and healthy years of life lost due to 
disability (YLD) as an aggregate estimate of population health (Anand & Hanson, 1997; Arnesen 
& Kapriri, 2004; Gold et al, 2002; Mathers et al, 2001; Melse & de Hollander, 2001; Murray & 
Acharya, 1997). One DALY represents the loss of a perfectly healthy year of life (Melse & de 
Hollander, 2001). 
 
DALY = YLL + YLD       (Equation 2) 
      Where: 
      YLL = Years of life lost 
      YLD = Years of life lived with disability 
 
Quantification of health impacts in terms of DALY’s requires a range of disease 
information including site-specific estimates of cancer incidence, mortality, age of diagnosis, and 
life expectancy. Additionally, DALY’s require estimates of average disease duration and 
severity, provisional to disease staging. 
In the model, epidemiological estimates of disease are input in terms of ‘years’ to ensure 
a comparable and consistent time scale to aggregate time lost due to fatal and non fatal health 
outcomes. Consistent with GBD study methodology, site specific cancer DALY’s are quantified 
by sex and eight age groups: 0-4, 5-14, 15-29, 30-44, 45-59, 60-69, 70-79, and 80+ years. 
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By combining population disease data of diverse severity into a common unit, the DALY 
serves as a comparative measure, suitable to assess the relative disease burdens associated with 
different cancers between regions. The model thus quantifies the BoD as ‘Total DALY’s’ and 
‘DALY’s / 100,000 Persons’ to enable BoD assessment between Toronto and S.W.O. 
 
3.3.1. Years of Life Lost (YLL): 
The mortality component of the DALY calculation, years of life lost due to premature 
death (YLL), is modelled as a function of age specific mortality and the remaining life 
expectancy at the age of death from site specific cancers 
YLLi = N X L         (Equation 3)  
where: 
      N =population estimates of mortality per age-sex group 
      L = remaining life expectancy at age of death  
 
3.3.1.1. Mortality 
Site specific estimates of mortality counts in the Toronto and S.W.O regions were 
ascertained by five year age interval, in accordance with ICD9 cause of death classification. For 
computational purposes, average age at death is assumed the midpoint of each age interval, and 
frequency counts are converted to a rate per 100,000 persons, considering the population count in 
each age category. 
 
3.3.1.2. Life Expectancy 
Life expectancy most commonly refers to the number of years an individual can expect to 
live on the basis of current death rates (Thomas & Hrudey, 1997). In the DALY, life expectancy 
is used to estimate the number of years of life a person has lost due to premature mortality. Four 
methods have been proposed to estimate years of life lost due to premature mortality: (i) cohort  
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life tables, (ii) period life table, (iii) standard life tables, and (iv) potential years of life lost 
(Murray, 1994), each with specific strengths and limitations, as described in Table 3.2 
Table 3.2. Methods to Estimate Life Expectancy, Strengths, and Limitations 
Method Description Strengths Limitations 
Cohort Life Expectancy Provides an estimate of 
the mortality experience 
of an entire group of 
individuals from the 
first birth the last death 
(Mathers et al, 2001) 
Most accurate 
description of mortality 
for national burden of 
disease assessments. 
Amendable to cost 
effectiveness analysis 
(Murray, 1994) 
Data may be difficult to 
generate (Mathers et al, 
2001) 
Not valid for GBD 
studies (Murray, 1994)1
Period Life Expectancy Follows the mortality 
experience of a 
synthetic cohort, taken 
cross-sectionally in 
time, subject to current 
age-specific mortality 
rates (Brand, 2005; 
Ellison & Gibbons, 
2006; Mathers et al, 
1999; Murray, 1994) 
Reflects the current 
survival experience and 
provides a better 
estimate for recently 
diagnosed cases (Ellison 
& Gibbons, 2006) 
Useful for national 
burden of disease 
studies (Murray, 1994) 
Emphasizes premature 
death in wealthy 
countries. Use of local 
life expectancy is not 





Based on a West Level 
26 table based and the 
highest observed life 
expectancy among 
Japanese to provide an 
ideal standard (Murray 
& Lopez, 1997; Murray, 
1994) 
Deaths at all ages 
contribute to estimates 
of premature mortality, 
and deaths at the same 
age contribute equally 




to life (Murray & 
Acharaya, 1997; Anand 
& Hanson, 1997) 
Potential Years of Life 
Lost 
Determined by 
subtracting age at death 
from an arbitrary 
defined upper limit to 
life, commonly set to 65 
or 75 years 
Ease of calculation 
Egalitarian treatment of 
deaths at the same age 
(Murray, 1994) 
Deaths after age 65 do 
not contribute to the 
BoD, PYLL thus 
contradicts a 
fundamental principle of 
DALY (Murray, 1994)2
Weight placed on death 
at younger ages & 
emphasizes disease that 
prevent longevity 
(Thomas & Hrudey, 
1997)  
1contradicts DALY principle of treating “like health outcomes as like” 
2The DALY is based on the principles of fairness and egalitarianism, grounded upon a “common set of minimalist values that is need for 




The GBD study used a Standard West Level 26 life table to assess the standard expected 
years of life lost (SEYLL) in a comparable manner across nations with different life 
expectancies. However, for national and regional BoD assessments, local or cohort life 
expectancy is recommended as a normative goal to calculate DALY’s, being amendable to cost-
effectiveness analysis (Murray, 1994). As such, the model quantified premature mortality 
specific to the current Canadian cohort life expectancy of 78 years for males and 83 years for 
females on the basis of an abridged cohort life table (WHO, 2006) 
 
3.3.2. Years of Life Lived with Disability (YLD) 
Internally consistent YLD estimates require a clear definition of the disease under 
analysis in terms of severity and stage (Table 3.3) (Mathers et al, 2003). Referring to Figure 3.1 
YLD estimates for site specific cancers require a more extensive and uncertain range of 
epidemiological data then the above YLL information including estimates of incidence, severity, 
duration, and age of onset distributed by stage, which in turn requires epidemiological estimates 
of remission and case-fatality (Mathers et al, 2001). 
Table 3.3 Definitions of Malignant Neoplasm Disease Staging 
Stage of Disease Case Definition 
Diagnosis Period of medical diagnosis and tests 
Primary Therapy Chemotherapy, radiotherapy, surgery 
Remission / Control & Waiting Clinical observation during control/remission phase 
Metastasis Dissemination of the disease 
Terminal Terminal stage prior to death 
      (As adapted from WHO GBD study, Mathers et al, 2001) 
 
The morbidity component of the DALY calculation, years of life lived with less then 
perfect health, is modelled as a function of estimates of site specific incidence, and the average 




YLD = I X DW X D        (Equation 4) 
  
      where: 
      I = age and sex specific estimates of incidence 
      DW = disability weight of cancer 
      D = average duration (years) 
3.3.2.1. Incidence: 
Although the population frequency of cancer can be estimated either as an indicator of 
incidence or prevalence, YLD’s are quantified on the basis of incidence counts. Incidence 
provides a direct estimate of new diagnosis, equivalent to the mortality incidence indicator for 
YLL’s, and is most sensitive to recent epidemiologic trends (Mathers et al, 2001; Melse et al, 
2000; Murray, 1994; Pruss-Usten et al, 2003). Like mortality, site-specific frequency counts are 
converted in the DALY model to a rate per 100,000 persons. 
 
3.3.2.2. Disease Model: 
The GBD (WHO, 2000) and Dutch study (Essink-Bot et al, 2002) disease model has been 
adapted, with provisional disability weights and durations for the cancer stages, to ensure 












    (Figure 3.2 Cancer Survival Model) 
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Based on Figure 3.2 a newly diagnosed case is assumed to follow one of three disease paths, 
(i) Incidence cases that are eventually cured of cancer undergo a period of diagnosis, 
treatment, and remission prior to being considered disability-free.  
(ii) Incidence cases that are diagnosed but are not cured of cancer enter a period of 
treatment, remission, metastasis, and finally a terminal stage prior to death.  
(iii) Incidence cases untreated are assumed to pass through the stages of diagnosis, 
metastasis, and a terminal period prior to death. 
 
 
.3.2.3. Disease Duration: 
Average duration of disease was considered separately for survivors and non-survivors, 
for the stages of disease, stratified by age and sex, for site-specific cancers. Consistent with GBD 
study methods (Murray & Lopez, 1997), it is accepted that 90% of cases in EME regions  are 
treated and 10% are untreated. Survivorship, the cure rate, is taken as the five year relative 
survival rate (RSR), describing the percent of cases alive five years after diagnosis, without 
adjustment for background all-cause mortality. 
Survivors are considered disability-free five years from the initiation treatment. For the 
non-survivors that eventually die of cancer, the average time to death (LNS) is assumed to follow 
an exponential distribution and is estimated from the one, three, and ten year RSR (Essink-Bot et 









8 The established market economy consists of the high income countries of the Organization for Economic 







=LNS        (Equation 5) 
Where:  
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The duration of the primary diagnosis, therapy, remission, metastasis, and terminal stages 
were de
ce 
n of the primary therapy stage for site-specific cancers is derived independent of 
survivo  
rapy 
n-survivors and is estimated by 
subtrac
n 
termined through literature review of expert opinion. The durations for the stages of 
diagnosis, metastasis, and terminal periods are assumed constant for all cancers; however, sin
diagnosis at an earlier stage (as in medical severity) considerably influences disease outcome, 
duration for primary therapy and remission stages varied pending treatment regime and/or 
survivorship. 
Duratio
rship, as a function of the distribution of cases undertaking various treatment regimes and
the time to complete the regime, considering medical severity at the time of diagnosis. The 
model assumes treatment regimes progress from: surgery (in-patient, out-patient), chemothe
(mild, moderate, severe), and/or radiotherapy (curative, palliative), and that cancer severity is 
diagnosed as local, regional, or distant (Flanagan et al, 2005). 
Remission is considered separately for survivors and no
ting the duration of all other stages from a defined average disease length, described at 
five years for survivors and LNS for non-survivors. As such, for survivors the average remissio
duration for site-specific cancer is calculated as 5-DTR, with cases assumed disability-free five 
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years after diagnosis (WHO, 2000). In contrast, for non-survivors average remission duration is 
derived as follows: (WHO, 2000) 
 
LNS – (DTR + DM + DT )       (Equation 6) 
       Where: 
LNS = mean survival duration non survivors  
       DD = duration of diagnosis 
       DTR = duration of treatment 
       DM = duration of metastasis 
       DT = duration of terminal phase 
 
Calculations to derive average disease duration across cancer staging and pathway are 
reviewed in Table 3.4. Based on the case-fatality rate (ie: the 5 year RSR) and the distribution of 
cases by disease path, durations are combined to generate a single estimate of the average site-
specific disease duration (stratified by age and sex) in the YLD model (WHO, 2000; Essink-Bot 
et al, 2002) 
Table 3.4 Derivation of disease duration based on survivorship 
Disease Path Disease Duration Assumptions 
(i) diagnosis, treatment, 
remission, ‘disability-free’ 
DD + DTR + (5-DTR) Cases assumed ‘cured’ experience 
negligible disability following initial 
diagnosis, treatment, remission durations 
(WHO, 2000) 
 
(ii) diagnosis, treatment, 
remission, metastasis, 
‘death’ 
DD + DTR + (LNS –  DTR + 
DM + DT) + DM + DT
Average survival duration can be derived 
from 1,3,10 year RSR’s  
Survivorship assumed to follow an 
exponential Weibull distribution 
(iii) diagnosis, metastasis, 
terminal, ‘death’ 
DD + DM + DT Duration of diagnosis, metastasis, and 
terminal phases are set to 6 weeks, 5 
months, and 1 month respectively, for all 
cancers (Flanagan et al, 2005; WHO, 
2000) 
Where: LNS = average survival duration non survivors, DD = duration of diagnosis, DTR = duration of treatment, DM = duration of metastasis, 








3.3.2.4. Disability Weights: 
Disability weights of cancer severity (distinct from duration) are incorporated in the 
calculation of YLD’s to standardize epidemiologic estimates of time lived with morbidity to time 
lost from premature mortality. The weights range from zero, indicating a state equivalent to 
perfect health, to one, indicating a state equivalent to death, and were determined for the GBD 
project by person trade-off method and expert opinion of social preferences for disease states 
(Mathers et al, 2001; Murray & Acharya, 1997; Reidpath et al, 2003).  
Person trade-off is a deliberative and iterative process whereby individuals are given the 
option of curing a certain number of people with a particular health state versus curing a certain 
number in a different health state. Disability weights are elicited when individuals are indifferent 
between the two options (Mathers et al, 2001; Murray & Acharya, 1997; Reidpath et al, 2003). 
As such, a weight of zero indicates indifference between a health state and full health, and a 
weight of one indicates indifference between the health state and death.  
Supporting a principle of egalitarianism in the DALY, disability weights are constant 
across social, environmental, and cultural contexts (Reidpath et al, 2003). For malignant 
neoplasms, disability weights have been determined for the states of disease: diagnosis/therapy, 
waiting (remission), metastasis, and terminal, constant across gender and age groups, and are 
listed in Table 3.5 
Table 3.5 GBD Disability Weights for Malignant Neoplasm 
Site & GBD Cause ICD 9  Diagnosis/Therapy Waiting Metastasis  Terminal
A1.Mouth & Oropharynx 
cancers 
140-149 0.09 0.09 0.75 0.81 
A2.Oesophagus cancer 150 0.20 0.20 0.75 0.81 
A7.Trachea, bronchus, and 
lung cancers 
162-165 0.15 0.15 0.75 0.81 
A15.Lymphomas 200-203 0.06 0.06 0.75 0.81 
A16.Leukemias 204-208 0.09 0.09 0.75 0.81 
Other Malignant Neoplasms 160-161 0.09 0.09 0.75 0.81 
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To calculate YLD’s, the disability weights across cancer stages must be derived into one 
disability weight associated site-specific cancer in the DALY model (Essink-Bot et al, 2002; 
Melse et al, 2000). As such, the average disability weight is calculated on the basis of the 
prevalence distribution across diagnosis, therapy, control, metastasis, and terminal stages, and 
the stage specific disability weight used in the GBD study. 
 
3.3.3. Social Value Choices: 
The DALY creates a common currency to estimate morbidity and mortality by explicitly 
incorporating numerous social value choices such as: a maximum expectation of life, a ‘like’ 
valuation for ‘like’ health outcomes, severity weighting for non fatal health states, a discount rate 
for future healthy life, and unequal valuation of time lived at different ages (Anand & Hanson, 
1997; Arnesen & Kapiriri, 2004; Melse & de Hollander, 2001; Murray & Acharya, 1997). Table 
3.6 provides a complete overview of the value choices incorporated in the DALY, arguments for 
and against, and introduces some limitations. The following paragraph reviews two of the most 




















Table 3.6. Value Choices & Assumptions of the DALY 
Value Choice Argument For… Argument Against… 
Standard 
expectancy of 
life of 80 years 
for men & 82.5 
years for 
females1
Equality: all individuals have the 
same standard life expectation despite 
income, geography, etc  
Arbitrarily determined (Anand & Hanson, 
1997; Arnesen & Kapiriri, 2004) 
 Male female differences reflect 
biological differences in survival 
potential (Murray et al, 1997) 
Male-female survival differences reflect 
differences in risk behaviours, modifiable 
through future public health interventions 
(Murray & Acharya, 1997) 
  Sex differences reflect genetic determinism, 
compelling risk behaviours in males (Anand 
& Hanson, 1997) 
  Murray & Acharya, (1997) argue for the same 
survival norm incorporated in the DALY 
  80 years of life for males and 82.5 years for 
females is unachievable in developing 





Elicited by social preferences for 
different health states (Murray & 
Acharya, 1997) 
Severity rating of a health state may change 
with adaptation/coping (Murray & Acharya, 
1997) 
Anand & Hanson (1997) describe 
‘compensated’ &‘uncompensated’ DW 
 Based on ‘expert’ preferences & 
knowledge (Murray & Acharya, 
1997) 
Health state preferences vary between 
individuals (Murray & Acharya) 
 Weights vary for treated and 
untreated forms of disability (Murray 
& Acharya, 1997) 
DW do not take into account quality of life, 
social resources, or the context in which life is 
lived (Anand & Hanson, 1997) 
 Disability weights vary among age 
groupings, reflecting the BoD 
DW do not reflect impacts of co-morbidities; 
weights could add to greater then 1 (death) 
(Anand & Hanson, 1997) 
Discounting4 Consistent with economic principles 
& health policy 
3% discount rate arbitrary (Murray & 
Acharya, 1997), reflects a compromise 
between economics and excessive sacrifice 
(r=0) 
 Eradication-research paradox & 
excessive sacrifice6 (Murray & 
Acharya, 1997) 
Time of illness: weighted more severe if 
experienced today, then if in a years time 
 “Time Paradox” (Murray & Acharya, 
1997) Delay investments in health 
until the future 
Discounting DALYs, reduces the value of life 
to a monetary value. 
  Argument for discounting rests on assumption 
the world may end which is an infinitely small 
chance (not 3% or even 1%) (Anand & 
Hanson, 1997) 
  Discounting compounds criticisms of age 
weights7 (Anand&Hanson, 1997; 
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Arnesen&Karpiriri,1997)  
Age weighting8 Differential value assigned to time 
lived at different ages is a reflection 
of social roles in society9 (Murray & 
Acharya, 1997) 
Differential age valuation inequitably is a 
reflection of  human capital principles & 
differential productivity (Murray & Acharya, 
1997), thus assigning a monetary value to life 
 Ethically justified because all 
individuals pass through the same life 
cycle 
Social value of life may differ among 
occupation, sex, income bracket (Anand & 
Hanson, 1997) 
 Instrumental justification, as ill health 
in middle ages indirectly impacts the 
health of  young and elderly 
(interdependence) (Anand & Hanson, 
1997) 
Principle of Universalism- same value of life 
no matter age (Anand & Hanson, 1997) 
1For maximum life expectation, 82.5 years for females was determined based on the Japanese female life expectancy, the country 
with the highest life expectancy globally. Male life expectancy was determined by incorporating recognized differences in 
survival of 1.9-3.2 years using modelling techniques (Murray & Acharya, 1997) 
2Disability weights: life years assigned different value pending the health state in which they are lived (Arnesen & Kapiriri, 2004) 
Ranging from 0=perfect health to 1=death 
3PTO = Person Trade-off method 
4Discounting: future years of life are assigned less value then years lived today (Arnesen & Kapiriri, 2004) if applied, discounting 
3% 
5Discounting future life justifies current environmental degradation, benefiting the current generation at the expense of future 
generations 
6For example, if r=0, the possibility of improved health technologies, care, and treatment, could eliminate disease in the future, 
justifying significant sacrifice ie: 100% research and resources, for future health benefits  
7The combined impact of age weights and discounting is a lower value of morbidity and mortality at younger ages; for example: 
the life of a 20 year old should be valued and saved more then an infant 
8Age weights: assign different value to life at different ages (Anand & Hanson, 1997; Arensen & Kapiriri, 2004; Murray & 
Acharya, 1997) Maximum DALYs are prevented at 24.5 years of age. 
9Social roles at some groups include caring for the well-being of other age groups (the young and old), providing physical, 
emotional, and financial support, and helping society flourish (Murray and Acharya, 1997) 
 
3.3.3.1. Discounting 
Discounting future time is a traditional concept in economic and social policy. In BoD 
assessments, a discount rate places less value on future healthy life to estimate the net present 
value of life (Murray & Acharya, 1997; Murray et al, 1994). Although a discount rate of 5% is 
standard in economic analysis, the World Bank Disease Control Priorities study and the GBD 
study have established a lower discount rate of 3% for BoD studies (Murray, 1994; Pruss-Usten 
et al, 2003), believed consistent with long term yield on investments. A 3% discount rate implies 
a year of healthy life gained in ten years time is worth 24% less then one gained this year. A 
discount rate is justified in BoD assessments to avoid placing excessive emphasis on childhood 
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deaths and intervention investments at the health expense of the current generation, ie: excessive 
sacrifice (Murray & Acharya, 1997).  
 
3.3.3.2. Age-weighting 
Studies have indicated social preferences for the value of life lived during young 
adulthood over life lived during childhood or the later years (Murray & Lopez, 1997; Murray et 
al, 1994). Age-weighting (K=1) places less value on healthy life during the younger and older 
ages, with peak valuation at age 24.5. Age-weights have been justified as an attempt to capture 
the instrumental value of time lived at different ages through the life cycle (Anand & Hanson, 
1997; Mathers et al, 2001; Melse & de Hollander, 2001; Murray & Acharya, 1997; Murray, 
1994). Since discounting and age-weighting have been widely criticized on conceptual, ethical, 
and empirical grounds (Anand & Hanson, 1997; Reidpath et al, 2003), the model has been 
developed to enable sensitivity analysis of the impacts of incorporating discounting and age-
weighting on BoD estimates. With the inclusion of the social value choices, the complete 
computational formulas for the YLL and YLD calculations can be described as, 
 
YLL  =   KCera  [e –(r + β )(L + a) [- (r + β ) (L + a) – 1] – e-(r + β)a [-(r + β)a – 1]] + 1 – K (1 – e-rL)  
             (r + β)2                    r  
   
           (Equation 7) 
 
YLD = DW {KCera [e –(r + β )(L + a) [-(r + β ) (L + a) – 1] – e-(r + β)a [-(r + β)a – 1]] + 1 – K (1 – e-rL) } 
                  (r + β)2              r 
          (Equation 8) 
where: 
a = age of death  
r = discount rate  
β = age weighting constant  
K = age-weighting modulation constant  
C = adjustment constant for age-weights  
L = standard life expectancy at age of death or 
duration of disability 
 DW = disability weight 
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3.4. Exposure Attributable Disease Burden 
3.4.1. Burden Attributable to Current Ambient Concentrations: 
A measure of attributable risk is required to estimate the health impacts associated with 
exposure to current concentrations of ambient air toxics. Modelling the environmentally 
attributable BoD requires: (i) an assessment of the population distribution of exposure for each of 
the air toxics, (ii) a quantitative estimate of the exposure-disease associations, and (iii) 
characterization of the risk (DeHollander et al, 1999; Pruss-Usten et al, 2003).   
For ambient air toxics, there has been little or no epidemiological work concerning the 
magnitude of associated cancer risk from environmental concentrations. Furthermore, with a 
ubiquitous population distribution of exposure, air quality is not a risk factor amendable to 
traditional ‘exposure’ ‘no exposure’ PAF categorization.  
As such, for carcinogenic substances that are assumed to act linear with no threshold on 
the concentration-response curve, the fraction of disease burden attributable to environmental 





AF ...exp. =        (Equation 9)  
      where: 
ABx.e. = population attributable burden of disease e 
IURx. = inhalation unit risk value of HAP x (ug/m3) 
LE = average life expectancy (years) 
Cx. = concentration of HAP x (ug/m3) 
Fexp.x.e. = fraction of population exposed 
Npop. = population count 
 
Similar to the PAF, the attributable fraction in Equation 9 requires information on the 
population distribution of exposure and a quantitative estimate of risk. For carcinogenic air 
toxics, quantitative risk estimates associating exposure and disease are based on potency 
estimates rather then relative risks. The carcinogenic potency of the six air toxics at 
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environmental concentrations is estimated as a slope factor (q*1) which predicts lifetime cancer 
risk assuming constant low dose cumulative exposure. 
Concentrations of the selected air toxics are determined specific for the Toronto and 
S.W.O regions through extensive literature review. As mentioned, the concentration-response 
function for carcinogenic substances is assumed to act linear non threshold such that it is 
theoretically possible any level of exposure can initiate the carcinogenic process. As such, annual 
mean concentrations, representative of chronic low dose cumulative exposure (Campbell et al, 
2004) are modelled, assuming dose-rate independence and the absence of ceiling or threshold 
effects. 
For consistency with the calculation of risk factor independent DALY’s, an abridged 
cohort life table estimates current Canadian life expectancy of 78 years for males and 83 years 
for females (WHO, 2006). The fraction of the population exposed is assumed equal to one, and 
the population count is standardized to 100,000 to enable comparison of the attributable disease 
burden between Toronto and S.W.O regions. 
Finally, to characterize the public health impacts attributable to exposure to current 
concentrations of ambient air toxics in terms of DALY’s, attributable fractions are multiplied by 
estimates of site-specific DALY’s per 100,000 persons (phase one) in Toronto and S.W.O, 
describe as follows, (DeZwart et al, 2006; Lopez et al, 2006; Murray et al, 2003; Steenland & 
Armstrong, 2006)  
eex
ex
DALYsAB xDALYAFBoD ... ∑∑=       (Equation 10)  
      where: 
      BoDAB.DALYs = attributable DALY BoD 
      ABBx.e. = population attributable BoD e to exposure x 




3.4.2. Counterfactual Analysis 
To inform policy and decision making in Ontario regarding abatement priorities for 
hazardous air pollutants, projection scenarios of future exposure distributions were developed 
and modelled in a counterfactual analysis. Counterfactual analysis enables a comparison of the 
burden of morbidity and mortality experienced under current exposure distributions to be 
compared with the burden predicted under alternative exposure distributions, termed 
counterfactuals (Ezzati et al, 2006; Lopez et al, 2006; Mathers et al, 2001; Murray et al, 2003; 
Pruss-Usten et al, 2003; Smith & Ezzati, 2005). As mentioned in section 2.4 counterfactual 
exposure distributions include theoretical minimum risk, plausible minimum risk, and feasible 
minimum risk levels. 
The impact of reducing ambient air toxics exposures on BoD estimates in Toronto and 
S.W.O is modelled for a plausible minimum risk and a feasible minimum risk level. The 
concentrations of the selected air toxics associated with plausible and feasible minimum risk 
distributions have been determined through literature review and are modelled by substituting the 
alternative counterfactual concentration (ug/m3) in place of the current concentration component 
of Equation 9 
The plausible minimum risk is modelled as the cancer risk expected assuming an 
exposure distribution if there were no anthropogenic releases of air toxics. The feasible minimum 
risk is modelled as the cancer risk expected under an exposure distribution that has been 
observed in the population with minimal vehicle or industrial emissions. Since natural sources of 
air toxics exist in the environment, zero risk to human health is not achievable for linear acting 
carcinogenic substances, such that a theoretical minimum risk level is not included in the model. 
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4. DATA SOURCES, ESTIMATES & UNCERTAINTIES 
4.1. Population Demographics 
Geographic regions were selected as representative high risk from exposure to ambient 
air toxics in Ontario; Toronto from motor vehicle emissions and S.W.O from industrial releases 
of the Chemical Valley. The Toronto area includes the municipal counties of Durham, Peel, 
York, and the City of Toronto, and S.W.O includes the counties of Chatham-Kent, Windsor-
Essex, and Lambton. 
Baseline population profiles were ascertained for the regions of interest by 5-year age and 
sex grouping from the 2001 Canadian Census, the most recent published census at the initiation 
of the project (Community Profiles, Statistics Canada, 2001). Detailed population counts can be 
found in Appendix B 
Census data is collected every five years and provides a valid and reliable source of 
demographic information on 98% of households in Canada. However, specific subgroups 
including children less then one, transient young males, and immigrants are more likely to be 
under reported in data collection. Under-representation would produce uncertainty in estimates 
of specific-rates if the subgroups differ on characteristics associated with either exposure or 
disease outcomes (Husted, 2005), biasing estimates of risk. 
 
4.2. Cancer Incidence & Mortality  
Incidence and mortality counts were ascertained from the Ontario Cancer Registry 
(OCR), Cancercare Ontario, and can be found in Appendix C. Cancercare Ontario is the 
principle advisory organization for the provincial government responsible for coordinating 
surveillance, care, prevention, and developing evidence based guidelines. Data was collected 
35 
from the SEER*Stat 6.2.4 CD software package (2006), upon request from Cancercare. 
SEER*Stat is a database updated annually with aggregate information on cancer incidence 
(1964-2003), mortality (1950-2003), survival, prevalence rates, crude and adjusted rates, and 
frequency data, with standard errors and confidence intervals. 
Data was ascertained at the municipal level and aggregated for regional analysis. 
Incidence and mortality counts were collected by sex and age group, for the reference year 2001. 
When cell counts smaller then five were noted but not disclosed by OCR to protect patient 
confidentiality, counts were averaged over a 5-year period (1999-2003) to produce a best 
estimate; when cell counts remained less then five over this period, the count was assumed one.   
As mentioned, cancer endpoints were classified to three digit code in accordance with the 
International Classification of Disease, 9th Version (ICD9) (Appendix A). The ICD represents a 
global standard for disease diagnoses, standardizing the management of epidemiological data for 
disease surveillance. Consistent with GBD and National Burden of Disease (NBD) study 
methodology (Mathers et al, 1999; Mathers et al, 2003; WHO, 2001), cancers diagnosed under 
“other” or “ill-defined” sites: 149 and 165, have been redistributed across primary sites, ie: 140-
147 and 162-164. Since ill-defined classifications typically include less then 1% of coding 
classifications (Mathers et al, 2001), pro-rata re-distribution was not expected to introduce 
parameter uncertainty to the model.  
 
4.3. Life Expectancy: 
As mentioned, the remaining life expectancy at death in the YLL calculation, and life 
expectancy in the calculation of the lifetime risk of the attributable fraction was ascertained from 
an abridged cohort life table, obtained from the World Health Organization (WHO, 2006), found 
36 
in Appendix D. Life expectancy was based upon the current Canadian life expectancy of 83 
years for females and 78 years for males (WHO, 2006), and deaths were assumed to occur at the 
midpoint of the age interval.  
 
4.4. Average Disease Duration: 
Average disease duration was derived for site-specific cancers on the basis of descriptive 
epidemiological estimates ascertained from Statistics Canada (Flanagan et al, 2005) and the 
World Health Organization (Mathers et al, 2001; WHO, 2000). 
Statistics Canada provided a rich source of site-specific data on stage distribution9, 
duration, and medical severity in the form of a treatment algorithm, reviewed by medical expert 
(Flanagan et al, 2005). The Statistics Canada database was published as part of the Public Health 
Impact of Disease in Canada research program, with limitations and methodologies of the 
primary data described further by Flanagan et al, (2005). 
Average duration of primary therapy for site-specific cancers was derived in two stages. 
First, considering a patients medical severity at diagnosis and typical treatment regimes 
(Appendix E1), and second considering medical severity at diagnosis and the age distribution of 
cases (Appendix E2). The modeled estimates of average duration for primary therapy for site-
specific cancers, disaggregated by age and sex interval are described in Appendix E3 
The average duration for the remission stage was derived separately for survivors and 
non-survivors based on relative survival rates at one, three, five, and ten years (methods 
described in section 3.3.2.3). The RSR’s, stratified by age and sex for each cancer site, can be 
found in Appendix F. The RSR’s were ascertained in accordance with ICD9 coding from the 
                                                 
9 The Ontario Cancer Registry currently does not collect data on stage of cancer (medical severity) at diagnosis. 
With greater uncertainty in epidemiological disease data parameters (ie: duration, medical severity), the estimates of 
YLD’s are likely associated with greater uncertainty then estimates of YLL’s. 
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SEER*Stat 6.2.4 database. Recall, the average duration of disease for survivors is set to five 
years, and for non-survivors the average duration of disease, stratified by age and sex for site-
specific cancers is found in Appendix G. The average duration of the remission stage for 
survivors can be found in Appendix H1 and for non-survivors in Appendix H2 
The duration of the stages of diagnosis, metastasis, and terminal periods has been set to 
six weeks (0.1 years), five months (0.417 years), and one month (0.083 years) respectively for all 
cancers and age groupings, regardless of survivorship (Flanagan et al, 2005; Mathers et al, 2001; 
WHO, 2000). On the basis of estimates of survival duration, cure rates, as well as stage durations 
for diagnoses, treatment, remission (survivors & non-survivors), metastasis, and terminal 
periods, estimates of average disease duration are listed in Table 4.1. 
Table 4.1 Average Duration of Disease by ICD9 Coding (age & sex disaggregated)1
Cancer site Age  Males Females Cancer Site Age  Males Females 
0-4 0 0 0-4 4.35 4.65 
5-14 0 4.55 5-14 4.13 0 
15-29 4.58 4.64 15-29 3.50 3.92 
30-44 4.58 4.70 30-44 2.45 2.84 
45-59 4.68 4.71 45-59 2.41 2.83 
60-69 4.72 4.83 60-69 2.34 2.73 
70-79 4.51 4.75 70-79 1.97 2.25 
140-149 
Oral Cavity & 
Pharynx 




80+ 1.48 1.61 
0-4 0 0 0-4 0 3.99 
5-14 0 0 5-14 4.61 4.56 
15-29 0 0 15-29 4.71 4.70 
30-44 2.52 0 30-44 4.88 5.04 
45-59 2.36 2.72 45-59 5.62 5.50 
60-69 2.21 2.54 60-69 5.40 5.26 
70-79 2.09 2.31 70-79 4.66 4.77 
150 
Esophagus 





80+ 3.10 3.43 
0-4 0 0 0-4 4.44 4.11 
5-14 0 4.68 5-14 4.44 4.33 
15-29 0 4.64 15-29 3.91 3.99 
30-44 4.74 4.65 30-44 4.60 4.42 
45-59 4.76 5.18 45-59 5.58 4.49 
60-69 4.88 5.03 60-69 5.12 5.06 
70-79 5.14 5.10 70-79 3.93 4.23 
160-161 
Middle Ear, 
Nasal, & Larynx 
80+ 3.84 4.06 
204-208 
Leukemias 
80+ 2.49 2.54 
1 determined as a weighted average of case distribution and treatment by stage 
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4.5. Disability Weights 
The GBD disability weights for malignant neoplasm were ascertained online from the 
WHO for the stages of malignant neoplasm as listed in Table 3.5. The weights have been well 
validated10 amongst a global representation of experts, demonstrating little empirical evidence of 
cross-cultural variability, with Pearson and Spearman rank coefficients for 22 indicator 
conditions >0.9, as described elsewhere (Essink-Bot et al, 2002; Mathers et al, 1999; Murray & 
Acharya, 1997; Schwarzinger et al, 2003).  
The average disability weight was calculated in the model by means in which the stage 
specific disability weight contributed in accordance with its fraction of its share of the 
prevalence. As an example, assume 90% of females age 15-29 with oral cancer are treated, the 
five-year RSR is 51.4%, 38.6% will be treated and not survive, such that the average disability 
weight is derived as:  
    Stage Disability Wt. % Cases Fraction Cases / Stage  
Diagnosis 0.09 100 1 0.09 
Treatment 0.09 90 0.9 0.081 
Remission 0.09 90 0.9 0.081 
Metastasis 0.75 48.6 0.486 0.365 
Terminal 0.81 48.6 0.486 0.394 
         Average Disability Weight: 0.202 
 
As such, the average disability weight is calculated, stratified by age and sex, as the sum 
of the fraction of cases undergoing each state multiplied by the associated stage disability weight 
for site specific cancers (Flanagan et al, 2005; Melse et al, 2000). Average disability weights for 
site specific cancers, stratified by age and sex interval, in the model are listed in Table 4.2. 
 
                                                 
10 Disability weights in GBD were originally estimated among 10 different expert groups (4 multinational groups of 
health care practitioners) using multi-measure approaches (ie: time trade offs, standard gamble, visual analogue 
scales, and person trade-off methods PTO) with groups from various parts of the world: USA, Mexico, Brazil, 
Morocco, Japan, Netherlands, etc. This approach for health valuation served as the foundation for the Disability 
Weights Project for Diseases in the Netherlands, and continuation of the European Disability Weights Project. 
Correlation coefficients of the 10 studies resulted in a Pearson product correlation coefficient of 0.954. Therefore, 
disability valuations appear quite stable universally despite heterogeneity of respondents (Murray & Lopez, 2000) 
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Table 4.2 Average Disability Weights, by ICD9 Code, disaggregated by age & sex 
ICD9 Code 140-149 150 160-161 162-165 200-203 204-208 
Males       
0-4 n/a n/a n/a 0.148 n/a 0.187 
5-14 n/a n/a n/a 0.194 0.108 0.199 
15-29 0.108 n/a n/a 0.237 0.102 0.249 
30-44 0.132 0.372 0.137 0.327 0.136 0.226 
45-59 0.179 0.384 0.152 0.343 0.171 0.206 
60-69 0.189 0.387 0.157 0.350 0.210 0.233 
70-79 0.178 0.388 0.176 0.361 0.240 0.259 
80+ 0.176 0.396 0.194 0.370 0.263 0.290 
Females       
0-4 n/a n/a n/a 0.115 0.171 0.177 
5-14 0.112 n/a 0.095 n/a 0.099 0.188 
15-29 0.085 n/a 0.111 0.207 0.073 0.227 
30-44 0.119 n/a 0.099 0.314 0.108 0.222 
45-59 0.157 0.353 0.142 0.328 0.151 0.220 
60-69 0.175 0.373 0.158 0.339 0.189 0.219 
70-79 0.183 0.372 0.177 0.351 0.226 0.252 
80+ 0.190 0.392 0.183 0.359 0.259 0.282 
n/a:  average disability weight could not be calculated b/c no cases diagnosed in this age group 
 
4.6. Risk Potency Estimates 
Risk potency values for of the each ambient air toxics are obtained from the International 
Toxicity Estimates for Risk (ITER) database, maintained by the organization for Toxicology 
Excellence and Risk Assessment (TERA). ITER is an electronic database containing quantitative 
and qualitative estimates of human health risk estimates for more then 600 carcinogenic 
environmental substances of health concern to organizations such as the United States 
Environmental Protection Agency (U.S. EPA), RIVM, and Health Canada. 
The potency values (slope factors) for the six carcinogenic air toxics were derived on the 
basis of TC05 and TC01 estimates (tumorigenic concentration) from Health Canada risk 
evaluations, representing exposure concentrations associated with either a 5% of 1% increased 
risk of cancer in human populations, and are consistent with values in the HEIDI II model as 
listed in Table 4.3 
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Table 4.3 Health Canada Inhalation Unit Risk (I.U.R) Cancer Potency Estimates  
Substance CAS # Risk Value Type of Value 
(ug/m3) 
IARC Class 
Acetaldehyde 75-07-0 5.88E-07 I.U.R 2B 
Formaldehyde 50-00-0 5.30E-06 I.U.R 2A 
Benzene 71-43-2 3.50E-06 I.U.R 1 
1,3-Butadiene 106-99-0 5.88E-06 I.U.R 2A 
Ethylene Oxide 75-21-8 2.27E-05 I.U.R 1 
Nickel (dusts) NA-11 1.25E-03 I.U.R 1 
 
Slope factors derived from Health Canada TC values are based on a measure of central 
tendency directly from the dose response curve, and thus express ‘best fit’ estimates of risk in 
contrast to the ‘upper bound’ estimates of risk commonly employed by the US EPA, which 
require additional conservative assumptions (McColl, Hicks et al, 2000). 
 
 
4.7. Concentrations of Ambient Air Toxics 
4.7.1. Current Concentrations 
Annual mean ambient concentrations of acetaldehyde, formaldehyde, benzene, 1,3-BD, 
ETO, and nickel refinery dusts were ascertained for the S.W.O Toronto regions as secondary 
data from the City of Toronto Board of Health reports, Ontario Air Quality Reports, the National 
Air Pollution Surveillance (NAPS) system, Canadian Environmental Protection Agency Priority 
Substance List Profiles, and the HEIDII II model.  Annual mean ambient concentrations (ug/m3) 
in Toronto and S.W.O of the six carcinogenic air toxics, along with the reference source, are 
provided in Table 4.4. Annual mean concentrations were ascertained between the years 2000 to 
2004 for each of the toxics, assumed representative of current concentrations with little 








Toronto   
Acetaldehyde 2.000 CEPA (2000) PSL Report Acetaldehyde 
Formaldehyde 3.300 CEPA (2000) PSL Report Formaldehyde 
Benzene 1.400 Gower, McColl (2007) HEIDI II (data_background); Tom 
Dann, NAPS Annual Data Summary (2003) 
1,3-Butadiene 0.200 NAPS Annual Data Summary (2003) 
Ethylene Oxide 0.059 Ontario Air Quality Report (2004):  
Ethylene = 1.197ug/m3, assume 5% as oxide 
Nickel (dusts) 0.00142 Gower, McColl (2007) HEIDI II (data_background); NAPS 
Annual Report (2002) 
S.W.O  
Acetaldehyde 2.400 CEPA (2000) PSL Report Acetaldehyde; 
Ambient concentration in Windsor 
Formaldehyde 2.605 Ontario Air Quality Report (2001), Windsor value 
Benzene 1.311 Ontario Air Quality Report (2004); 
NAPS Annual Data Summary (2001) 
1,3-Butadiene 0.343 Ontario Air Quality Report (2004); 
NAPS Annual Data Summary (2001) 
Ethylene Oxide 0.175 Ontario Air Quality Report (2004). Ethylene in Sarnia = 
3.5ug/m3, assume 5% as oxide 
Nickel (dusts) 0.00162 Gower, McColl (2007) HEIDI II (data_background); 
NAPS Annual Report (2002) 
 
 
4.7.2. Counterfactual Concentrations 
Counterfactual concentrations of each of the ambient air toxics were ascertained from 
Health Canada PSL reports, Ontario Air Quality Reports, ATSDR, and the US EPA Air Toxics 
Network. The parametric estimates and reference source of concentrations corresponding to 
plausible and feasible minimum risk distributions are provided in Tables 4.5a,b.  
Feasible minimum risk concentrations are generally represented by concentrations that 
have been achieved in rural communities, with minimal air emissions of toxics from either 
industrial or motor vehicle releases. As emissions modelling was beyond the scope of the project, 
it was accepted that feasible minimum risk concentrations generally corresponded to a reduction 
in current concentrations by approximately 50%.  
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Concentrations of the six air toxics corresponding to plausible minimum risk levels were 
ascertained from the US EPA Air Toxics Network as ‘background’ concentrations. Background 
concentrations express contributions to ambient concentrations from natural sources, and 
persistent emissions from past and distant sources. Plausible minimum risk concentrations are 
representative of ambient levels expected if there were no anthropogenic releases of the air 
toxics, corresponding approximately with a 75% reduction in current concentrations. 




Acetaldehyde 1.000 Health Canada PSL Report, average concentrations in rural 
Canada recorded <1ug/m3 
Formaldehyde 1.240 Ontario Air Quality Report (2001), annual mean concentration in 
Windsor 1.24ug/m3 
Benzene 0.600 Health Canada PSL Report (1993), mean concentrations of 
benzene in rural Canada range 0.6 to 1.2ug/m3 
1,3-Butadiene 0.100 Health Canada PSL, mean ambient concentrations of 1,3-BD in 
rural Canada recorded at 0.1ug/m3 
Ethylene Oxide 0.029 Remote locations in California, ETO ranged in concentration 
from 0.029 to 0.36ug/m3 (ATSDR) 
Nickel Refinery 
Dusts 
0.001 Health Canada PSL Report (Tom Dann, 1991), mean 
concentrations in 11 Canadian cities ranged 0.001 to 0.02ug/m3 
 
 




Acetaldehyde 0.511 US EPA Air Toxics Network (1996) Nationwide Assessment 
Acetaldehyde (background concentration) 
Formaldehyde 0.755 US EPA Air Toxics Network (1996) Nationwide Assessment 
Formaldehyde (background concentration) 
Benzene 0.395 US EPA Air Toxics Network (1996) Nationwide Assessment 
Benzene (background concentration) 
1,3-Butadiene 0.050 US EPA Air Toxics Network (1996) Nationwide Assessment 1,3-
Butadiene (background concentration) 
Ethylene Oxide 0.0062 Health Canada Priority Substance List Report 
Nickel Refinery 
Dusts 
0.0002 US EPA Air Toxics Network (1996), rural Michigan mean 






Estimates of the burden of disease from six cancer outcomes in Toronto and S.W.O will 
be presented in two sections: (i) the total BoD analyses, which presents baseline DALY 
estimates, independent of attributable exposure (section 5.1), and (ii) the counterfactual analyses, 
which presents exposure attributable DALY’s, assuming current and counterfactual scenarios 
(section 5.2). 
 
5.1. Phase One Results: DALY Burden of Disease 
The following subsections will present estimates of the disease burden in terms of 
DALY’s from six cancers in the S.W.O and Toronto regions as absolute estimates of site specific 
BoD (section 5.1.1.), and as site-specific rank order based on absolute estimates (5.1.2). Results 
are presented as both crude estimates, and as age and sex stratified estimates to examine the 
impact of alternative social value choices (age weighting and discounting) of the relative 
importance of the six cancers through sensitivity analyses (section 5.1.3.). Although DALY’s 
were calculated with and without the inclusion of age weighting and discounting for the 
sensitivity analysis, the discussion and result tables will assume the inclusion of age weights an 
discounting at a rate of 3%, unless otherwise noted. 
 
5.1.1. Absolute Estimates of the BoD 
A combined total of 32,074.10 DALY’s were lost from six cancer endpoints in the 
Toronto and S.W.O regions in 2001 (84% in Toronto and 16% in S.W.O). Table 5.1 summarizes 
crude estimates of the BoD from cancers of the (i) oral cavity and pharynx, (ii) esophagus, (iii) 
ear, nasal, and larynx, (iv) lung, bronchus, and trachea, (v) lymphomas and multiple myelomas, 
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and (vi) leukemias, in Toronto and S.W.O regions as estimates of Total DALY’s lost and 
DALY’s lost per 100,000 persons. 
Table 5.1 Estimates of the Total BoD and BoD / 100,000 Persons, age & sex aggregated 
 Total DALY’s DALY’s / 100,000 Persons 
TORONTO YLL YLD DALY’s YLL YLD DALY’s 
Oral, Pharynx 1,205.49 260.00 1,465.49 50.73 11.17 31.14
Esophagus 1,357.54 67.98 1,425.53 56.94 2.93 30.29
Ear, Nasal, Larynx 513.51 66.69 580.20 22.27 2.89 12.33
Lung, Bronchus, 
Trachea 
14,782.75 1,169.66 15,952.41 631.56 49.95 338.94
Lymphoma, Multiple 
Myeloma 
4,103.53 811.59 4,915.12 
 
173.80 34.58 104.43
Leukemias 2,352.25 364.30 2,716.55 99.39 15.59 57.72
S.W.O      
Oral, Pharynx 186.13 53.07 239.20 68.24 19.92 44.33
Esophagus 185.67 14.46 200.12 68.04 5.42 37.09
Ear, Nasal, Larynx 114.58 15.05 129.62 43.38 5.62 24.02
Lung, Bronchus, 
Trachea 
3,164.93 256.72 3,391.65 1,166.72 95.35 628.58
Lymphoma, Multiple 
Myeloma 
473.70 97.38 571.09 174.57 36.21 105.84
Leukemias 432.94 54.19 487.13 160.09 20.21 90.28
 
For the six cancer endpoints, results indicate the BoD associated with mortality 
exceedingly outweighs the BoD associated with long term disability, with the YLL component 
dominating the total BoD by approximately nine-fold in S.W.O (4,557.95 YLL’s / 490.87 
YLD’s) and Toronto (24.315.07 YLL’s / 2,740.22 YLD’s)11, consistent with relatively high case 
fatality rates for malignant neoplasm, notably lung and esophagus cancers (CCS, 2006). 
In accordance with a Torontonian population seven and a half times the size of S.W.O 
(Appendix B) the BoD associated with each cancer site in Toronto is expectedly larger then 
S.W.O; however with a standardized population size, the total BoD in S.W.O (930 DALY’s) 
nearly doubles the BoD in Toronto (575 DALY’s), a pattern consistently demonstrated among 
each of cancer site.  
                                                 
11 Results did not involve statistical analysis of association and/or uncertainty 
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Estimates of the disease burdens of the selected cancer sites are presented separately for 
males and females in Tables 5.2a and 5.2b for Toronto and S.W.O. In both the Toronto and 
S.W.O, females experience a greater BoD for all cancer sites excluding middle ear, nasal, and 
larynx; and lung, bronchus, and trachea, yet the total BoD from all sites combined is slightly 
greater among males in both S.W.O (998.73 DALY’s vs. 865.03 DALY’s) and Toronto (617.53 
DALY’s vs. 534.26 DALY’s) when comparing the DALY rates per 100,000 persons. 
Table 5.2a Site-specific DALY’s lost in Toronto, disaggregated by sex 
Males Total DALY’s DALY’s / 100,000 Persons 
Oral cavity & Pharynx 536.22 23.38
Esophagus 365.61 15.94
Middle Ear, Nasal, & Larynx 518.79 22.62
Lung, Bronchus, & Trachea 9,460.02 412.43
Lymphomas & Multiple Myeloma 2,173.08 94.74
Leukemias 1,110.92 48.43
Females  
Oral cavity & Pharynx 929.27 38.51
Esophagus 1,059.92 43.93
Middle Ear, Nasal, & Larynx 61.41 2.55
Lung, Bronchus, & Trachea 6,492.39 269.08
Lymphomas & Multiple Myeloma 2,742.04 113.64
Leukemias 1,605.63 66.55
 
Table 5.2b Site-specific DALY’s lost in S.W.O, disaggregated by sex 
Males Total DALY’s DALY’s / 100,000 Persons 
Oral cavity & Pharynx 90.45 34.42
Esophagus 59.64 22.69
Middle Ear, Nasal, & Larynx 113.09 43.03
Lung, Bronchus, & Trachea 1,907.48 725.79
Lymphomas & Multiple Myeloma 230.65 87.76
Leukemias 223.50 85.04
Females  
Oral cavity & Pharynx 148.75 53.75
Esophagus 140.49 50.76
Middle Ear, Nasal, & Larynx 16.53 5.97
Lung, Bronchus, & Trachea 1484.17 536.27
Lymphomas & Multiple Myeloma 340.44 123.01
Leukemias 263.63 95.26
 
Absolute estimates of site specific DALY’s lost, disaggregated by sex and age grouping, 
are presented in Tables 5.3a through 5.3f. Results may better be presented in Figures 5.1a 
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through 5.6d providing an illustration of the age distribution of DALY’s lost due to site-specific 
cancers throughout the life cycle, with estimates of rates per population size of 100,000 persons. 
When stratified by age group (0-4, 5-14, 15-29, 30-44, 45-59, 60-69, 70-79, and 80+), 
results indicate the BoD associated with cancer in both Toronto and S.W.O regions is relatively 
small prior to the age of 30 and dominate in individuals ages 60+. Interestingly, despite a larger 
Torontonian population, S.W.O experiences a greater absolute burden of lung, bronchus, and 
trachea cancers among females aged 0-4; leukemia’s among males aged 15-29; and middle ear, 
nasal, and larynx cancer among females aged 15-29 and 60-69. Results likely reflect small cell 
sizes with few numbers of incidence and fatal cases among particular age groups. With small 
numbers of incidence and mortality counts, DALY estimates of site specific cancers may be 
easily skewed. Analysis of the BoD between the two regions reveals an inconsistent pattern 
regarding regional dominance cancer site by age distribution, with inconsistent patterns among 




Table 5.3a Estimates of Total DALY’s and DALY’s / 100,000: The Burden of Disease from Cancers of the Oral Cavity & Pharynx in Toronto and 
S.W.O Regions, disaggregated by age and sex  
 Total DALY’s DALY’s / 100,000 
 Males Females Total Males Females Total 
Age S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto 
0-4 0 0 0 0 0 0 0 0 0 0 0 0 
5-14 0 0 0 1.18 0 1.18 0 0 0 0.38 0 0.19 
15-29 0.70 33.04 0.56 2.80 1.26 35.85 1.31 6.99 1.05 0.59 1.18 3.77 
30-44 1.52 68.55 26.71 77.11 28.23 145.66 2.45 11.46 42.60 12.31 22.64 11.89 
45-59 39.86 170.81 39.07 353.19 78.93 524.00 76.33 39.45 73.90 77.01 75.11 58.77 
60-69 30.74 135.49 60.74 288.23 91.47 423.73 144.43 82.31 263.33 159.07 206.28 122.53 
70-79 11.58 79.28 16.72 158.50 28.30 237.78 73.40 72.11 81.03 110.99 77.72 94.08 
80+ 6.05 49.05 4.95 48.26 11.00 97.31 106.76 118.33 41.75 63.04 62.76 82.46 
 
                    
Table 5.3b Estimates of Total DALY’s and DALY’s / 100,000: The Burden of Disease from Cancers of the Esophagus in Toronto and S.W.O Regions, 
disaggregated by age and sex  
 Total DALY’s DALY’s / 100,000 
 Males Females Total Males Females Total 
Age S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto 
0-4 0 0 0 0 0 0 0 0 0 0 0 0 
5-14 0 0 0 0 0 0 0 0 0 0 0 0 
15-29 0 0 0 0 0 0 0 0 0 0 0 0 
30-44 0 27.69 0 123.44 0 151.13 0 4.63 0 19.71 0 12.34 
45-59 5.46 50.85 35.49 398.63 40.94 449.49 10.45 11.74 67.12 86.92 38.96 50.41 
60-69 31.74 134.89 45.54 298.99 77.28 433.88 149.17 81.95 197.43 165.01 174.27 125.47 
70-79 16.69 115.71 47.04 177.38 63.73 293.08 105.76 105.24 227.97 124.21 175.01 115.96 















Table 5.3c Estimates of Total DALY’s and DALY’s / 100,000: The Burden of Disease from Cancers of the Middle Ear, Nasal, and Larynx in Toronto 
and S.W.O Regions, disaggregated by age and sex  
 Total DALY’s DALY’s / 100,000 
 Males Females Total Males Females Total 
Age S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto 
0-4 0 0 0 0 0 0 0 0 0 0 0 0 
5-14 0 0 0 0.51 0 0.51 0 0 0 0.17 0 0.08 
15-29 0 0 0.73 0 0.73 0 0 0 1.37 0 0.68 0 
30-44 0.81 47.13 2.89 27.04 3.70 6.06 1.31 7.88 4.60 4.32 2.97 6.06 
45-59 45.02 194.38 0 16.34 45.02 23.63 86.22 44.89 0 3.56 42.84 23.63 
60-69 48.70 179.58 11.63 1.67 60.33 52.41 228.86 109.10 50.42 0.92 136.05 52.41 
70-79 17.93 81.07 0.97 8.65 18.90 35.50 113.62 73.74 4.70 6.06 51.90 35.50 
80+ 0.63 16.63 0.31 7.20 0.94 20.19 11.08 40.11 2.62 9.40 5.36 20.19 
 
 
Table 5.3d Estimates of Total DALY’s and DALY’s / 100,000: The Burden of Disease from Cancers of Lung, Bronchus, and Trachea in Toronto and 
S.W.O Regions, disaggregated by age and sex L 
 Total DALY’s DALY’s / 100,000 
 Males Females Total Males Females Total 
Age S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto 
0-4 0 0.38 0.32 0 0.32 0.38 0 0.26 2.06 0 1.00 0.13 
5-14 0 0.93 0 0 0 0.93 0 0.28 0 0 0 0.15 
15-29 1.20 1.20 1.17 32.57 2.36 33.77 2.23 0.25 2.18 6.80 2.20 3.55 
30-44 46.23 244.48 75.53 449.29 121.76 693.76 74.59 40.86 120.47 71.74 97.66 56.66 
45-59 495.10 2969.40 453.16 1941.28 948.25 4910.68 948.10 685.79 857.11 423.29 902.33 550.77 
60-69 702.83 3459.62 456.12 1865.20 1158.95 5324.82 3302.78 2101.77 1977.52 1029.39 2613.48 1539.86 
70-79 535.34 2182.74 401.21 1678.93 936.55 3861.67 3392.53 1985.39 1944.30 1175.68 2571.88 1527.89 













Table 5.3e Estimates of Total DALY’s and DALY’s / 100,000: The Burden of Disease from Lymphoma’s and Multiple Myelomas in Toronto and S.W.O 
Regions, disaggregated by age and sex  
 Total DALY’s DALY’s / 100,000 
 Males Females Total Males Females Total 
Age S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto 
0-4 0 0 0 1.18 0 1.18 0 0 0 0.83 0 0.41 
5-14 0.58 76.54 1.04 40.61 1.62 117.16 1.63 23.55 2.86 13.22 2.25 18.53 
15-29 2.73 15.69 0.49 89.81 3.22 105.49 5.07 3.32 0.91 18.76 2.99 11.09 
30-44 5.79 263.81 33.83 306.97 39.63 570.78 9.35 44.09 53.96 49.02 31.78 46.61 
45-59 48.43 539.01 122.60 849.79 171.03 1388.80 92.74 124.48 231.90 185.30 162.75 155.76 
60-69 68.23 602.12 59.31 669.91 127.54 1272.03 320.63 365.80 257.12 369.72 287.60 367.85 
70-79 91.20 451.81 95.51 582.21 186.71 1034.02 577.96 410.96 762.84 407.70 512.73 409.12 




Table 5.3f Estimates of Total DALY’s and DALY’s / 100,000: The Burden of Disease from Leukemia in Toronto and S.W.O Regions, disaggregated by 
age and sex  
50
 Total DALY’s DALY’s / 100,000 
 Males Females Total Males Females Total 
Age S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto S.W.O Toronto 
0-4 1.48 5.92 0 3.38 1.48 9.30 8.90 3.98 0 2.39 4.59 3.20 
5-14 1.02 131.76 2.82 45.01 3.84 176.76 2.89 40.53 7.73 14.65 5.35 27.96 
15-29 64.67 51.92 0 143.06 64.67 194.98 120.06 10.98 0 29.89 60.21 20.49 
30-44 27.33 256.35 75.29 321.62 102.62 577.98 44.09 42.85 120.09 51.36 82.31 47.20 
45-59 39.89 184.80 45.46 340.40 101.56 560.10 76.39 42.68 85.99 74.22 81.22 58.90 
60-69 28.59 203.53 72.97 356.57 101.56 560.10 134.34 123.65 316.37 196.79 229.02 161.97 
70-79 41.28 180.73 48.86 304.82 90.14 485.55 261.57 164.39 236.80 213.45 247.53 192.11 











Figure 5.1a         Figure 5.1b 





































Figure 5.1c        Figure 5.1d 














































Figure 5.2a        Figure 5.2b 




































Figure 5.2c        Figure 5.2d 













































Figure 5.3a        Figure 5.3b 






































Figure 5.3c        Figure 5.3d 53










































Figure 5.4a        Figure 5.4b 




































Figure 5.4c        Figure 5.4d 




































Figure 5.5a        Figure 5.5b 




































Figure 5.5c        Figure 5.5d 55













































Figure 5.6a        Figure 5.6b 


































Figure 5.6c        Figure 5.6d      
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5.1.2. Disease Burden Rankings 
 The DALY model serves as a useful tool for ranking the relative importance of cancer 
sites to the total BoD in Toronto and S.W.O to inform resource allocation and priorities, such 
that disease control strategies and interventions focus on the largest public health issues. 
 In both Toronto and S.W.O regions, cancers of the lung, bronchus, and trachea are the 
leading cause of morbidity and mortality, followed by lymphomas and multiple myelomas, and 
leukemia’s. Table 5.4 describes the leading causes of DALY’s in the two regions in rank order, 
with absolute estimates of total DALY’s [K=1, r=0.03] provided for reference in parenthesis. 
Results clearly indicate identical disease burden rankings between the two regions, despite large 
discrepancies in DALY estimates on an absolute scale. 
Table 5.4 Ranking of the BoD for Site-specific Cancer, age & sex aggregated 
S.W.O Toronto 
Lung, Bronchus, Trachea (3391.62) Lung, Bronchus, Trachea (15952.41) 
Lymphoma’s & Multiple Myeloma (571.09) Lymphoma’s & Multiple Myeloma (4915.12) 
Leukemia’s (487.13) Luekemia’s (2716.55) 
Oral Cavity & Pharynx (239.20) Oral Cavity & Pharynx (1465.49) 
Esophagus (200.12) Esophagus (1425.53) 
Middle Ear, Nasal, and Larynx (129.62) Middle Ear, Nasal, and Larynx (138.30) 
 
Tables 5.5a and 5.5b present the leading cause of disease in descending order, separately 
for males and females by age distribution. Absolute quantities of DALY estimates were provided 
in Tables 5.3a through 5.3f for reference.  
The rankings of the disease burden from all cancer sites during younger age groups (0-
29) demonstrate inconsistent patterns between males and females in Toronto and S.W.O regions, 
again reflecting the small disease burden during youth. Among individuals aged 30-44 years, 
males and females in S.W.O experience identically ranked disease burdens from the six cancer 
sites; Toronto generates different relative rankings among this age group, however the three sites 
with the largest burdens are consistent with both S.W.O, and the age and sex aggregated ranks 
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(Table 5.4). Relative rankings in Toronto and S.W.O during the ages 45-59 are also consistent 
with age and sex aggregated BoD rankings (Table 5.4), with the exception of middle ear, nasal, 
and larynx cancers among males. During the oldest age groups when cancer is most prominent, 
individuals aged 60-69 and 70-79 consistently rank lung, bronchus, and trachea cancers; 
lymphomas and multiple myeloma; and leukemia’s as the leading cause of morbidity and 
mortality in both regions. Similarly in the oldest age group (80+), individuals experience the 
largest health impacts from the aforementioned cancers with a reversal of the 2nd and 3rd rankings 

































Table 5.5a Ranking of Site-specific BoD in Toronto, sex and age disaggregated1
Age Males Females 
0-4        1 Luekemias  Leukemia’s  
             2 Lung, Bronchus, Trachea  Lymphoma’s  
             3 Oral Cavity & Pharynx;  
Esophagus;  
Middle Ear, Nasal, & Larynx;  
Lymphomas  
Oral Cavity & Pharynx;  
Esophagus;  
Middle Ear, Nasal, &Larynx;  
Lung, Bronchus, & Trachea  
5-14      1 Leukemias  Leukemia’s  
             2 Lymphomas & Multiple Myelomas Lymphoma’s & Multiple Myelomas  
             3 Lung, Bronchus, & Trachea Oral Cavity & Pharynx 
             4 Oral Cavity & Pharynx;  
Esophagus;  
Middle Ear, Nasal, & Larynx 
Middle Ear, Nasal, & Larynx 
             5  Esophagus; 
Lung, Bronchus, & Trachea 
15-29    1   Leukemia’s  Leukemia’s  
             2 Oral Cavity & Pharynx  Lymphoma’s & Multiple Myeloma’s 
             3 Lymphomas & Multiple Myelomas  Lung, Bronchus & Trachea  
             4 Lung, Bronchus, & Trachea  Oral Cavity & Pharynx  
             5 Esophagus;  
Middle Ear, Nasal, & Larynx  
Esophagus;  
Middle Ear, Nasal, & Larynx  
30-44    1 Lymphoma’s & Multiple Myeloma’s  Lung, Bronchus, & Trachea  
             2 Leukemia’s  Leukemia’s  
             3 Lung, Bronchus, & Trachea  Lymphoma’s & Multiple Myeloma’s  
             4 Oral Cavity & Pharynx  Esophagus 
             5 Middle Ear, Nasal, & Larynx  Oral Cavity & Pharynx 
             6 Esophagus  Middle Ear, Nasal, & Larynx  
45-59    1 Lung, Bronchus & Trachea  Lung, Bronchus, & Trachea  
             2 Lymphoma’s & Multiple Myeloma’s  Lymphoma’s & Multiple Myeloma’s  
             3 Middle Ear, Nasal, & Larynx  Esophagus  
             4 Leukemia’s  Oral Cavity & Pharyx  
             5 Oral Cavity & Pharynx  Leukemia’s  
             6 Esophagus  Middle Ear, Nasal, & Larynx  
60-69    1 Lung, Bronchus, & Trachea  Lung, Bronchus, & Trachea  
             2  Lymphoma’s & Multiple Myeloma’s Lymphoma’s & Multiple Myeloma  
             3 Leukemia’s  Leukemia’s  
             4 Middle Ear, Nasal, & Larynx  Esophagus  
             5 Oral Cavity & Pharynx  Oral Cavity & Pharynx  
             6 Esophagus  Middle Ear, Nasal, & Larynx  
70-79    1 Lung, Bronchus, & Trachea  Lung, Bronchus, & Trachea 
             2 Lymphoma’s & Multiple Myeloma  Lymphomas & Multiple Myeloma  
             3 Leukemias  Luekemias  
             4 Esophagus  Esophagus  
             5 Middle Ear, Nasal, & Larynx  Oral Cavity & Pharynx  
             6 Oral Cavity & Pharynx  Middle Ear, Nasal, & Larynx  
80+       1  Lung, Bronchus, & Trachea  Lung, Bronchus, & Trachea  
             2 Lymphomas & Multiple Myeloma  Lymphoma’s & Multiple Myeloma  
             3 Leukemia’s  Leukemia’s  
             4 Oral Cavity & Pharynx  Esophagus  
             5 Esophagus  Oral Cavity & Pharynx  
             6 Middle Ear, Nasal, & Larynx  Middle Ear, Nasal, & Larynx  
1 Absolute quantities can be found in Tables 5.3a through 5.3f 
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Table 5.5b Ranking of Site-specific BoD in S.W.O, sex and age disaggregated1
Age Males Females 
0-4        1 Luekemias  Lung, Bronchus, & Trachea 
             2 Oral Cavity & Pharynx;  
Esophagus;  
Middle Ear, Nasal & Larynx;  
Lung, Bronchus, & Trachea;  
Lymphoma’s & Multiple Myeloma  
Oral Cavity & Pharynx;  
Esophagus; 
Middle Ear, Nasal, & Larynx;  
Lymphomas & Multiple Myeloma;  
Leukemia’s  
5-14      1 Leukemia’s  Leukemia’s  
             2 Lymphomas & Multiple Myeloma  Lymphoma’s & Multiple Myeloma  
             3 Oral Cavity & Pharynx;  
Esophagus;  
Middle Ear, Nasal, & Larynx;  
Lung, Bronchus & Trachea  
Oral Cavity & Pharynx;  
Esophagus;  
Middle Ear, Nasal & Larynx;  
Lung, Bronchus & Trachea  
15-29    1 Leukemia’s  Lung, Bronchus, & Trachea  
             2 Lymphoma’s  Middle Ear, Nasal, & Larynx 
             3 Lung, Bronchus, & Trachea  Oral Cavity & Pharynx  
             4 Oral Cavity & Pharynx  Lymphomas  
             5 Esophagus;  
Middle Ear, Nasal  & Larynx  
Leukemia’s;  
Esophagus  
30-44    1  Lung, Bronchus, & Trachea  Lung, Bronchus & Trachea  
             2 Leukemia’s  Leukemia’s  
             3  Lymphoma’s  Lymphoma’s  
             4 Oral Cavity & Pharynx  Oral Cavity & Pharynx  
             5 Middle Ear, Nasal, & Larynx Middle Ear, Nasal, & Larynx  
             6 Esophagus  Esophagus  
45-59    1 Lung, Bronchus, & Trachea  Lung, Bronchus, & Trachea  
             2 Lymphoma’s  Lymphoma’s  
             3 Middle Ear, Nasal, & Larynx  Leukemia’s  
             4 Leukemia’s  Oral Cavity & Pharynx  
             5 Oral Cavity & Pharynx  Esophagus  
             6 Esophagus  Middle Ear, Nasal, & Larynx  
60-69    1 Lung, Bronchus, & Trachea  Lung, Bronchus, & Trachea  
             2 Lymphoma’s  Leukemia’s  
             3 Middle Ear, Nasal, & Larynx  Oral Cavity & Pharynx  
             4 Esophagus  Lymphoma’s  
             5 Oral Cavity & Pharynx  Esophagus  
             6 Leukemia’s  Middle Ear, Nasal, & Larynx  
70-79    1 Lung, Bronchus, & Trachea  Lung, Bronchus, & Trachea  
             2 Lymphoma’s  Lymphoma’s  
             3 Leukemia’s  Leukemia’s  
             4 Middle Ear, Nasal, & Larynx  Esophagus  
             5 Esophagus  Oral Cavity & Pharynx  
             6 Oral Cavity & Pharynx  Middle Ear, Nasal, & Larynx  
80+       1 Lung, Bronchus, & Trachea  Lung, Bronchus, & Trachea  
             2 Leukemia’s  Lymphoma’s  
             3 Lymphoma’s  Leukemia’s  
             4 Oral Cavity & Pharynx  Esophagus  
             5 Esophagus Oral Cavity & Pharynx  
             6 Middle Ear, Nasal, & Larynx  Middle Ear, Nasal, & Larynx 
1 Absolute quantities can be found in Tables 5.3a through 5.3f 
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5.1.3. Sensitivity Analysis 
The impacts of incorporating social value choices in the DALY model (age weighting 
K=1, and discounting r=0.03) on site-specific disease burden rankings, and absolute estimates of 
DALY’s was examined through sensitivity analysis. Tables 5.6a and 5.6b present the disease 
ranks in S.W.O and Toronto regions assuming four alternative value choice scenarios: (i) without 
age weighting or discounting, (ii) with age weights, no discount rate, (iii) discounting, no age 
weights, and (iv) both age weighting and discounting.  
Results in S.W.O demonstrate no difference on the relative order of health impacts from 
site-specific cancers when alternative value assumptions are included in the analysis. In Toronto, 
the age-weight reverses the relative importance of health impacts from esophagus and oral 
cancers, between fourth and fifth ranks when a discount rate is not applied to counter balance the 
impact; however, the three leading causes of DALY’s remain unchanged. 
 
Table 5.6a BoD Rankings in S.W.O with Alternative Value Choices, age-weights and discount rate 
K=0, r=0 K=1, r=0 K=0, r=0.03 K=1, r=0.03 
Lung, Bronchus, & 
Trachea  
(6678.94) 
Lung, Bronchus, & 
Trachea  
(4192.25) 
Lung, Bronchus, & 
Trachea  
(5193.91) 























Oral Cavity & Pharynx 
(438.13) 
Oral Cavity & Pharynx 
(308.55) 
Oral Cavity & Pharynx 
(326.27) 










Middle Ear, Nasal, & 
Larynx  
(227.71) 
Middle Ear, Nasal, & 
Larynx  
(156.16) 
Middle Ear, Nasal, & 
arynx 
 (173.93) 










Table 5.6b BoD Rankings in Toronto with Alternative Value Choices, age-weights and discount rate 
K=0, r=0 K=1, r=0 K=0, r=0.03 K=1, r=0.03 
Lung, Bronchus, & 
Trachea  
(31166.05) 
Lung, Bronchus, & 
Trachea  
(19857.16) 
Lung, Bronchus, & 
Trachea  
(24060.50) 





























Oral Cavity & Pharynx 
(1465.49) 








Middle Ear, Nasal, & 
Larynx  
(261.13) 
Middle Ear, Nasal, & 
Larynx  
(159.69) 
Middle Ear, Nasal, & 
Larynx  
(211.17) 




A graphical display of impacts associated with age-weighting and discounting on DALY 
estimates throughout the life cycle are provided for S.W.O and Toronto in Figures 5.7a through  
5.12b. The charts illustrate the estimates of DALY’s calculated as rates per population of 
100,000. Absolute estimates are found in Appendix I for reference. 
Results clearly demonstrate the application of age weights has a greater impact on DALY 
estimates compared to the time preference of a positive discount rate of three percent. Age 
weights produce DALY estimates giving greater weight to disease during young adulthood (ages 
5-14 and 15-29) and less weight to disease in the youngest and oldest ages (0-4, 30-44, 45-59, 





Figure 5.7a        Figure 5.7b 
















































Figure 5.8a        Figure 5.8b 























































Figure 5.9a        Figure 5.9b 




















































Figure 5.10a        Figure 5.10b 

























































Figure 5.11a        Figure 5.11b 

















































Figure 5.12a        Figure 5.12b 


















































5.2. Phase Two Results: Exposure Attributable Health Impacts 
Results of the attributable BoD model are presented as crude estimates of the cancer 
burden in Toronto and S.W.O attributable to chronic inhalation exposure to current (section 
5.2.1) and alternative reduced concentrations (section 5.2.2) of acetaldehyde, formaldehyde, 
benzene, 1,3-butadiene, ethylene oxide, and nickel refinery dusts. Sensitivity analysis of the 
attributable BoD results with alternative DALY value choices (age weighting and discounting) 
on the relative importance of current and alternative ambient exposures to the total BoD is 
presented in sub-sections 5.2.1.3 and 5.2.2.2. 
 Results are presented as crude estimates of the exposure attributable BoD separately for 
males and females without stratifying by age, since risk was assumed constant through life. The 
exposure attributable BoD tables and discussion are again presented with the application of age 
weighting and a 3% discount rate, unless otherwise noted. 
 
5.2.1. Exposure Attributable Disease Burden (Current Concentrations) 
The disease burden attributable to exposure to current environmental concentrations of 
acetaldehyde, formaldehyde, benzene, 1,3-BD, ETO, and nickel refinery dusts in Toronto and 
S.W.O was quantified in terms of DALY’s by means of attributable fractions (A.F) (Equation 9). 
The attributable fractions listed in Table 5.7 were derived as estimates of the proportion of 
disease attributable to current long term annual mean ambient concentrations in Toronto and 





Table 5.7 Attributable fraction of DALY’s for related Cancers associated with current concentrations 
(annual ambient mean ug/m3) of each of the air toxics  
 Substance 
Region Acetaldehyde Formaldehyde Benzene 1,3-BD ETO Nickel (dusts) 
Toronto       
Males 1.49E-03 2.24E-02 6.28E-03 1.51E-03 1.72E-03 2.28E-03 
Females 1.40E-03 2.11E-02 5.90E-03 1.42E-03 1.61E-03 2.14E-03 
S.W.O       
Males 1.78E-03 1.80E-02 5.88E-03 2.59E-03 5.09E-03 2.60E-03 
Females 1.68E-03 1.69E-02 5.53E-03 2.43E-03 4.79E-03 2.44E-03 
 
As males have a lower life expectancy then females (Appendix D) but assumed exposed 
to the same ubiquitous concentrations of air toxics, the fraction of disease attributable to each 
exposure is constantly higher among males then females within each of the regions. Between the 
two regions, S.W.O has larger A.F’s for disease associated with current exposure to four of the 
air toxics: acetaldehyde, 1,3-BD, ETO and nickel refinery dusts; whereas Toronto has larger 
A.F’s for males and females from exposure to formaldehyde and benzene, reflecting the 
predominant toxics concentrations in the regions (Table 4.4).  The largest discrepancy in the 
A.F’s between Toronto and S.W.O results from exposure to ETO, reflecting the difference in the 
environmental concentration (ug/m3) between the regions. The toxic with the largest A.F for 
cancer (formaldehyde) reflects its elevated concentration in both S.W.O and Toronto (Table 4.4), 
and the toxic with the lowest attributable fraction (acetaldehyde), reflects a lower potency value 
and classification of a possible rather then probable or known human carcinogen. 
 
5.2.1.1. Absolute Estimates of the Exposure Attributable BoD  
Absolute estimates of the BoD attributable to current environmental concentrations of 
acetaldehyde, formaldehyde, benzene, 1,3-BD, ETO, and nickel refinery dusts in Toronto and 
S.W.O regions are presented in Tables 5.8a (total) and 5.8b (standardized), on the basis of site-
specific cancer associations as determined through literature review (Table 3.1)  
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Overall, current exposures to the six carcinogenic air toxics in Toronto and S.W.O are 
responsible for 0.58%12 of the total BoD from the six cancer endpoints. Consistent with a greater 
total DALY BoD in S.W.O (Phase 1) the exposure attributable BoD in S.W.O (5.60 DALY’s) is 
again nearly double that in Toronto (3.30 DALY’s) when calculated as a rate per 100,000 
persons. The exposure attributable BoD was also slightly greater among males then females in 
both Toronto (5.91 DALY’s vs. 5.30 DALY’s) and S.W.O (3.48 DALY’s vs. 3.18 DALY’s) per 
100,000 persons. 
Table 5.8a Estimates of the Exposure Attributable BoD: Absolute DALY Estimates in S.W.O and Toronto, 
disaggregated by sex 
  S.W.O Toronto 
Substance Site-specific Cancers Males Females Total Males Females Total 
Acetaldehyde Oral Cavity & Pharynx 0.161 0.249 0.411 0.797 1.299 2.096
 Esophagus 0.106 0.236 0.342 0.544 1.481 2.025
 Ear, Nasal, & Larynx 0.202 0.028 0.230 0.772 0.086 0.857
 Total 0.470 0.513 0.982 2.113 2.866 4.979
Formaldehyde Oral Cavity & Pharynx 1.629 2.517 4.416 12.024 19.582 31.606
 Ear, Nasal, & Larynx 2.036 0.280 2.316 11.633 1.294 12.927
 Total 3.665 2.797 6.642 23.657 20.876 44.532
Benzene Lymphomas & 
Multiple Myeloma 
1.357 1.882 3.239 13.651 16.188 29.839
 Leukemia’s 1.315 1.457 2.772 6.979 9.479 16.458
 Total 2.672 3.339 6.011 20.630 25.667 46.297
1,3-Butadiene Lymphoma’s & 
Multiple Myeloma 
0.596 0.827 1.424 3.276 3.885 7.161
 Leukemia’s 0.578 0.641 1.219 1.657 2.275 3.950
 Total 1.174 1.468 2.642 4.951 6.160 11.111
Ethylene Oxide Lymphoma’s & 
Multiple Myeloma 
1.175 1.629 2.804 3.731 4.425 8.156
 Leukemia’s 1.138 1.262 2.400 1.908 2.591 4.498
 Total 2.313 2.891 5.204 5.639 7.015 12.654
Nickel (dusts) Lung, Bronchus, & 
Trachea 
4.952 3.621 8.573 21.528 13.884 35.412
 Ear, Nasal, Larynx 0.294 0.040 0.334 11.810 0.131 1.312








                                                 
12 Attributable percent calculated as follows: total exposure attributable DALY’s / total baseline DALY’s X 100% 
(ie: 187 DALY’s / 32,074 DALY’s X 100% = 0.58% of disease is attributable to current exposures) 
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Table 5.8b Estimates of the Exposure Attributable BoD: DALY’s / 100,000 persons in S.W.O and Toronto, 
disaggregated by sex 
  S.W.O Toronto 
Substance Site-specific Cancers Males Females Total Males Females Total 
Acetaldehyde Oral Cavity & Pharynx 0.061 0.090 0.076 0.035 0.054 0.045
 Esophagus 0.040 0.085 0.063 0.024 0.061 0.043
 Ear, Nasal, & Larynx 0.077 0.010 0.043 0.034 0.004 0.018
 Total 0.179 0.185 0.182 0.092 0.119 0.106
Formaldehyde Oral Cavity & Pharynx 0.620 0.910 0.768 0.524 0.812 0.672
 Ear, Nasal, & Larynx 0.775 0.101 0.429 0.507 0.054 0.275
 Total 1.395 1.011 1.198 1.031 0.865 0.946
Benzene Lymphomas & 
Multiple Myeloma 
0.516 0.680 0.600 0.595 0.671 0.634
 Leukemia’s 0.500 0.527 0.514 0.304 0.393 0.350
 Total 1.017 1.207 1.114 0.899 1.064 0.984
1,3-Butadiene Lymphoma’s & 
Multiple Myeloma 
0.227 0.299 0.264 0.143 0.161 0.152
 Leukemia’s 0.220 0.231 0.226 0.073 0.094 0.084
 Total 0.447 0.530 0.490 0.216 0.255 0.236
Ethylene Oxide Lymphoma’s & 
Multiple Myeloma 
0.447 0.589 0.520 0.063 0.183 0.173
 Leukemia’s 0.433 0.456 0.445 0.083 0.107 0.096
 Total 0.880 1.045 0.964 0.246 0.291 0.269
Nickel (dusts) Lung, Bronchus, & 
Trachea 
1.884 1.308 1.589 0.939 0.575 0.752
 Ear, Nasal, Larynx 0.112 0.015 0.062 0.051 0.005 0.028
 Total 1.996 1.323 1.651 0.990 0.58 0.780
 
5.2.1.2. Rankings of the Exposure Attributable BoD 
The rank order of relative importance of the six carcinogenic air toxics contributions to 
the total BoD is presented in descending order in Table 5.9 disaggregated by sex, to inform 
public health policy regarding the exposures of highest priority for reduction on the basis of the 
magnitude of associated health impacts. Absolute estimates of exposure attributable DALY’s can 
be found in Tables 5.8a for reference. 
Table 5.9 Rank ordering of the importance of the six ambient air toxics to the BoD in Toronto and S.W.O on 
the basis of associated health impacts, disaggregated by sex 
S.W.O Toronto 
Males Females Total Males Females Total 
Nickel  Nickel  Nickel  Formaldehyde  Benzene  Benzene  
Formaldehyde  Benzene  Formaldehyde  Nickel Formaldehyde  Formaldehyde 
Benzene  Ethylene Oxide  Benzene  Benzene  Nickel  Nickel 
Ethylene Oxide  Formaldehyde  Ethylene Oxide  Ethylene Oxide  Ethylene Oxide  Ethylene Oxide  
1,3-Butadiene  1,3-Butadiene  1,3-Butadiene  1,3-Butadiene  1,3-Butadiene  1,3-Butadiene  
Acetaldehyde  Acetaldehyde  Acetaldehyde  Acetaldehyde  Acetaldehyde  Acetaldehyde  
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 In S.W.O results indicate that the current environmental concentration of nickel refinery 
dust is clearly the priority for reduction among both males and females, on the basis of the 
current total attributable health impacts, 8.91 DALY’s. In Toronto, the foremost air toxic of 
priority for exposure reduction is less evident with inconsistency between males and females, 
and relatively similar contributions to the total BoD from ambient concentrations of benzene 
(46.30 DALY’s) and formaldehyde (44.53 DALY’s). In both regions, the top three priorities for 
exposure reduction are formaldehyde, benzene, and nickel refinery dusts; whereas current 
concentrations of ETO, 1,3-BD, and acetaldehyde appear of lesser public health concern, with 
minor inconsistencies in rank orders between the sexes. 
 
5.2.1.3. Sensitivity Analysis 
As presented in Table 5.10a and 5.10b, the rank order of air toxics for priority reduction, 
based on the BoD attributable to current environmental concentrations, is relatively insensitive to 
the impact of incorporating alternative value choices (age-weight or discount rate) in the DALY 
estimates. The only exception is a reversed order of importance of benzene and formaldehyde in 
S.W.O between the 2nd and 3rd rank priority for exposure reduction, pending the application of 
age weights. Tables 5.10a and 5.10b present the ranks of air toxics ranks in descending order of 








Table 5.10a Ranking of Exposure Attributable Health Impacts under Alternative Value Choices (age-weights 
and discount rate) in S.W.O 

























Ethylene Oxide  
(10.08) 
Ethylene Oxide  
(6.80) 
Ethylene Oxide  
(7.60) 



















Table 5.10b Ranking of Exposure Attributable Health Impacts under Alternative Value Choices (age-weights 
and discount rate) in Toronto 

























Ethylene Oxide  
(24.21) 
Ethylene Oxide  
(16.85) 
Ethylene Oxide  
(17.92) 




















5.2.2. Counterfactual Scenarios: 
Hypothetical exposure scenarios of the six carcinogenic air toxics were modeled for 
concentrations associated with plausible and feasible minimum risk levels to predict the 
magnitude of the BoD that could be avoided in the future if present ambient concentrations are 
reduced, fitting with the relevant latency time lag between the exposure and the cancer. 
Attributable fractions associated with feasible and plausible minimum risk concentrations 
of the six carcinogenic air toxics are presented in tables 5.11a and 5.11b for males and females, 
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based on alternative chronic exposure concentrations determined through literature review 
(Tables 4.5a,b) and risk potency values as derived from Health Canada risk evaluations. 
Table 5.11a Attributable fraction of DALY’s for related Cancers, associated with a feasible minimum risk 
concentration of each air toxic 
 Substance 
 Acetaldehyde Formaldehyde Benzene 1,3-BD ETO Nickel (dusts) 
Males 7.44E-04 8.43E-03 2.69E-03 7.54E-04 8.44E-04 1.60E-03 
Females 6.99E-04 7.92E-03 2.53E-03 7.08E-04 7.93E-04 1.51E-03 
 
 
Table 5.11b Attributable fraction of DALY’s for related Cancers, associated with a plausible minimum risk 
concentration of each air toxic 
 Substance 
 Acetaldehyde Formaldehyde Benzene 1,3-BD ETO Nickel (dusts) 
Males 3.80E-04 5.13E-03 1.77E-03 3.77E-04 1.80E-04 3.21E-04 
Females 3.57E-04 4.82E-03 1.67E-03 3.54E-04 1.70E-04 3.01E-04 
 
As the alternative ambient concentrations for the plausible and feasible exposure 
distributions were the same (ug/m3) for the Toronto and S.W.O regions, the A.F’s for site-
specific disease for males and females were also the same for the two regions. 
 
5.2.2.1. Estimates of the Avoidable Disease Burden 
The attributable BoD (DALY’s / 100,000 persons) from the six cancer sites, associated 
with alternative reduced ambient concentrations of each of the six air toxics, are presented in 
Tables 5.12a,b (feasible minimum risk concentrations) and 5.13a,b (plausible minimum risk 
concentrations) for males and females in Toronto and S.W.O. Tables 5.12 and 5.13 also 
summarize the percent reduction in the current attributable disease burden if current 





Table 5.12a Attributable BoD / 100,000 Persons in S.W.O, assuming concentrations associated with feasible 
minimum risk distributions 
Substance Site-specific Cancers Males Females Total Reduction % Reduce 
Acetaldehyde Oral Cavity & Pharynx 0.026 0.038 0.032 0.044 
 Esophagus 0.017 0.035 0.026 0.037 
 Ear, Nasal, & Larynx 0.032 0.004 0.018 0.025 
 Total 0.074 0.077 0.076 0.106 58.33
Formaldehyde Oral Cavity & Pharynx 0.290 0.426 0.360 0.409 
 Ear, Nasal, & Larynx 0.363 0.047 0.201 0.228 
 Total 0.653 0.473 0.560 0.637 53.21
Benzene Lymphomas & 
Multiple Myeloma 
0.236 0.311 0.275 0.326 
 Leukemia’s 0.229 0.241 0.235 0.279 
 Total 0.465 0.552 0.510 0.604 54.23
1,3-Butadiene Lymphoma’s & 
Multiple Myeloma 
0.066 0.087 0.077 0.187 
 Leukemia’s 0.064 0.067 0.066 0.160 
 Total 0.130 0.155 0.143 0.347 70.85
Ethylene Oxide Lymphoma’s & 
Multiple Myeloma 
0.074 0.098 0.086 0.434 
 Leukemia’s 0.072 0.076 0.074 0.371 
 Total 0.146 0.173 0.160 0.805 83.43
Nickel (dusts) Lung, Bronchus, & 
Trachea 
1.163 0.808 0.981 0.608 
 Ear, Nasal, Larynx 0.069 0.009 0.038 0.024 
 Total 1.232 0.817 1.019 0.632 38.27
 
Table 5.12b Attributable BoD / 100,000 Persons in Toronto assuming concentrations of air toxics associated 
with a feasible minimum risk distribution 
Substance Site-specific Cancers Males Females Total Reduction % Reduce 
Acetaldehyde Oral Cavity & Pharynx 0.017 0.027 0.022 0.022 
 Esophagus 0.012 0.031 0.022 0.022 
 Ear, Nasal, & Larynx 0.017 0.002 0.009 0.009 
 Total 0.046 0.060 0.053 0.053 49.95
Formaldehyde Oral Cavity & Pharynx 0.197 0.305 0.252 0.419 
 Ear, Nasal, & Larynx 0.191 0.020 0.103 0.171 
 Total 0.388 0.325 0.356 0.591 62.42
Benzene Lymphomas & 
Multiple Myeloma 
0.255 0.288 0.272 0.362 
 Leukemia’s 0.130 0.168 0.150 0.200 
 Total 0.385 0.456 0.422 0.562 57.14
1,3-Butadiene Lymphoma’s & 
Multiple Myeloma 
0.071 0.081 0.076 0.076 
 Leukemia’s 0.037 0.047 0.042 0.042 
 Total 0.108 0.128 0.118 0.118 50.00
Ethylene Oxide Lymphoma’s & 
Multiple Myeloma 
0.080 0.090 0.085 0.088 
 Leukemia’s 0.041 0.053 0.047 0.049 
 Total 0.121 0.143 0.132 0.137 50.85
Nickel (dusts) Lung, Bronchus, & 
Trachea 
0.661 0.405 0.530 0.223 
 Ear, Nasal, Larynx 0.036 0.004 0.020 0.008 
 Total 0.697 0.409 0.549 0.231 29.58
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Table 5.13a Attributable BoD / 100,000 Persons in S.W.O, disaggregated by sex, assuming concentrations 
associated with a Plausible minimum risk distribution 
Substance Site-specific Cancers Males Females Total Reduction % Reduce 
Acetaldehyde Oral Cavity & Pharynx 0.013 0.020 0.017 0.059 
 Esophagus 0.009 0.018 0.013 0.050 
 Ear, Nasal, & Larynx 0.016 0.002 0.009 0.033 
 Total 0.038 0.041 0.039 0.143 78.36
Formaldehyde Oral Cavity & Pharynx 0.177 0.259 0.219 0.549 
 Ear, Nasal, & Larynx 0.211 0.029 0.122 0.307 
 Total 0.397 0.288 0.341 0.856 71.51
Benzene Lymphomas & 
Multiple Myeloma 
0.156 0.205 0.181 0.419 
 Leukemia’s 0.151 0.159 0.155 0.359 
 Total 0.306 0.364 0.336 0.778 69.87
1,3-Butadiene Lymphoma’s & 
Multiple Myeloma 
0.033 0.044 0.038 0.225 
 Leukemia’s 0.032 0.034 0.033 0.193 
 Total 0.065 0.077 0.071 0.418 85.42
Ethylene Oxide Lymphoma’s & 
Multiple Myeloma 
0.016 0.021 0.018 0.501 
 Leukemia’s 0.015 0.016 0.016 0.429 
 Total 0.031 0.037 0.1034 0.930 96.46
Nickel (dusts) Lung, Bronchus, & 
Trachea 
0.233 0.162 1.96 1.393 
 Ear, Nasal, Larynx 0.014 0.002 0.008 0.054 
 Total 0.246 0.163 0.204 1.447 87.65
 
Table 5.13b Attributable BoD / 100,000 Persons in Toronto, disaggregated by sex, assuming concentrations of 
air toxics associated with a Plausible minimum risk distribution 
Substance Site-specific Cancers Males Females Total Reduction % Reduce 
Acetaldehyde Oral Cavity & Pharynx 0.009 0.014 0.011 0.033 
 Esophagus 0.006 0.016 0.011 0.032 
 Ear, Nasal, & Larynx 0.009 0.001 0.005 0.014 
 Total 0.024 0.030 0.027 0.079 74.45
Formaldehyde Oral Cavity & Pharynx 0.120 0.186 0.154 0.518 
 Ear, Nasal, & Larynx 0.116 0.012 0.063 0.212 
 Total 0.263 0.198 0.216 0.730 77.12
Benzene Lymphomas & 
Multiple Myeloma 
0.168 0.189 0.179 0.455 
 Leukemia’s 0.086 0.118 0.102 0.247 
 Total 0.254 0.307 0.281 0.702 71.71
1,3-Butadiene Lymphoma’s & 
Multiple Myeloma 
0.036 0.040 0.038 0.144 
 Leukemia’s 0.018 0.024 0.021 0.063 
 Total 0.054 0.064 0.059 0.177 75.00
Ethylene Oxide Lymphoma’s & 
Multiple Myeloma 
0.017 0.019 0.018 0.155 
 Leukemia’s 0.009 0.011 0.010 0.086 
 Total 0.026 0.031 0.028 0.241 89.49
Nickel (dusts) Lung, Bronchus, & 
Trachea 
0.132 0.081 0.106 0.646 
 Ear, Nasal, Larynx 0.007 0.001 0.004 0.024 
 Total 0.139 0.082 0.110 0.670 85.92
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If current concentrations of each of the six toxics were reduced to concentrations 
associated with a feasible minimum level of risk, results indicate a total of 3.13 DALY’s per 
100,000 persons in S.W.O, and 1.63 DALY’s per 100,000 persons in Toronto could be avoided 
in the future, such that the exposure attributable BoD would be reduced to 0.28%13 of the total 
burden. 
Reducing ambient concentrations of ethylene oxide in S.W.O and formaldehyde in 
Toronto to feasible concentrations would predict the greatest reduction in the BoD from 
lymphohematopoeitic cancers S.W.O (0.81 DALY’s per 100,000), and head and neck cancers in 
Toronto (0.59 DALY’s / 100,000 persons). Ambient concentrations of nickel would be 
responsible for the largest BoD of all the exposures under a feasible distribution (1.02 DALY’s 
per 100,000 persons in S.W.O and 0.55 DALY’s per 100,000 persons in Toronto), associated 
with lung and respiratory cancers. 
If ambient concentrations of the six air toxics were further reduced to a plausible level of 
risk (ie: if there were no anthropogenic releases of toxics into the environment), the model 
predicts a total of 4.57 DALY’s per 100,000 persons in S.W.O and 2.60 DALY’s per 100,000 
persons in Toronto would be avoidable in the future, such that only 0.12% of the total BoD 
would be attributable to natural sources of air toxics in the ambient environment (a total 
reduction of 0.46%14 from the BoD from current exposures). The greatest reduction in the 
exposure attributable BoD would occur by reducing the burden from lung and respiratory 
cancers associated with ambient nickel concentrations in S.W.O (1.45 DALY’s / 100,000 
persons) and head and neck cancers associated with ambient formaldehyde in Toronto (0.730 
DALY’s  / 100,000 persons). 
                                                 
13 96 DALY’s avoidable. Therefore: 96 DALY’s / 32,074 DALY’s X 100% = 0.30% of BoD avoidable.  
14 147 DALY’s avoidable. Therefore: 147 DALY’s / 32,074 DALY’s X 100% = 0.46% of the BoD is avoidable 
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Assuming plausible minimum risk concentrations of each of the air toxics, ambient 
exposure to formaldehyde in S.W.O (0.34 DALY’s / 100,000 persons) and benzene in Toronto 
(0.28 DALY’s / 100,000 persons) would be associated with the largest health impacts. The 
complete rank order of the relative importance of the six carcinogenic air toxics to the BoD, 
assuming the counterfactual distributions is reviewed in Table 5.14 with absolute estimates of the 
total attributable DALY’s found in Tables 5.12 and 5.13 for reference 
Table 5.14 Ranked order of the air toxics contributing to the disease burden in S.W.O and Toronto, assuming 
concentrations associated with feasible and plausible minimum risk levels 
Feasible Minimum Risk Plausible Minimum Risk 
SWO Toronto SWO Toronto 
Nickel  Nickel  Formaldehyde Benzene 
Formaldehyde Benzene Benzene  Formaldehyde 
Benzene Formaldehyde  Nickel  Nickel  
Ethylene Oxide  Ethylene Oxide  1,3-Butadiene  1,3-Butadiene  
1,3-Butadiene  1,3-Butadiene  Acetaldehyde Ethylene Oxide 
Acetaldehyde  Acetaldehyde  Ethylene Oxide Acetaldehyde  
 
 
6.2.2.2. Sensitivity Analysis with Counterfactual Exposures 
 
If ambient concentrations of each of the six carcinogenic air toxics are independently 
reduced to concentrations associated with plausible or feasible minimum risk distributions, the 
incorporation of alternative value choices (age weights or time preference) has no impact on the 
relative order of exposures contributing the largest disease burden in each of the regions, as 








Table 5.15a Ranking of the BoD under alternative value choices, assuming a feasible minimum risk 
concentration 
Toronto S.W.O 












































































Table 5.15b Ranking of the BoD under alternative value choices, assuming plausible minimum risk 
concentrations 
Toronto S.W.O 























































































The burden of disease (BoD) model was specifically designed to enable systematic and 
comprehensive analysis of the environmentally attributable health impacts associated with long 
term inhalation exposure to six ambient air toxics in two highly exposed regions of Ontario. 
Methods and model templates were adapted from the World Health Organization (WHO), the 
National Risk Institute for Public Health and the Environment (RIVM), and Statistics Canada to 
meet the requirements of the novel and multidisciplinary assessment (Flanagan et al, 2005; 
Mathers et al, 1999; Mathers et al, 2001; DeZwart et al, 2006). 
The model estimated the BoD attributable to carcinogenic hazardous air pollutants 
(HAP’s) in two phases. The first phase quantified the total BoD in Toronto and S.W.O regions in 
terms of DALY’s (disability-adjusted life years). DALY’s are a time based measure enabling 
comparative evaluation of risk factors and disease burdens between regions, cancer sites, and 
ambient exposures. The second phase estimated the BoD specifically attributable to ambient 
exposures by multiplying site-specific DALY’s (phase one) by attributable fractions in a 
counterfactual analysis. Explicitly comparing the DALY BoD between current and 
counterfactual HAP exposure scenarios can facilitate informed decision making and priority 
setting in Ontario concerning abatement of HAP emissions based on health benefits anticipated 
with reduced exposures. 
Although the model has drawn upon the best available evidence, many simplifying 
assumptions have been required, such that the model should be regarded as a relative tool to 
evaluate exposure reduction priorities, rather then an absolute quantitative assessment of the 
exposure attributable BoD. The following sections of the discussion will review the validity of 
the model to accurately quantify and characterize both the total BoD and the exposure 
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attributable BoD, examine uncertainties, strengths and limitations of the model, and finally 
explore the policy implications of the results and future work. 
 
 
6.1. Validity of the DALY Model (as a Robust Measure of the Burden of Disease)15
6.1.1. Overview of Phase One Results 
In Toronto and S.W.O regions results revealed a total of 32,704 DALY’s were lost from 
cancers of the head and neck (ICD9 codes 140-149; 150; 160-161), respiratory system (162-
165), and lymphohematopoeitic system (200-203; 204-108) during the reference year 2001 
(27,055 in Toronto and 5,019 in S.W.O). When analysis was standardized to a population of 
100,000 persons, S.W.O experienced nearly double the BoD compared to Toronto. Years of life 
lost due to premature mortality dominated the years of life lived with disability, consistent with 
high case-fatality rates for many cancer sites, and greater uncertainty in the YLD estimates. In 
both the Toronto and S.W.O regions the leading causes of the BoD were from (i) lung, bronchus, 
and trachea cancers, followed by (ii) lymphomas and multiple myelomas, and (iii) leukemia’s. 
Subgroup analysis revealed the disease burden associated with the six selected cancers to be rare 
prior to the age of 30 and dominant in individuals 60 years and older. The incorporation of 
alternative value choices (age weighting and discounting) had a negligible impact on the relative 
order of cancer sites to the BoD based on the magnitude of absolute DALY estimates. 
To provide a useful measure of the BoD from the selected cancer endpoints within each 
of the regions, the DALY estimates must be internally consistent, that is reflect the 
epidemiological characteristics of disease (incidence, mortality, duration, severity), specific to 
each region. The following subsections will thus discuss the validity of the DALY in estimating 
                                                 
15 Murray & Acharaya (1997) have argued DALY’s as a robust measure of population health status “not terribly 
sensitive to many of the assumptions underlying them, and are based on clearly articulated and debateable ethical 
principles” 
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the BoD including the use of time as a metric for analysis, the disability weights for cancer 
severity, and the impacts of age weights and discounting future health on the DALY estimates, 
independent from the process of causal attribution of cancer to ambient exposures. 
 
6.1.2. Time as the Unit of Analysis 
 The DALY uses time as the metric of analysis to incorporate data on years of life lost 
(premature mortality), years lived with disability, and average disease duration for survivors and 
non survivors, into a comparable time unit to provide an aggregate indicator of the BoD. The 
model quantified the BoD in the Toronto and S.W.O regions on the basis of site specific 
incidence and mortality estimates ascertained for the defined reference year 2001. With new 
diagnosis and fatal events modelled for the year 2001, the analysis was thus cross sectional in 
time, such that estimates of site specific incidence and mortality counts will show variability 
from year to year. Annual variation in disease estimates is especially likely as data was 
ascertained by age and sex grouping at the level of the municipality, producing relatively small, 
sometimes negligible cell counts for many sites. Particularly in S.W.O, with a population size 
approximately seven and a half times smaller then Toronto, absolute estimates of the BoD from 
head and neck cancers (ICD9 sites 140-149, 150, 160-161), which are rarer then cancers of the 
lung or lymphatic organs, will be dependent on the reference year for which estimates were 
analyzed. Although estimates of smaller disease burdens and populations will be more likely to 
vary between neighbouring years, it is unlikely variation from the choice of a reference year of 
analysis would dramatically affect the disease burden rankings. 
 However differences in the size and structure of the population over time from population 
aging, immigration, or emigration, could cause the DALY estimates (and possibly ranks) of the 
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BoD from site-specific cancers to vary over time, when cancer counts are modelled rather then 
age-standardized rates. The impacts of immigration would likely be less of a concern in S.W.O 
with a relatively homogeneous, 87% Canadian born population (Statistics Canada, 2007). 
However in Toronto with approximately 52% of residents born outside of Canada in 2001 
(Statistics Canada, 2007), the impacts of migration on the BoD from cancer could be significant 
if new immigrants differ on genetic factors (ie: glutathione-s-transferase allelic subtype) or 
lifestyle factors (dietary) which could increase or decrease their underlying cancer susceptibility. 
Furthermore, rates of disease may be lower in Toronto then S.W.O as a result of the ‘healthy 
immigrant effect’, similar to the ‘healthy worker effect’, whereby individuals who migrate are 
more likely to be of better health status, then those who do not migrate, which could partially 
account for differences in disease patterns.  
 Finally with the BoD assessment cross-sectional in time, differences in epidemiological 
estimates of site-specific staging, severity, and duration with improvements in treatment 
therapies or earlier detection will influence the transferability of disease estimates as 
representative in the future. Incorporating disease estimates into DALY’s for the defined 
reference year of 2001 thereby provides public health officials with a baseline for the purpose of 
future disease surveillance and comparison of epidemiological disease characteristics. 
 
6.1.3. The Disability Weights: 
The severity weighting for time lived with disability has been extensively debated in the 
literature on DALY’s (Essink-Bot et al, 2002; Murray & Acharya, 1997; Anand & Hanson, 
1997; Murray, 1994). Although the inclusion of an ‘average’ weight for cancer sites supports the 
egalitarian foundation of DALY’s as a SMPH (Murray & Acharya, 1997), the weights fail to 
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consider the influence of the social environment, infrastructure, or the impact of co-existing 
health conditions on quality of life16. 
Regional variations in the distribution of social and environmental conditions have not 
only been found to influence the risk of developing cancer, but also the severity associated with 
its impact (CCS, 2006; Reidpath et al, 2003). A socially supportive environment may reduce the 
overall severity associated with disease by decreasing stress and pain during the treatment stage, 
in particular chemotherapy, enhance the overall response to treatment, and thus the cancer 
outcome (whether an individual will experience the metastasis and terminal stages). With 
individuals in lower SES more likely to have lower levels of social support, and also be exposed 
to a plethora of cancer risk factors, uniform disability weights for site specific severity across all 
social and cultural contexts may underestimate disability among disadvantaged and high risk 
subgroups. 
The average disability weights for site specific cancers were derived in the model ranging 
between 0.085 and 0.396. Weights towards to the more ‘mild’ end of the severity scale for 
publicly dreaded diagnoses, with high case fatality rates, reflects the derivation of average 
weights, based on GBD stage associated severity. For all cancer sites, the stage specific disability 
weights associated with the diagnosis, therapy, and remission phases of disease are rated less 
then 0.2 on the severity scale, such that only the cases that eventually die of cancer (based on the 
5-year RSR) were more heavily weighted by the 0.75 to 0.81 severity associated with the 
metastasis and terminal stages. Disability weights disaggregated by age and sex reflect lower 
five-year RSR’s (or high case fatality rates) for cancers of the esophagus (ICD9 site 150) and 
                                                 
16 Global Burden of Disease Disability Weights may thus be especially likely to underestimate the ‘true’ BoD, with 
disability rated lower compared to more individualistic or self-rated health scales such as the Health Utilities Index 
or QALY weighting scales 
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lung, bronchus, and trachea (ICD9 sites 162-165), and decreasing rates of survival from all 
cancers with increasing age. 
Variations in the GBD disability weights on the ‘mild’ end of severity may have a larger 
impact on the BoD estimates then variation in weights towards the more ‘severe’ end of the scale 
because the lower the disability weights are, the more sensitive they are to variation (de 
Hollander et al, 1999; Melse et al, 2000). With disability weights generally derived less then 0.3, 
the relative impact of a 0.1 change in severity with the introduction of a new treatment or change 
in the case fatality rate may have a large impact on the BoD estimates, suggesting the weights 
provide an estimate of site specific severity most useful for comparison purposes rather then as 
stable epidemiological parameters. 
Furthermore the disability weights failed to account for the impact of co-morbidity since 
adding disability weights for different diseases could in theory sum to more then one (death). As 
more then 60% of the total BoD (19,242.60 DALY’s) was lost from cancers in persons 60 years 
and older, who are most likely to experience multiple chronic conditions, the true BoD may have 
been underestimated in the model. The number, type, and severity of co-morbid conditions could 
influence the selection of therapy and survival outcome of patients, since some types of co-
morbidities could exacerbate the morbidity associated with aggressive chemotherapy or 
radiotherapy treatments (cardiac, renal), or compliance to therapeutic regimes (mental, 
psychiatric) (Yates, 2001). 
 
6.1.4. Sensitivity of the DALY Estimates to Social Value Choices: 
Sensitivity of the DALY estimates to a positive discount rate for future healthy life, and 
differential value of time lived throughout the lifecycle were examined through sensitivity 
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analysis. Consistent with extensive sensitivity analyses of the GBD estimates (Murray et al, 
1994), results in S.W.O indicated the incorporation of alternative value choices [K=1, r=0] [K=0, 
r=0.03] [K=0, r=0], altered the absolute estimates of the BoD, but had no effect on the rank order 
or the share contribution of site specific cancers to the total BoD. Sensitivity analysis of the BoD 
estimates in Toronto also support the notion of the DALY as a robust measure of the BoD, 
relatively insensitive to the impacts of alternative social value choices, with changes in the 
absolute estimates but unaltered rank estimates with one exception. When DALY’s in Toronto 
were estimated with age weights but no discount rate, the site specific rankings of esophageal 
and oral cavity cancers were reversed between fourth and fifth ranks reflecting similar share 
contributions (5-6%) of each cancer site to the total BoD under all value choice scenarios. 
 Contrasting two extreme approaches, the classic [K=0, r=0] and development economist 
[K=1, r=0.03], the application of unequal age weights and a 3% discount rate reduced the total 
BoD by approximately half, 51.2% in S.W.O and 51.5% in Toronto, of the BoD with equal age 
weights and no discounting for future health. 
In general, the application of unequal age weights (K=1) placed greater emphasis on 
disease among young individuals in ages groups 0-4, 5-14, 15-29, and 30-44. In contrast, the 
application of a 3% discount rate exerts a counter effect, shifting the disease burden from the two 
youngest age groups (0-4, 5-14), to increase the share of the burden among the age groups 45 
years and older. Since the disease burden from cancer is relatively rare in the youngest age 
groups, and the largest burden is concentrated in the oldest (60+ years), insensitivity of the 
DALY estimates to a time preference or age weights is not surprising. However, the sensitivity 
analysis does support the idea that the incorporation of age-weighting places a double BoD 
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among the elderly by shifting the disease burden away from later life, a population which 
naturally experiences a larger disease burden. 
 
6.2. Validity of the Risk Model (in Causally Attributing the BoD to Ambient Exposures) 
6.2.1. Overview of the Results 
Of the total BoD from six cancer endpoints (32,074 DALY’s), a total of 187 DALY’s or 
0.58% was attributable to inhalation exposure to current ambient concentrations of acetaldehyde, 
formaldehyde, benzene, 1,3-butadiene, ethylene oxide, and nickel refinery dusts in Toronto (156 
DALY’s) and S.W.O (30 DALY’s), assuming each of the air toxics exerts independent and 
additive effects. When calculated as a rate per 100,000 persons, S.W.O was found to experience 
nearly double the exposure attributable BoD (5.6 DALY’s) compared to Toronto (3.3 DALY’s). 
In S.W.O, current environmental exposure to nickel refinery dusts, followed by formaldehyde, 
and benzene made the largest contributions to ill health of the six carcinogenic toxics. In 
Toronto, the largest health impacts resulted from current environmental exposure to benzene, 
followed by formaldehyde, then nickel refinery dusts. Current concentrations of ethylene oxide, 
1,3-BD, and acetaldehyde appear to be of lesser public health concern based on the magnitude of 
their associated health impacts. Further subgroup analysis by gender suggested the relative 
impact of each of the air toxics to the total disease burden in each region varied among males and 
females.  
The counterfactual analysis predicted that reducing long term concentrations of the six 
carcinogenic air toxics in the Toronto and S.W.O regions to lower levels that have been recorded 
in other regions (feasible minimum risk levels), would reduce the exposure attributable BoD in 
the future by 96 DALY’s (17 DALY’s in S.W.O and 79 DALY’s in Toronto), fitting with the 
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relevant latency periods of the site-specific cancers. Feasible distributions of the six air toxics 
would thereby reduce the BoD attributable to ambient air toxics exposures to 0.28% of the total 
BoD. Although the rank order of exposures causing the largest health impacts would remain 
unchanged from the current rank order in S.W.O, the relative importance of nickel, benzene, and 
formaldehyde is reversed from the current order in Toronto. 
If concentrations of the six air toxics were further reduced from current concentrations to 
concentrations expected if there were no anthropogenic releases of the air toxics (a plausible 
distribution), a total of 147 DALY’s could be avoided, again fitting with the relevant latency 
period of the associated cancers (25 DALY’s in S.W.O and 122 DALY’s in Toronto). 
Independently mitigating release of each of the six air toxics from anthropogenic sources would 
predict that only 0.12% of the total BoD in Toronto and S.W.O would be attributable to natural 
sources of the air toxics in the environment. Under the plausible exposure distribution, 
environmental concentrations of benzene in Toronto and formaldehyde in S.W.O would be 
responsible for the largest BoD from cancer endpoints included in the model. 
However as a result of both the nature of the disease and the risk factor, there are inherent 
difficulties in modelling the BoD from cancer attributable to long term cumulative air toxics 
exposures. The following subsections will discuss the attributable fraction calculations, the 
multicasual nature of cancer, the temporal dimension of the exposure-cancer relationship, and the 
impacts of aggregating small population health effects, as related to the validity of the model in 





6.2.2. The Attributable Fractions: 
The attributable fractions in the counterfactual analysis were calculated on the basis of a 
lifetime risk estimate, considering the ambient concentration (ug/m3) and potency of each toxic, 
divided by the current Canadian life expectancy for males and females to derive an annual risk, 
which was thus assumed constant through each year of life.  
Although analyses did not derive exposure attributable fractions by age subgroup, or 
assess the impacts of age weighting and discounting on the exposure attributable BoD through 
the lifecycle, the greater exposure attributable BoD in S.W.O may at least partially be a 
reflection of differences in the population age structure between the two regions, with 18% of the 
population 60 years or older in S.W.O compared to 15% in Toronto, and dominance of baseline 
DALY’s among the elderly (phase 1).  
As the exposure attributable BoD was derived by multiplying the baseline DALY’s from 
phase one, by the attributable fractions relating exposure to disease, the exposure attributable 
BoD in each region represents both the magnitude of the attributable risk and the baseline 
prevalence of disease. For example in S.W.O, ambient nickel was the leading cause of the 
exposure attributable BoD, however as the attributable fraction of the current environmental 
concentration was ranked fourth highest, the impact of nickel to the BoD results from its 
association with the large baseline burden of lung cancer, approximately 68% of the total share 
of the disease burden in S.W.O (phase one).  
Contrary to a situation with low attributable risk but high prevalence of disease, current 
exposure to ambient formaldehyde was associated with the highest attributable fractions for 
disease in Toronto and S.W.O, however a less prevalent form of cancer (head and neck), but was 
responsible for the second largest attributable BoD in both areas, thus demonstrating the 
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attributable BoD analysis requires assessment of both the baseline prevalence of disease and the 
magnitude of associated risk. 
Evidently describing the BoD to ambient exposures is more ambiguous then many other 
risk factor-disease relationships in public health (Doll & Peto, 1981), requiring consideration of 




The BoD attributable to exposure to ambient air toxics is difficult to characterize, but 
easy to underestimate, as a result of the multifactoral nature of cancer. The ambient environment 
operates distally in the etiology of cancer, with the exposure-cancer relationship mediated 
through a number of more proximal and intermediate risk factors. Rather then fitting with the 
traditional ‘necessary’ and/or ‘sufficient’ criteria of the causal web,17 air toxics act as component 
causes in cancer causality. Component causes act in conjunction with other component causes to 
create a sufficient cause of cancer (Schwartz & Carpenter, 1999) which alone can produce 
disease (Husted, 2005) as graphically illustrated in Figure 6.1 
 
 
                                                 
17 most risk factors for chronic disease are neither necessary nor sufficient 
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Figure 6.1 Sufficient Cause of Cancer. The figure describes ambient air toxics as a component cause of cancer, 
within a sufficient cause. Genetic susceptibility (DNA repair mechanisms), Age (exposure duration), and 
Behavioural factors influencing the exposure (smoking, occupation), also act as component causes. 
 
As annual mean concentrations of the six air toxics were assumed homogenous 
throughout the S.W.O and Toronto regions, the BoD attributable to this normative exposure can 
easily go unrecognized, without differentiating inter-individual risk in each region; contrasting 
with risk factors such as smoking or occupation for which risk can more easily be identified 
through dichotomous ‘exposed’ and ‘not exposed’ categories. 
Additionally, because individual risk factors for cancer (including ambient exposures) 
overlap and interact, the upper limits of the attributable fractions for cancer are theoretically 
unbounded and can thus exceed 100%. When cancer is a result of multiple risk factors, it is 
avoidable by eliminating any of the factors, especially important as multiple risk factors are often 
correlated and concentrated among subgroups as ‘clusters’ acting to increase cancer 
susceptibility and vulnerability. For example, cancer risk in Canada has been strongly associated 
with socioeconomic and demographic conditions (CCS, 2006), which themselves are strongly 
linked to environmental quality (Kay et al, 2000), suggesting individuals in neighbourhoods 
closer in proximity to industrial facilities (S.W.O) or traffic-dense highways (Toronto) may be at 
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greater cancer risk from exposure to a plethora of risk factors, including low SES and elevated 
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Figure 6.2: Example of a causal pathway relating exposure to ambient air toxics to cancer 
 
The BoD attributable to current ambient air toxics exposures in S.W.O was estimated 
1.68 times larger then the exposure attributable BoD in Toronto, consistent with higher ambient 
concentrations of four of the air toxics. However, comparisons of the disease burden attributable 
to exposure to ambient air toxics between the Toronto and SWO regions may not be especially 
accurate as a result of dramatic differences in the baseline DALY estimates, reflecting 
differences in ethnic origins and demographics between the two regions. Furthermore, with the 
baseline BoD in S.W.O, independent of risk factor attribution, also 1.62 times greater then the 
baseline BoD in Toronto, a greater total BoD (phase one) in S.W.O would be suggestive of risk 
factor clusters for cancer in this region, potentially occupational. Failure to consider differential 
risk of exposure attributable cancer as a result of exposure to co-risks or competing risk factors 
may have lead to a biased estimate of the exposure attributable BoD and oversight of potentially 
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cost effective intervention strategies to reduce the exposure attributable BoD in the Toronto and 
S.W.O regions by reducing co-risks simultaneously. 
 
6.2.4. Temporal Dimension of the Exposure-Cancer Relationship 
The BoD attributable to ambient air toxics exposures was assessed as a function of life 
long cumulative exposure, with annual mean ambient concentrations from a defined reference 
year assumed representative of current and past exposure distributions. Murray et al, (2003) has 
distinguished between the concepts of the ‘attributable’ and ‘avoidable’ disease, graphically 
illustrated in Figure 6.3. 
The attributable burden refers to the BoD which retrospectively could have been avoided 
or prospectively could be reduced if previous exposure was reduced to a counterfactual 
distribution. Whereas, the avoidable burden refers to the future BoD which prospectively can be 
avoided if current or prospective exposure is reduced to a counterfactual exposure distribution.  
 However as the counterfactual analysis was ecological in design, the temporal dimension 
of the exposure-cancer relationship was not considered in the assessment. The purpose of the 
model was to derive a rough estimate of the BoD from selected cancers ‘attributable’ to chronic 
exposure to current concentrations of ambient air toxics in Toronto and S.W.O, in order to 
predict the BoD which prospectively could be avoided (T1) if present concentrations (T0) were 
reduced to counterfactual distributions, fitting with the relevant latency period of the associated 
cancer sites, and otherwise assuming no competing health risks and business-as-usual (B.A.U) 
trends in emissions.  
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Figure 6.3 Distinction between the “Avoidable” and the “Attributable” Burden of Disease Adapted from 
Mathers et al, (2003) a = disease burden at t0 attributable to past exposure. The burden not attributable to the 
exposure of interest (yellow) may be reducing, constant, or increasing over time. b= disease burden at t0 not 
attributable to the exposure of interest (ie: attributable to another risk factor). The dashed lines represent the burden 
of cancer following at reduction in exposure at t0. c = the burden of disease avoidable at Tx with a 50% reduction in 
exposure (to a feasible distribution) at t0. d = remaining BoD at Tx after the 50% reduction in exposure. 
 
Although results of the counterfactual analysis were insensitive to a time preference 
failure to consider the temporal dimension of the long latency period of cancer whereby exposure 
occurs years or decades prior to clinical manifestation of disease, may limit the models ability to 
predict the avoidable BoD in the future as a result of the changing population demographics in 
Canada. The Ontario Ministry of Finance (2007) predicts the proportion of the Ontario 
population over 65 will double by the year 2031; as the BoD associated with cancer dominates 
during the elderly years, a more accurate analysis of the exposure attributable BoD assessment 
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requires modelling assuming a projected population age structure. Furthermore, as the 
carcinogenic risk associated with exposure to ambient air toxics is a function of cumulative 
exposure, small health benefits associated with mitigating exposures would be more likely to 
accumulate in the future, accruing to the future generations rather then the current cohort. 
 
6.2.5. Aggregating Small Exposure Attributable Impacts in the Population 
Attributable fractions associating current chronic exposures to selected ambient air toxics 
and site specific cancers in Toronto and S.W.O regions, were relatively small ranging between 
0.0014 and 0.006318 (representing 0.14% to 0.63% of the disease burden). However, as cancer is 
the leading cause of premature mortality in Canada (Canadian Cancer Society, 2006), and 
ambient air quality is a ubiquitous risk factor to which everyone is exposed, small attributable 
fractions relating exposure and disease have summed to hundreds (187) of DALY’s in two risk 
regions with elevated exposures in Ontario (156 in Toronto and 30 in S.W.O).  
Furthermore, when larger public health risks for cancer, such as cigarette smoking, have 
been discovered, intervened, and dominate health research priorities and resource allocation, 
more subtle risks causing hundreds of DALY’s should also be considered as large public health 
concerns,19 likely being concentrated among high risk subgroups and potentially modifiable with 
existing technologies and interventions. 
Evidently if concentrations of all the air toxics in the two highly exposed regions of 
Ontario were individually reduced to concentrations associated with levels that have been 
observed in less polluted rural communities (approximately a 50% reduction in toxics 
                                                 
18 0.14% of the burden of oral, esophagus, ear, and nasal cancers among Toronto females is attributable to exposure 
to current concentrations of acetaldehyde; whereas 0.63% of the burden of leukemia and lymphomas among males 
in S.W.O is attributable to current ambient concentrations of benzene 
19 It would be useful to compare exposure attributable DALY’s with DALY’s lost from other risk factors in a 
comparative risk analysis 
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concentrations), the model predicted 96 DALY’s per year could be avoidable (16 in S.W.O and 
79 in Toronto). Furthermore, if there were no anthropogenic emissions of the air toxics in 
Toronto and S.W.O, an estimated 147 DALY’s would be avoided per year, representing a 
reduction of 79% of the current exposure attributable BoD, and a 0.46% of the total disease 
burden (phase one results) associated with six cancer sites in Toronto and S.W.O. 
Although the assessment suggests exposure attributable health impacts may be 
considerable, there are inherent uncertainties in the estimates as a result of the predicative nature 
of health impact assessment, and are critical to convey to decision makers weighing disease and 
exposure reduction priorities. As such, the next section will discuss in further detail the inherent 




Uncertainty deals with gaps in knowledge when estimating the baseline and exposure 
attributable BoD, and is reflected in the model by inaccurate and imprecise estimates of input 
parameters (Finkel, 1990; McColl, Hicks et al, 2000; Thomas & Hrudey, 1997).  
 Finkel (1990) describes three main forms of uncertainty in risk assessment models: (i) 
model uncertainty, which results from a lack of information on the structural or functional form 
of the model, (ii) parameter uncertainty, which results from measurement, systematic, or random 
errors, and (iii) decision-rule uncertainty, which results from the selection of health outcome 
measures, statistics, and value judgments in the model. 
 Uncertainty is distinguished from variability. Variability exists in the model as a result of 
natural heterogeneity in the population on factors such as demographics, age, exposure, and 
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underlying susceptibility which can lead to differential risk, and create a range of estimates 
around the true value. 
 Improvements in scientific knowledge with more accurate data collection, measurement, 
and methodologies will in theory reduce uncertainty, however can only help better understand 
variability which itself is a natural occurrence and can’t be reduced (Thomas & Hrudey, 1997). 
 Major sources of model, parameter, and decision-rule uncertainty in the BoD model are 
thoroughly presented in Table 6.1. Since the project did not involve the collection of primary 
epidemiologic or risk data, and the controversy surrounding the validity of the DALY and its 
social value choices, have been extensively discussed thus far, the following discussion will 
focus on the main sources of model and parameter uncertainty related to the ability of the BoD 
model to predict exposure attributable health impacts. Variability will be dealt with in the 
context of variability leading to uncertainty.  
 Most of the uncertainties are not specific to the model but rather typical of any health 
impact assessment (HIA) exercise as a result of the simplifying assumptions required to model 
aggregated health and environmental data.  The following discussion will review uncertainty in 
determining the structure of the exposure-response relationship (linear, sub-linear, supra-linear; 









Table 6.1 Sources of Uncertainty in the Model (Adapted from Scoping Study on Information Gaps and 
Uncertainties in the IP/RP Compendium Documents, NERAM 1999) 
Sources Subtypes Examples 
Parameter Measurement Errors *inaccuracies in exposure estimates of annual mean 
ambient concentrations for Toronto and S.W.O 
  *use of ambient exposure as an indirect measure of 
internal dose 
  *“representativeness” of the counterfactual scenario 
concentrations for the Toronto and S.W.O regions 
  *variability in estimates of case distribution of cancer 
severity at diagnosis, not routinely collected information 
by Ontario Cancer Registry 
  *transferability of the 5-year relative survival rates of 
site-specific cancer over time with advances in treatment 
and detection 
  *use of 5-year RSR as case-fatality rate without 
consideration of death from competing causes 
 Random Errors *extrapolation of risk estimates from epidemiological 
studies with small sample sizes 
  *small cell sizes from subgroup analysis by age and sex 
grouping, w.r.t. incidence and mortality counts at the 
census level 
 Systematic Errors *extrapolating risk estimates from epidemiological 
studies with inadequate adjustment for confounding 
factors, ie: failure to consider smoking in Doll et al, 
(1990) relating nickel and lung cancer; potential co-
exposure to DTC in Delzell et al, (1996) relating 1,3-BD 
and leukemia; or co-exposures such as arsenic in Doll et 
al, (1990) 
Model Surrogate Variables *use of ambient mean concentration as an indicator of 
long term cumulative exposures 
  *assumption of 5% of ethylene concentration as an 
oxide 
  *use of average incidence and mortality counts (over 5 
year period) to estimate annual count when <5 cases not 
reported by Ontario Cancer Registry 
 Excluded Variables *co-exposures, ie: attributable disease burden 
calculation for leukemia in Toronto considering 
benzene, 1,3-BD, and ETO in the attributable fraction: 
AFoverall = 1 – (1 – AFbenz)(1- AF1,3-BD)(1-AFETO)   
(Steenland & Armstrong, 2006)
  *competing risk factors (ie: increased risk of cancer in 
older ages from lifetime of cumulative exposure to 
various risks: dietary, low physical activity etc) (Doll & 
Peto, 1981) 
  *Co-morbidities and co-existing health conditions in 
disability weight of DALY 
  *disability weights don’t consider quality of life 
 Incorrect Model Form *assumption of linear non-threshold dose response vs. 
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demonstrated evidence of sublinear dose response curve 
for formaldehyde (Monticello et al, 1996) and ETO 
(Snellings et al, 1984) 
  *mechanism: high level inhalation exposures and cancer 
associations may be inconsistent with cumulative low 
dose mechanisms (ie: saturable pathways) 
  *cross-sectional / ecological consideration of exposure-
disease in study design 
Decision-Rule Measure to Describe 
Risk 
*use of DALY’s (vs. QALY’s or PYLL or other Value 
of Statistical Life methods ie: willingness-to-pay) 
  *presentation of BoD estimates, and attributable BoD 
predictions to 2 decimal places in tables displays a false 
sense of accuracy in the estimates 
  *life expectancy based on cohort life expectancy vs. 
period or standard life tables 
  *calculation of the A.F. as constant throughout life, ie: 
exposure attributable cancer risk likely varies at 
different ages 
 Summary Statistic to 
Summarize Risk 
*absolute quantities vs. relative rankings 
 Definition of 
“acceptable risk” 
*de-minimis risk level 
*consideration of risk perception (ignorance) 
 Immediate vs. Delayed 
Health Consequences 
*discounting future time at a rate of 3% 
 
 
6.3.1. Assumption of Linearity and No-Threshold in Dose-Response 
The exposure attributable BoD was modeled under the assumption that carcinogens act 
linear without threshold on the dose-response curve. Linearity is based on the concept of 
proportionality, whereby reducing an exposure concentration by 50% would predict a 50% 
reduction in tumor induction. No-threshold is based on the hypothesis that any level of non-zero 
exposure can produce enough DNA damage to initiate the carcinogenic process through a ‘one-
hit’ genotoxic mechanism. Exposure leads to a cascade of cellular changes by means of 
biological amplification with hyperplasia, genotoxicity, cytotoxicity, and DNA cross-linking 
activity, prior to metastasis and potentially terminal disease (Thomas & Hrudey, 1997).  
The linear non-threshold hypothesis implies that any level of non-zero exposure to 
carcinogenic air toxics possess some cancer risk, which may be small but non-zero (McColl, 
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Hicks et al, 2000; Thomas & Hrudey, 1997), such that zero risk to human health is not 
achievable assuming the non-threshold hypothesis, with natural sources of air toxics in the 
environment. However, this does not imply that there is not a safe level of exposure, or 
acceptable level of risk to which the population is willing to be exposed, since the absence of risk 
does not equate with safety (Thomas & Hrudey, 1997) 
In the model, risk values for the six carcinogenic air toxics were derived on the basis of 
TC05 and TC01 (tumorigenic concentration) estimates from Health Canada, representing 
exposure concentrations associated with either a 5% or 1% increased risk of site specific cancers 
in human populations (Table 6.2). 
Table 6.2 Health Canada derived quantitative cancer risk estimates and reference studies 
Substance Value Name Risk Value Target 
Organ 
Species Study 
Acetaldehyde TC05 8600ug/m3 Nasal Rat Woutersen et al, 1986 
Formaldehyde TC05 9500ug/m3 Nasal Rat Monticello et al, 1996 
Benzene TC05 1500ug/m3 Blood Human Rinsky et al, 1987 
1,3-Butadiene TC01 1700ug/m3 Blood Human Delzell et al, 1995 
Ethylene Oxide TC05 2200ug/m3 Blood Rat Several, Snellings et al, 
1984 
Nickel, dusts TC05 40-100ug/m3 Lung Human Doll et al, 1990 
 
The TC risk values for all six air toxics were derived by Health Canada assuming the 
default linear modeling approach for carcinogens, despite suggestions from chronic toxicity 
studies that the dose-response function for two of the toxics, formaldehyde and ethylene oxide, 
may act sub-linear (Health Canada, 2001; Health Canada, 1999), with the dose response slope 
becoming steeper with increasing dose. Significant increases in cell proliferation and DNA-
protein cross links have been most frequently observed at or above formaldehyde concentrations 
of 4.8mg/m3 (Monticello et al, 1996), and cytogenic damage has been most frequently observed 
at or above ETO concentrations of 9.2mg/m3 (Snellings et al, 1984), implying the existence of a 
threshold. Thus if the dose-response for formaldehyde and ETO is indeed sublinear, assuming 
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the default linear non-threshold approach in the model may have actually overestimated the BoD 
in Toronto and S.W.O associated with low dose cumulative exposures. However, with 
uncertainties in mechanistic understandings of the dose-response functions, the model predicted 
the exposure attributable BoD under the protective and precautionary approach to avoid making 
a type-II error (false negative) in the interest of public safety. 
Furthermore, assuming a single molecule of genotoxic air toxic carries some small (but 
non zero) risk for cancer argues against the phenomenon of ‘hormesis’ in which low dose 
chemical stimulations have been suggested as adaptive and beneficial to human health  (Cook & 
Calabrese, 2006). With uncertainty in the dose-response relationships, setting permissible limits 
to environmental carcinogens on the basis of a biphasic or hormetic dose-response curve may 
unjustifiably impose greater involuntary risks on the two highly exposed populations included in 
the analysis.  
 The controversy regarding the shape of the dose-response curve in estimating population 
health impacts is further complicated by additional uncertainties of extrapolating risk estimates 
from studies in experimental animals and occupationally exposed workers to human populations 
and real world conditions, which will be further discussed in the next section.  
 
 
6.3.2. Uncertainties in Inferring Population Risk from Epidemiology and Toxicology 
The two main sources of evidence to evaluate cancer risk from environmental exposures 
come from epidemiological and toxicological studies. Epidemiological studies infer population 
cancer risk using indirect evidence from human populations exposed to environmental toxics 
unintentionally (McColl, Hicks, 2000), most often in the workplace (ie: benzene, 1,3-butadiene, 
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nickel). Whereas, toxicology infers risk in humans using predicative inference from experimental 
animals (ie: acetaldehyde, formaldehyde, and ethylene oxide).  
Although there is no strict formula to judge cancer causality, the IARC and Health 
Canada classify carcinogenicity based on a weight-of-evidence approach considering elements 
such as the strength of the association (RR), dose-response gradient, consistency, temporality, 
specificity, biological plausibility, and coherence (Hill’s Criteria of Causality) provided by 
epidemiological and toxicology studies.  
There are trade-offs in the strengths and limitations of inferring population cancer risk 
from epidemiological and toxicology studies, however both types of evidence introduce 
uncertainty to the model in the need to extrapolate risk estimates between populations and from 
high to low exposures. 
 
6.3.2.1. Uncertainties in Epidemiology 
 The ability to extrapolate quantitative cancer risk estimates from primary epidemiological 
studies is dependant on both the study design (cohort vs. case-control vs. ecological) and quality 
(control for random and systematic errors). 
 As a result of poor sensitivity to detect small or subtle cancer risks in populations from 
low and ubiquitous environmental exposures (Hrudey & Thomas, 1997; McColl, Hicks et al, 
2000), epidemiological studies are most often conducted in the occupational setting among 
workers exposed to elevated concentrations of contaminants (Table 6.3). Extrapolating 
quantitative cancer risk estimates downwards from high concentrations in the workplace 
introduces a degree of uncertainty to the capability of the model to predict attributable health 
impacts encountered at lower environmental concentrations. For example, in the model leukemia 
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risk from chronic exposure to 1,3-BD in Toronto and S.W.O at concentrations of approximately 
0.3mg/m3 required low dose extrapolation from the TC01 value of 1.7mg/m3 derived by Health 
Canada from the Delzell et al, (1996) cohort, which demonstrated evidence of elevated cancer 
risk among workers occupational exposed to concentrations of approximately 2mg/m3. 
Table 6.3. Uncertainties in Inferring Population Risk from Health Canada reference studies for 
benzene, 1,3-butadiene, and nickel refinery dusts on the basis of excess cancer risks among 
individuals exposed to elevated concentrations in the workplace  
Criteria Benzene 1,3-Butadiene  Nickel refinery dust 
Reference Rinsky et al, 1987 Delzell et al, 1996 Doll et al, 1990 
Study Design Cohort Cohort Cohort 
Dose-response Elevated risk with 
cumulative exposure 
(<10ppm over a 40-year 
work period) 
Increased risk with 
cumulative exposure 
Increased risk with 
length of exposure 
Power Limited by small 
sample size 
Sample size >15,000 
workers 
Sample size >54,000 
workers 




effect; 49 years of 
follow up 
Demonstrated latency 
effect 20 years post 
exposure 




Uncertainty in exposure 
estimates and 
measurements 




DTC exposure; study 





with co-exposure to 
arsenic; failure to 
consider information on 
smoking status 
 
 In addition to the uncertainty introduced to the model with high to low concentration 
extrapolation, epidemiological studies are often plagued by a number of methodological 
problems such as confounding (Delzell et al, 1996; Doll et al, 1990) and poor exposure 
characterization (Delzell et al, 1996; Doll et al, 1990; Rinsky et al, 1987), which limit the ability 
to extrapolate risk estimates from the occupational setting to the general population with a high 
degree of confidence. 
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 Confounds are factors that are independent risk factors for disease, are associated with 
the exposure of interest, but are not in the same causal pathway linking the exposure and disease 
(Husted, 2005). Simultaneous exposure to DTC with 1,3-BD in Delzell et al, (1996), arsenic with 
nickel in Doll et al (1990), and failure to stratify the analysis of nickel and lung cancer by 
smoking status in Doll et al (1990), suggest potentially confounded risk associations in the 
primary epidemiological studies which serve the basis of the Health Canada exposure-cancer 
associations. Extrapolating risk estimates from epidemiological studies based on spurious 
exposure-disease relationships may have lead to biased estimate of the BoD attributable to 




6.3.2.2. Uncertainties in Toxicology 
 Chronic toxicity studies in experimental animal models are most useful in risk assessment 
in their ability to establish biologically plausible mechanistic information on organ susceptibility 
and to evaluate the cumulative effects of site specific toxicity in a rigorously controlled 
laboratory environment. Table 6.4 reviews chronic toxicity studies for acetaldehyde, 








Table 6.4 Uncertainty in population risk inference from acetaldehyde, formaldehyde, and ethylene 
oxide on the basis of Health Canada reference toxicology studies 
Criteria Acetaldehyde Formaldehyde Ethylene Oxide 
Reference Study Woutersen et al, 1986 Monticello et al, 1986 Several, notably Snellings 
et al, 1984 




with evidence of cell 
proliferation, mutagenic, 






action, potent alkylating 
activity 
Dose-response Concentration related 
increase in squamous cell 
carcinomas and 









increased risk of 
leukemias 
Largest source of 
uncertainty 
No lesions observed in 
other organs tested; lack 




inferring dose response to 
the general population 
Lack of certainty 
about the shape of the 
dose response curve; 
linear vs. sublinear? 
Some evidence of brain 




information on variations 
in metabolism and kinetic 
differences 
 
Toxicology studies are in theory more sensitive then epidemiologically studies to detect 
cancer risks however, extrapolating risk estimates from animal models to human populations 
requires consideration of a number of modifying effects.  
Interspecies extrapolation involves extrapolating risk estimates from the lowest dose 
demonstrating pathology in chronic toxicity tests to a corresponding risk in humans at 
environmental concentrations. Species differences in body surface area, anatomy, metabolism, 
and physiology are adjusted using allometric conversion factors (McColl, Hicks et al, 2000). 
Extrapolating risk estimates between species is associated with enormous uncertainty, especially 
as the technique may not adequately account for species differences in underlying susceptibility 
for site specific cancer risks; for example, mice and rats which are obligate nasal breathers may 
be especially susceptible to nasal and upper respiratory cancers from high dose inhalation 
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exposures of acetaldehyde and formaldehyde administered in the lab to intentionally overwhelm 
natural metabolic and detoxification mechanisms. 
 Like epidemiological studies, risk estimates from toxicology studies require extrapolation 
from higher then environmental doses administered in the lab to risk estimates corresponding 
with environmental concentrations. Unlike occupational exposures which occur on a continuum 
and are often confounded by co-exposures, animal models are administered a limited number of 
doses (usually four non-zero exposures) of a single substance in a controlled environment, which 
may not be representative of real world human exposure conditions. 
 Unfortunately, the lowest end of the dose-response curve, which is of greatest relevance 
for environmental exposures, is associated with the greatest degree of uncertainty for risk 
extrapolations from chronic toxicity studies (McColl, Hicks et al, 2000). Difficulty in accurately 
quantifying and characterizing disease at the lowest administered doses suggests some site-
specific carcinogenic outcomes may go unrecognized in laboratory studies.  
 As the model derived the exposure attributable BoD on the basis of site-specific effects, 
failure to uncover site-specific risk in toxicity studies (type-II error), or selective exclusion of 
site specific risks from analyses, could have lead to an underestimate of the exposure associated 
BoD. For example, exposure to ETO in rats has been associated with a biologically plausible risk 
of brain tumors, however assessment was limited to estimates of leukemia and lymphoma 
outcomes on the basis of Health Canada’s risk evaluation, thus potentially underestimating the 





6.3.3. Uncertainty in Estimating Environmental Exposures in the Population 
 Exposure estimates contribute to a large amount of the uncertainty in the BoD model. 
With limited or poor quality data on ambient exposures, many oversimplifications were required 
to model the exposure attributable health impacts in Toronto and S.W.O regions. 
 A common assumption in risk assessment is that all individuals within a defined 
geographic boundary are exposed to the same concentrations of contaminants. However, 
individuals residing closer in proximity to the Chemical Valley in S.W.O or freeways in Toronto 
more likely experience elevated chronic exposure from industrial and motor vehicle releases, 
compared to more distant or rural areas, such that variability in the population distribution of 
exposure leads to uncertainty in the model when exposure is assumed homogeneous. Thus, 
modeling annual mean ambient concentrations as constant throughout each region may 
misrepresent true differences in exposure concentrations between cities, neighbourhoods, or 
subgroups. Without stratifying levels of ambient exposures in each region (ie: high, medium, low 
exposure), the exposure attributable BoD may be biased, pending the representiveness of the 
proxy point estimate to characterize the exposures (McColl, Hicks et al, 2000). 
 In addition to spatial variability, differences in individual micro-environments and time-
activity patters including behaviour, occupation, age, co-risks, and genetic polymorphisms, act to 
increase or decrease susceptibility to exposure, and therefore lead to uncertainty in the exposure 
estimates among individuals in the population (McColl, Hicks et al, 2000; NERAM, 1999).  
 Furthermore, estimating health impacts associated with independent exposures, without 
consideration of multiple low dose co-exposures in the ambient environment also introduces 
significant uncertainty to the model. Unlike chronic toxicity studies, in real world conditions air 
toxics exposures cannot be easily isolated, such that four types of interaction (effect 
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modification) are possible: (i) additivity, in which the effects of two toxics arithmetically sum 
(ii) potentiation, whereby an exposure associated effect occurs with enhancement from another 
toxic (iii) synergism, whereby an effect associated with simultaneous exposures to two or more 
toxics is greater then the arithmetic sum, ie: multiplicative, and (iv) antagonism, in which an 
effect associated with simultaneous exposures of two or more toxics is less then the arithmetic 
sum, ie: protective (Thomas & Hrudey, 1997). With little known about the shape of the 
concentration response curve at low environmental concentrations, the effects of the six 
carcinogenic air toxics were assumed independent and additive. 
 Finally, the ability of the model to predict the BoD that could be reduced or avoided by 
mitigating current exposures to plausible or feasible exposure distributions is limited by temporal 
considerations of the latency period in the exposure-disease relationships. The time lag between 
exposure abatement and disease reduction would be influenced by the time frame over which 
mitigation occurs; for example, whether exposure mitigation occurs as a snap shot intervention 
or a gradual phase out over a defined time period. The longer the time lag between exposure and 
disease, the greater the uncertainty in the counterfactual analysis. 
 Although there are uncertainties in the ability of the model to predict health impacts 
attributable to exposure, cost-effective intervention shouldn’t be postponed with evidence of a 
sizeable and potentially modifiable health burden. Assessing the BoD which could be avoided 
using hypothetical exposure distributions aids policy in mapping intervention strategies and 
exposure reduction priorities with minimal environmental data requirements. As such, the next 
section will further explore the policy implications of the BoD model and results for disease and 
exposure reduction priorities in the Toronto and S.W.O regions. 
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6.4. Policy Implications 
 
The magnitude of the BoD that could be avoided, or the health benefits that could be 
anticipated, by modifying current environmental exposures in two highly exposed regions, to 
alternative reduced levels has profound implications on policy regarding emission reduction 
priorities. 
Consistent with a larger population size, results indicated the BoD attributable to long 
term concentrations of acetaldehyde, formaldehyde, benzene, 1,3-BD, ETO, and nickel refinery 
dusts was greater in Toronto then S.W.O; however on a per capita basis, the BoD associated with 
six cancers in S.W.O exceed that of Toronto. Differences in exposure attributable disease rates 
per 100,000 persons suggests disparities between the two regions reflect broader social 
structures, that is the sources of release, infrastructure, and regulations governing emissions 
which in turn leads to the ubiquity of the ambient exposures in each region (Schwartz & 
Carpenter, 1999). 
Chronic inhalation exposure to nickel refinery dusts contributed to the largest proportion 
of the exposure attributed cancer burden in S.W.O, proving to be a clear priority for exposure 
reduction among both males and females. Interestingly, according to the National Pollutant 
Release Inventory in 2001, one facility in S.W.O released more nickel (and compounds) to the 
environment then any other facility in Ontario outside the Chemical Valley or Copper Cliff-
Falconbridge nickel belt by approximately 30-fold20 (NPRI, 2001). A reduction in the 
environmental concentration of nickel in SWO to levels achieved in other Canadian cities 
predicts a reduction in the BoD attributable to nickel by 0.632 DALY’s / 100,000 persons.  
                                                 
20 Imperial Oil in Sarnia released 30.334 tonnes of nickel and compounds (NPRI, 2001) 
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However, assuming a feasible distribution of each of the six air toxics in SWO (Table 
4.5a), the greatest reduction in the BoD (0.805 DALY’s / 100,000 persons) would be predicted 
with reducing ETO exposure. 
The ambient concentration of ethylene oxide was modeled assuming a 5% conversion of 
ambient ethylene to the oxide. With four facilities in the Chemical Valley21 responsible for the 
largest industrial releases of ethylene in Ontario (NPRI, 2001), 83.4% of the BoD from 
lymphomas and leukemia’s that is currently attributable to ambient ETO concentrations in SWO, 
could be avoided in the future with the mitigation of ethylene release from industry (assuming 
5% conversion to oxide).  
As mitigating release of the six HAP’s to concentrations associated with plausible 
minimum risk levels (zero anthropogenic emissions) may not be a realistic policy option 
considering local employment and economy, decision makers should consider the ALARA 
principle ‘as low as reasonably achievable’ in developing regulatory guidelines to reduce 
emissions with cost-effective interventions including best available control technologies (BACT) 
or best practicable control technologies (BPCT) (McColl, Hicks et al, 2000). Furthermore, as 
exposure to hazardous air pollutants is involuntarily imposed on individuals, an acceptable or 
‘de-minimis’ level of public risk is especially essential to consider in policy development 
regarding mitigation of ubiquitous exposure to carcinogenic toxics, acting without threshold. 
As mentioned, in Toronto the air toxic of foremost priority for exposure reduction is 
more ambiguous then S.W.O, with relatively similar attributable disease burdens associated with 
current chronic exposure to formaldehyde and benzene, and variability in the rank order of 
importance between the sexes. As new Canada-wide standards governing benzene content in 
gasoline have corresponded with 45% reductions in average Canadian ambient benzene 
                                                 
21 Bayer, DOW, Imperial Oil, Nova Chemical 
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concentrations (ug/m3) since 1995 (Environment Canada, 2001), policies governing heavy duty 
motor vehicle emissions (diesel) or the implementation of additional alternative transportation 
initiatives may result in the largest health benefits in Toronto. However, this may not be entirely 
feasible in Toronto as some studies have suggested that attempts to improve air quality with 
better fuel quality have been offset by increased driving frequency and coal based power 
production (Campbell et al, 2004). 
As the largest contribution of urban ambient formaldehyde (70-90%) results from 
secondary formation of the combustion of volatile organic compounds (ATSDR, 1999; Health 
Canada, 2001), there may be limited ability to regulate natural sources of formaldehyde in 
Toronto. However, as formaldehyde is an off-gas product of benzene photo-oxidation, and 
vehicular emissions account for the largest anthropogenic release of ambient formaldehyde, the 
most practical strategy to reduce the burden of head and neck cancers associated with chronic 
formaldehyde exposure may be policy aimed to decrease ambient benzene and precursor VOC’s. 
Multicausality offers the opportunity to tailor policy and interventions to cost-effectively 
reduce the BoD attributable to multiple exposures and diseases. Although this assessment was 
limited to quantifying carcinogenic outcomes, policy or intervention to reduce the BoD from 
site-specific cancers by mitigating exposure may also reduce the BoD from other chronic 
conditions, such as cardiovascular events or asthma, or the BoD from co-exposures 
simultaneously. For example, in Toronto reducing benzene release with cleaner emission 
standards for heavy duty vehicles or alternative transportation planning, may act to reduce the 
BoD from lymphomas and leukemia’s from benzene itself, but also by reducing emissions of 
1,3-BD and ETO from motor vehicles in the process. Whereas in Sarnia, standards regulating 
benzene emissions from industrial processes at the Chemical Valley may not only be associated 
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with fewer cases of leukemia and lymphomas, but also secondary benefits such as improved 
environmental quality for local residents and less stigma associated with living in the local 
community, potentially serving to increase tourism and the local economy in the process. 
As such, exposure reduction policy should be guided by the DPSEEA framework 
(Driving Force – Pressure – State – Exposure – Effect – Action) which considers the linkages 
between each of the components of the framework, distal and proximal factors, and recognizes 
action to reduce the exposure attributable BoD should occur at various levels with intersectoral 
collaboration (Kay et al, 2000; Pruss et al, 2001) . 
 
 
6.5. Strengths & Limitations of the Model: 
 
6.5.1. Strengths 
Comprehensive and objective environmental BoD models support informed decision 
making and policy development to protect and promote public health (Cohen et al, 2005; Kay et 
al, 2000). Assessing the BoD associated with current and reduced HAP exposures in two highly 
exposed regions of Ontario aids in examining inequalities in exposure between geographic 
boundaries, and is important for health planning, surveillance, and priority setting. By 
incorporating community specific estimates of cancer morbidity and mortality with transparent 
value choices, the DALY serves as a useful indicator of both population health status and also 
facilitates resource allocation, amendable to cost-effectiveness analysis. Sensitivity analysis 
allows judgment of the impact of alternative value choices (severity weighting, life expectancy, 
discount rate, age weights) on the BoD and exposure attributable BoD results (Fox-Rusby & 
Hanson, 2001; Pruss-Usten et al, 2003). Furthermore, modeling the exposure attributable BoD 
doesn’t require new data collection, rather purposeful analysis of key environmental and health 
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indicators, thereby providing a valuable baseline to compare future disease trends and monitor 
exposures (De Hollander et al, 1999).  
With uncertainty in the current scientific knowledge regarding the contribution of 
hazardous air pollutants to the BoD, this regional level assessment provides valuable information 
on a difficult to quantify environment-health relationship, and thereby contributes to an 
improved understanding of HAP associated health impacts. Assumptions and uncertainties have 
been provided transparently to aid in fully informed decision making and policy development to 
reduce exposure attributable health impacts in Ontario, with a goal to support sustainable 
development and environmental protection. 
 
6.5.2. Limitations 
Many of the limitations are the result of the predicative nature of the model and 
simplifying assumptions required when aggregating disease and exposure data in the population, 
as previously discussed. One issue that has yet to be discussed in detail concerns risk 
characterization.  An accurate characterization of true risk requires consideration of the public 
risk perception. As risk perception was not considered in the quantitative estimates of the BoD, 
an ‘acceptable’ level of exposure associated cancer risk should be considered by policy makers 
in setting mitigation priorities for exposures often regarded as ‘externalities’ (Pruss-Usten et al, 
2003; Sexton, 2006).  
Additionally, the analysis also failed to provide a range of estimates around the DALY 
estimates and the counterfactual analysis. A more comprehensive characterization of the BoD 
and the uncertainty around the results would involve 95th percentiles around point estimates. 
Furthermore, with uncertainty in population exposure estimates, modeling an annual mean 
concentration for each region fails to capture the variability in the population distribution of 
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exposure among subgroups, and serves as a proxy for estimates of internal dose. As individuals 
have different micro-environments, and the body has natural physiological defense mechanisms  
including muccocilliary clearance and DNA repair, biomarkers of exposure and spatial analysis 
would serve as a more reliable tool for exposure estimation, however was beyond the scope of 
this model. 
 Furthermore, pending the trans-boundary contribution of air toxics from boarding states 
of the U.S.A, there may be limited ability for Canadian regulatory actions to reduce health 
impacts associated with ambient exposures as air quality is not confined to geographic borders. 
Finally, the model was limited to quantifying carcinogenic endpoints associated with 
chronic inhalation exposure to six ambient air toxics in two high risk regions of Ontario. Results 
should thus be considered as an underestimate of the total BoD associated with exposures, 
failing to consider the initiation or exacerbation of other chronic conditions such as asthma, 
respiratory, and cardiovascular events. Furthermore, as SWO and Toronto were selected as 
highly exposed regions in Ontario on the basis of local emissions from industry and urbanization, 
results and implications should not be generalized to other industrial or urban areas outside of 
Canada or rural areas within Canada. 
 
6.6. Future Work:
To better inform public health policy it would be useful to examine regional variability in 
the BoD by exposure and age distribution. Stratifying on the basis of exposure levels (high, 
medium, low) or subgroup (occupation, age, smoking status) may aid in differentiating 
variability in exposure associated cancer risk. Furthermore, examining the role of risk factor 
clusters for cancer, predisposing, and enabling factors, may be of particular public health policy 
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interest in SWO, and display the need to focus policy towards protecting highly vulnerable 
subgroups. Such modelling may require a collaborative effort among environmental and health 
organizations such as Environment Canada and Health Canada, to provide better estimates of the 
exposure attributable BoD using spatial analysis methods including probability density functions 
or monte carlo simulations.  
In addition to the counterfactual concentrations in the analysis, future work should 
analyze the reduction in the BoD associated with the implementation of more comprehensive, 
policy oriented hypothetical scenarios, such as the BoD which could be avoided with the 
implementation of a particular policy or technology. For example, it would be interesting to 
examine the reduction in the BoD expected with the implementation of a particular 
transportation policy, assuming modified long term concentrations. In SWO, it would be 
interesting to predict the avoidable BoD if one of the four petrochemical plants in the Chemical 
Valley were to close; potentially of particular relevance for the nickel associated BoD. Such 
work requires emission and distribution modelling, however would enable cost-effective 
emission reduction priority setting. 
Finally, with the globalization of environmental health, ambient exposures and chronic 
disease rates are expected to double or triple over the next two decades in some developing 
countries (Yach et al, 2004), such that it would be useful to extend this model internationally, to 
estimate exposure attributable health impacts in developing countries such as China and India 
where the health and environmental implications of urbanization and industrialization are only 





Results of the BoD model indicated 0.58% of the total burden of morbidity and mortality 
from six cancer endpoints in S.W.O and Toronto is attributable to current exposure to six 
hazardous air pollutants. Although the attributable fractions relating air toxics exposures to 
disease were independently small, the attributable burden of disease summed to hundreds of 
DALY’s lost as a result of the ubiquitous nature of the ‘involuntary’ risk factor. Furthermore, 
because of the pressures demographic, economic, and social development put on the 
environment, there is a need to develop informed and efficient policy that supports economic 
growth, while supporting sustainable development and healthy environmental quality for current 
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1,3-BD  1,3-Butadiene 
 
AF   Attributable Fraction 
 
ATSDR  Agency for Toxicological Substance Disease Registry 
 
B.A.U   Business-As-Usual (trends) 
 
BoD   Burden of Disease 
 
CCME   Canadian Council of Ministers of the Environment 
 
CCS   Canadian Cancer Society 
 
CEPA   Canadian Environmental Protection Agency 
 
CEYLL  Cohort Expected Years of Life Lost (cohort life expectancy) 
 
CRA   Comparative Risk Assessment 
 
DALY   Disability Adjusted Life Year 
 
DD   Duration of Diagnosis Stage 
 
DM   Duration of Metastasis Stage 
 
DT   Duration of Terminal Stage 
 
DTR   Duration of Treatment Stage 
 
DTC   Dithiocarbamate 
 
DW   Disability Weight 
 
EBD   Environmental Burden of Disease 
 
EME   Established Market Economies 
 
ETO   Ethylene Oxide 
 
ETS   Environmental Tobacco Smoke 
 
GBD   Global Burden of Disease 
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HAP   Hazardous Air Pollutants 
 
HEIDI   Health Effects Indicator Decision Index 
 
HIA   Health Impact Assessment 
 
IARC   International Agency for Research on Cancer 
 
ICD9   International Classification of Disease, Version 9 
 
ITER   International Toxicity Estimates for Risk 
 
I.U.R   Inhalation Unit Risk (potency) 
 
K   Age weighting 
 
LNS   Average time to death for cancer patients who eventually die 
 
NAPS   National Air Pollution Surveillance (system) 
 
NBD   National Burden of Disease 
 
NERAM  Network for Risk Assessment and Management 
 
NFPRER  National Frameworks for Petroleum Refinery Emission Reductions 
 
NPRI   National Pollutant Release Inventory 
 
OCR   Ontario Cancer Registry 
 
OECD   Organization of Economic Developed (countries) 
 
PHI   Public Health Impact of Disease in Canada (research program) 
 
PSL   Priority Substance List (report) 
 
PTO   Person Trade Off (method) 
 
QALY   Quality Adjusted Life Years 
 
PAF   Population Attributable Fraction 
 
PAR   Population Attributable Risk 
 
PEYLL  Period Expected Years of Life Lost 
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PIF   Population Impact Fraction 
 
PYLL   Potential Years of Life Lost 
 
r   Discounting 
 
RIVM   Institute for Public Health and the Environment 
 
RR   Relative Risk 
 
RSR   Relative Survival Rate 
 
SES   Socioeconomic Status 
 
SEYLL  Standard Expected Years of Life Lost 
 
SMPH   Summary Measure of Population Health 
 
t0   Present (time period) 
 
T1   Future (time period) 
 
TC   Tumorigenic Concentration (1% or 5%) 
 
TERA   Toxicology Excellence and Risk Assessment 
 
S.W.O   Southwestern Ontario 
 
U.S. EPA  United States Environmental Protection Agency 
 
VOC’s   Volatile Organic Compounds 
 
WHO   World Health Organization 
 
YLD   Years of Life Lived with Disability 
 









International Classification of Disease Coding System, Version Nine: Malignant Neoplasm 
 
Code  Cancer 
 
140-149 Oral Cavity & Pharynx 
140  Malignant neoplasm of the lip 
141  Malignant neoplasm of the tongue 
142  Malignant neoplasm of the major salivary glands 
143  Malignant neoplasm of the gum 
144    Malignant neoplasm of the floor of the mouth 
145   Malignant neoplasm of other unspecified parts of the mouth 
146  Malignant neoplasm of oropharynx 
147  Malignant neoplasm of nasopharynx 
148   Malignant neoplasm of hypopharynx 




160-161 Middle Ear, Nasal, & Larynx 
160 Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses 
161 Malignant neoplasm of larynx 
 
162-165 Lung, Bronchus, Trachea 
162 Malignant neoplasm of trachea, bronchus, and lung 
163 Malignant neoplasm of pleura 
165 Malignant neoplasm of other and ill-defined sites within the respiratory 
and interthoracic organs   
 
200-203 Lymphomas and Multiple Myeloma 
200 Lymphomasarcoma and reticulosarcoma 
201 Hodgkin’s disease 
202 Other malignant neoplasms of lymphoid and histiocytic tissue 
203 Multiple myeloma and immunoproliferative neoplasms 
 
204-208 Leukemia 
204 Lymphoid leukemia 
205 Myeloid leukemia 
206 Monocytic leukemia 
207 Other specified leukemia 












 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 73,450 16,675 35,025 23,420 148,570 70,065 16,355 33,090 22,135 141,645 
5-9 77,080 21,015 39,200 27,320 164,615 72,550 20,075 36,835 25,880 155,340 
10-14 72,455 21,100 37,600 29,275 160,430 68,210 20,345 35,540 27,685 151,780 
15-19 73,515 18,955 36,295 28,585 157,350 69,765 18,150 34,540 26,200 148,625 
20-24 80,760 14,845 33,815 23,785 153,205 84,380 14,420 33,475 23,090 155,365 
25-29 94,175 13,640 33,145 21,355 162,315 102,290 14,320 35,665 22,375 174,650 
30-34 105,545 16,965 38,780 24,705 185,995 111,000 18,690 41,905 27,295 198,890 
35-39 113,140 23,760 46,030 30,805 213,735 112,900 25,610 47,225 34,040 219,775 
40-44 99,940 23,540 42,925 32,145 198,550 103,880 24,130 44,085 35,490 207,585 
45-49 85,215 19,505 36,485 28,975 170,180 93,140 19,975 38,135 31,360 182,610 
50-54 75,620 17,045 33,025 27,050 152,740 83,490 17,005 33,725 26,745 160,965 
55-59 55,795 11,935 24,130 18,210 110,070 62,180 11,615 23,770 17,475 115,040 
60-64 47,575 8,605 17,905 13,945 88,030 55,525 8,960 17,820 13,615 95,920 
65-69 44,635 7,310 13,370 11,260 76,575 51,800 8,005 14,155 11,315 85,275 
70-74 39,640 6,050 9,865 8,390 63,945 49,100 7,315 11,330 9,445 77,190 
75-79 29,990 4,280 6,285 5,440 45,995 42,990 6,225 9,045 7,355 65,615 
80-84 16,845 2,265 3,215 2,785 25,110 26,570 3,695 5,235 4,540 40,040 
85+ 11,165 1,345 1,955 1,875 16,340 25,095 3,175 4,350 3,890 36,510 
Total 1,196,540 248,835 489,050 359,325 2,351,456 1,284,930 258,065 499,895 369,930 2,412,820 
 
Southwestern Ontario 
 Males Females 
Age Lambton Kent Essex Total Lambton Essex Kent Total 
0-4 3,315 3,145 10,160 16,620 3,215 3,005 9,375 15,595 
5-9 4,230 3,605 10,850 18,685 4,040 3,585 10,380 18,005 
10-14 4,810 4,020 10,895 16,725 4,570 3,845 10,075 18,490 
15-19 4,910 4,210 10,335 19,455 4,705 4,060 10,110 18,875 
20-24 3,740 3,290 10,710 17,740 3,730 3,090 10,570 17,390 
25-29 3,030 2,825 10,810 16,665 3,205 2,935 11,135 17,275 
30-34 3,440 3,145 11,695 18,280 3,515 3,265 11,650 18,430 
35-39 4,290 4,135 13,070 21,495 4,755 4,335 12,935 22,025 
40-44 5,090 4,515 12,600 22,205 5,300 4,530 12,410 22,240 
45-49 5,005 4,000 10,780 19,785 5,125 3,935 11,115 20,175 
50-54 4,660 3,670 9,945 18,275 4,680 3,675 10,170 18,525 
55-59 3,765 2,805 7,590 14,160 3,655 2,935 7,580 14,170 
60-64 2,960 2,395 5,920 11,275 3,140 2,550 6,315 12,005 
65-69 2,745 2,075 5,185 10,005 3,055 2,285 5,720 11,060 
70-74 2,505 1,910 4,730 9,145 2,860 2,265 5,640 10,765 
75-79 1,810 1,410 3,415 6,635 2,540 2,135 5,195 9,870 
80-84 980 770 1,780 3,530 1,645 1,480 3,185 6,130 
85+ 590 505 1,040 2,135 1,355 1,380 2,815 5,550 







Mortality Counts in Toronto for Site Specific Cancer (disaggregated by age & sex) 
 
Oral Cavity & Pharynx (ICD9 codes 140-149) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0  0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0 0 0
25-29 1 0 0 0 1 0 0 0 0 0
30-44 1 0 0 0 1 0 0 0 0 0
35-39 1 0 0 0 1 0 0 0 0 0
40-44 0 0 0 0 0 2 1 0 0 3
45-49 0 0 1 0 1 6 0 0 1 7
50-54 1 0 1 0 2 2 1 2 0 5
55-59 1 1 0 0 2 5 1 2 0 8
60-64 1 0 1 0 2 8 1 2 0 11
65-69 8 1 0 0 9 13 2 1 1 17
70-74 3 0 1 1 5 11 1 1 1 14
75-79 4 1 0 1 6 10 0 0 1 11
80-84 6 1 1 0 8 7 0 1 0 8
85+ 5 1 1 1 8 4 1 1 1 7
 
 
Esophagus (ICD9 code 150) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0 0 0
25-29 0 0 0 0 0 0 0 0 0 0
30-44 0 0 0 0 0 0 1 0 0 1
35-39 0 0 0 0 0 1 0 0 1 2
40-44 1 0 0 0 1 1 1 0 0 2
45-49 0 0 0 0 0 3 0 1 1 5
50-54 0 0 0 0 0 7 1 2 0 10
55-59 2 1 0 0 3 7 2 0 1 10
60-64 4 1 1 1 7 8 2 2 2 14
65-69 2 1 0 0 3 9 2 3 2 16
70-74 7 1 2 0 10 10 2 2 2 16
75-79 7 1 2 0 10 7 2 2 2 13
80-84 2 1 1 0 4 7 2 1 1 11





Appendix C continued:  
Mortality Counts in Toronto for Site Specific Cancer (disaggregated by age & sex) 
 
 
Middle Ear, Nasal, & Larynx (ICD9 codes 160-161) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0 0 0
25-29 0 0 0 0 0 0 0 0 0 0
30-44 0 0 0 0 0 0 0 0 0 0
35-39 0 0 0 0 0 0 0 1 0 1
40-44 1 0 0 1 0 0 0 0 0 0
45-49 3 0 0 0 3 0 0 0 0 0
50-54 2 0 1 0 3 0 0 0 0 0
55-59 5 0 0 1 6 0 0 1 0 1
60-64 5 1 2 0 8 0 0 0 0 0
65-69 5 0 1 0 6 0 0 0 0 0
70-74 7 0 0 0 7 0 1 0 0 1
75-79 5 0 1 0 6 0 0 0 0 0
80-84 2 0 0 0 2 1 0 0 1 2
85+ 3 1 0 0 4 0 0 0 0 0
 
 
Lung, Bronchus & Trachea (ICD9 codes 162-165) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0 0 0
25-29 0 0 0 0 0 0 0 1 0 1
30-44 1 0 0 0 1 1 0 1 0 2
35-39 2 0 0 0 2 1 0 0 2 3
40-44 2 1 1 2 6 5 3 3 2 13
45-49 13 3 5 5 28 13 2 6 5 26
50-54 35 7 11 5 58 16 8 5 4 33
55-59 57 7 19 23 106 29 6 10 11 56
60-64 55 21 25 18 119 33 12 8 15 67
65-69 131 18 25 25 199 74 17 10 11 112
70-74 126 19 36 28 209 75 19 14 18 126
75-79 115 28 28 14 185 87 23 20 12 142
80-84 72 11 16 17 116 55 13 9 12 89






Appendix C continued:  
Mortality Counts in Toronto for Site Specific Cancer (disaggregated by age & sex) 
 
 
Lymphomas and Multiple Myeloma (ICD9 codes 200-203) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0 0 0 0 0 0 0 0 0 0
5-9 1 0 0 0 1 0 0 0 0 0
10-14 1 0 0 0 1 1 0 0 0 1
15-19 0 1 0 0 1 0 0 1 0 1
20-24 0 0 0 0 0 1 0 0 0 1
25-29 0 0 0 0 0 0 0 0 0 0
30-44 2 1 0 0 3 1 0 0 0 1
35-39 2 0 1 0 3 5 1 0 0 6
40-44 2 0 0 0 2 3 1 0 0 4
45-49 3 0 1 1 5 4 0 2 1 7
50-54 6 2 2 0 10 10 5 1 3 19
55-59 7 1 3 1 12 14 2 5 2 23
60-64 8 2 5 5 20 14 3 6 3 26
65-69 17 3 4 3 27 18 4 6 6 34
70-74 22 3 7 0 32 24 5 4 9 42
75-79 27 8 4 4 43 25 8 7 7 42
80-84 24 3 4 5 36 27 2 5 1 35




Leukemia’s (ICD9 codes 204-208) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0 0 0 0 0 0 0 0 0 0
5-9 1 1 0 0 2 0 0 0 0 0
10-14 1 0 0 0 1 1 0 0 0 1
15-19 1 0 0 0 1 0 0 1 1 2
20-24 1 0 0 0 1 0 0 0 0 0
25-29 0 0 0 1 1 2 0 0 0 2
30-44 2 0 1 0 3 3 0 1 0 4
35-39 2 1 0 0 3 3 0 0 0 3
40-44 2 0 1 0 3 3 1 1 0 5
45-49 2 0 0 0 2 4 0 0 0 4
50-54 2 1 1 0 4 4 1 1 1 7
55-59 0 0 2 1 3 6 0 2 1 9
60-64 4 0 0 1 5 12 1 2 1 16
65-69 9 1 1 0 11 11 2 2 2 17
70-74 9 0 1 2 12 12 3 2 2 19
75-79 12 1 3 1 17 19 2 4 6 31
80-84 9 1 2 2 14 7 2 2 1 12





Appendix C continued: 
Mortality counts in SWO for Site Specific Cancer (disaggregated by age & sex) 
 
Oral Cavity & Pharynx (ICD9 codes 140-149) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0
25-29 0 0 0 0 0 0 0 0
30-44 0 0 0 0 0 0 0 0
35-39 0 0 0 0 0 1 0 1
40-44 0 0 0 0 0 0 0 0
45-49 1 0 0 1 0 1 0 1
50-54 0 0 0 0 0 0 0 0
55-59 0 0 0 0 0 1 0 1
60-64 0 0 1 1 1 2 0 3
65-69 0 0 1 1 1 2 0 3
70-74 1 0 0 1 1 1 0 2
75-79 0 0 0 0 0 0 0 0
80-84 0 1 0 1 0 0 1 1
85+ 0 1 0 1 0 0 0 0
 
 
Esophagus (ICD9 code 150) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0
25-29 0 0 0 0 0 0 0 0
30-44 0 0 0 0 0 0 0 0
35-39 0 0 0 0 0 0 0 0
40-44 0 0 0 0 0 0 0 0
45-49 0 0 0 0 0 0 1 1
50-54 0 0 0 0 0 1 0 1
55-59 0 0 0 0 0 0 0 0
60-64 1 0 0 1 1 1 1 3
65-69 0 1 1 2 0 0 1 1
70-74 0 1 0 1 0 2 2 4
75-79 1 1 0 2 0 3 1 4
80-84 0 0 1 1 1 2 0 3







Appendix C continued: 
Mortality counts in SWO for Site Specific Cancer (disaggregated by age & sex) 
 
 
Middle Ear, Nasal, & Larynx (ICD9 codes 160-161) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0
25-29 0 0 0 0 0 0 0 0
30-44 0 0 0 0 0 0 0 0
35-39 0 0 0 0 0 0 0 0
40-44 0 0 0 0 0 0 0 0
45-49 0 0 0 0 0 0 0 0
50-54 1 1 0 2 0 0 0 0
55-59 0 1 0 1 0 0 0 0
60-64 1 0 1 2 0 1 0 1
65-69 0 1 1 2 0 0 0 0
70-74 0 1 1 2 0 0 0 0
75-79 0 1 0 1 0 0 0 0
80-84 0 0 0 0 0 0 0 0
85+ 0 0 0 0 0 0 0 0
 
 
Lung, Bronchus, & Trachea (ICD9 codes 162-165) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0
25-29 0 0 0 0 0 0 0 0
30-44 0 0 0 0 0 0 0 0
35-39 0 0 0 0 0 1 0 1
40-44 0 2 0 2 1 1 0 2
45-49 1 2 0 3 1 1 1 3
50-54 2 5 1 8 2 6 2 10
55-59 8 9 5 22 3 9 2 14
60-64 6 13 5 24 7 9 3 19
65-69 12 21 7 40 5 16 3 24
70-74 16 31 9 56 14 15 4 33
75-79 12 21 7 40 6 20 5 31
80-84 9 15 0 24 8 9 3 20






Appendix C continued: 
Mortality counts in SWO for Site Specific Cancer (disaggregated by age & sex) 
 
 
Lymphomas & Multiple Myelomas (ICD9 codes 200-203) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0
15-19 0 1 0 1 0 0 0 0
20-24 0 0 0 0 0 0 0 0
25-29 0 0 0 0 0 0 0 0
30-44 0 0 0 0 0 1 0 1
35-39 0 0 0 0 0 0 0 0
40-44 0 0 0 0 0 0 0 0
45-49 0 1 1 2 0 0 0 0
50-54 0 0 0 0 2 2 0 2
55-59 0 0 0 0 2 3 1 6
60-64 0 2 0 2 1 0 0 1
65-69 1 1 1 3 1 3 0 4
70-74 1 7 0 8 2 4 2 8
75-79 0 5 2 7 2 2 2 6
80-84 0 1 1 2 2 3 1 6




Leukemia’s (ICD9 codes 204-208) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0
25-29 1 1 0 2 0 0 0 0
30-44 0 0 0 0 0 0 1 1
35-39 0 1 0 1 0 0 0 0
40-44 0 0 0 0 1 1 0 2
45-49 0 0 0 0 0 0 0 0
50-54 0 1 0 1 0 0 0 0
55-59 0 1 0 1 1 1 1 3
60-64 0 1 0 1 1 1 1 3
65-69 0 1 0 1 2 2 0 4
70-74 1 2 1 4 0 2 0 3
75-79 0 2 1 3 1 3 1 5
80-84 0 1 2 3 0 1 2 3





Appendix C continued: 
Site Specific Cancer Incidence counts in Toronto (disaggregated by age & sex) 
 
Oral Cavity & Pharynx (ICD9 codes 140-149) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0 0 0 0 0 0 0 0 0 0 
5-14 0 0 0 0 0 0 0 1 1 2 
15-29 3 0 0 0 3 3 0 1 1 5 
30-44 5 5 5 6 21 3 2 8 2 15 
45-59 67 10 27 17 121 30 2 6 3 41 
60-69 36 2 10 10 58 18 6 1 4 29 
70-79 34 6 7 9 56 16 2 3 1 22 
80+ 15 1 2 0 18 19 0 1 7 27 
 
Esophagus (ICD9 codes 150) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0 0 0 0 0 0 0 0 0 0 
5-14 0 0 0 0 0 0 0 0 0 0 
15-29 0 0 0 0 0 0 0 0 0 0 
30-44 3 2 0 0 5 0 0 0 0 0 
45-59 6 2 4 2 14 3 1 0 0 4 
60-69 10 6 0 4 20 1 0 3 1 5 
70-79 19 3 5 4 31 8 0 2 2 12 
80+ 6 2 2 2 12 10 2 1 0 13 
 
Middle Ear, Nasal, & Larynx (ICD9 codes 160-161) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0 0 0 0 0 0 0 0 0 0 
5-14 0 0 0 0 0 0 0 1 0 1 
15-29 0 0 0 0 0 0 0 0 0 0 
30-44 2 3 0 0 5 1 0 2 0 3 
45-59 14 1 6 3 24 2 1 1 0 4 
60-69 21 2 5 9 37 2 0 1 0 3 
70-79 20 4 2 4 30 1 1 2 0 4 
80+ 4 0 4 1 9 0 0 0 1 1 
 
Lung, Bronchus, & Trachea (ICD9 codes 162-165) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 1 0 0 0 1 0 0 0 0 0 
5-14 0 0 0 1 1 0 0 0 0 0 
15-29 1 0 0 0 1 0 0 0 1 1 
30-44 29 1 3 3 36 11 5 5 3 24 
45-59 128 35 48 41 252 77 29 26 24 156 
60-69 221 36 58 42 357 118 28 27 31 204 
70-79 251 53 74 36 414 186 38 34 34 292 








Appendix C continued:  
Site Specific Cancer Incidence counts in Toronto (disaggregated by age & sex) 
 
Lymphomas & Multiple Myeloma (ICD9 codes 200-203) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 0 0 0 0 0 1 0 2 0 3 
5-14 2 0 5 2 4 2 2 0 2 6 
15-29 8 3 6 6 23 17 2 10 10 40 
30-44 40 8 17 11 76 23 12 12 9 56 
45-59 82 19 35 21 157 63 17 19 22 121 
60-69 84 10 27 17 138 78 12 16 15 121 
70-79 76 21 21 17 135 106 19 23 12 160 
80+ 61 6 12 3 82 76 11 10 8 105 
 
Leukemia’s (ICD9 codes 204-208) 
 Males Females 
Age Toronto Durham Peel York Total Toronto Durham Peel York Total 
0-4 9 0 0 3 12 2 0 2 4 8 
5-14 6 2 1 6 20 4 0 0 4 8 
15-29 9 2 2 2 15 0 0 4 2 6 
30-44 15 2 6 3 26 6 2 4 5 17 
45-59 29 5 10 6 45 10 5 5 9 29 
60-69 33 10 6 7 56 22 9 5 5 39 
70-79 49 3 6 10 68 27 6 6 3 42 
80+ 24 7 7 3 41 35 3 5 6 49 
 
 
Site-specific Cancer Incidence Counts in S.W.O (disaggregated by age & sex) 
 
Oral Cavity & Pharynx (ICD9 codes 140-149) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0 
5-14 0 0 0 0 0 0 0 0 
15-29 0 1 0 1 0 1 0 1 
30-44 0 1 1 2 0 1 1 2 
45-59 8 17 2 27 2 5 2 9 
60-69 2 10 2 14 0 2 0 2 
70-79 0 9 4 13 1 5 1 7 
80+ 0 1 1 2 1 4 0 5 
 
Esophagus (ICD9 code 150) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0 
5-14 0 0 0 0 0 0 0 0 
15-29 0 0 0 0 0 0 0 0 
30-44 0 0 0 0 0 0 0 0 
45-59 1 4 1 6 0 0 0 0 
60-69 0 3 0 3 1 1 3 5 
70-79 0 3 2 5 0 1 0 1 





Appendix C continued: 
Site-specific Cancer Incidence Counts in S.W.O (disaggregated by age & sex) 
 
Middle Ear, Nasal, & Larynx (ICD9 codes 160-161) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0 
5-14 0 0 0 0 0 0 0 0 
15-29 0 0 0 0 0 1 0 1 
30-44 0 0 1 1 2 3 0 5 
45-59 0 1 1 2 0 0 0 0 
60-69 2 5 2 9 0 0 1 1 
70-79 0 3 1 4 0 1 1 2 
80+ 2 0 0 2 1 0 0 1 
 
Lung, Bronchus & Trachea (ICD9 codes 162-165) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 1 0 1 
5-14 0 0 0 0 0 0 0 0 
15-29 0 1 0 1 0 1 0 1 
30-44 0 1 2 3 2 3 0 5 
45-59 13 19 12 44 6 27 13 46 
60-69 17 45 20 82 11 28 12 51 
70-79 15 47 27 89 9 25 25 59 
80+ 1 16 10 27 12 18 8 38 
 
Lymphomas & Multiple Myeloma (ICD9 codes 200-203) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 0 0 0 0 0 0 0 
5-14 0 1 0 1 0 2 0 2 
15-29 0 3 1 4 0 1 0 1 
30-44 1 4 2 7 0 7 1 8 
45-59 1 11 1 13 0 9 2 11 
60-69 7 8 6 21 2 10 7 19 
70-79 7 11 6 24 4 15 2 21 
80+ 1 2 1 7 2 5 2 9 
 
Leukemias (ICD9 codes 204-208) 
 Males Females 
Age Lambton Essex Kent Total Lambton Essex Kent Total 
0-4 0 1 2 3 0 0 0 0 
5-14 0 1 0 1 0 2 1 3 
15-29 1 1 0 2 0 0 0 0 
30-44 0 1 1 2 0 1 1 2 
45-59 3 8 0 11 2 3 0 5 
60-69 1 5 2 8 2 4 0 6 
70-79 1 8 0 9 2 3 2 7 









Current Canadian Cohort Life Expectancy for Males and Females: by 5-year age group 
 
Age Group Males Females 
0 77.8 82.6 
1-4 77.2 81.9 
5-9 73.3 78.0 
10-14 68.3 73.0 
15-19 63.4 68.1 
20-24 58.6 63.2 
25-29 53.8 58.3 
30-34 49.0 53.4 
35-39 44.2 48.5 
40-44 39.4 43.6 
45-49 34.7 38.8 
50-54 30.1 34.2 
55-59 25.7 29.6 
60-64 21.5 25.2 
65-69 17.6 21.0 
70-74 14.0 17.0 
75-79 10.8 13.3 
80-84 8.1 10.1 
85-89 5.9 7.3 
90-94 4.2 5.1 
95-99 2.9 3.4 






















Derivation of Average Duration of Primary Therapy considering medical severity at 
diagnosis and duration of treatment regime 
 
Site-specific Cancer Severity at 
Diagnosis 
Treatment Regime Progression 
(% cases x duration)1
Duration 
(years) 
Oral Cavity & Pharynx Local In-patient surgery (70% x 0.077) + mild chemo (3% x 0.5) + moderate 
chemo (13% x 0.346) + radiotherapy (4% x 0.096) 
0.118 
 Regional Inpatient surgery (70% x 0.077) + mild chemo (18% x 0.5) + moderate 
chemo (22% x 0.346) + curative radiotherapy (2% x 0.077) 
0.221 
 Distant Inpatient surgery (41% x 0.077) + moderate chemo (15% x 0.5) + severe 
chemo (28% x 0.192) + palliative radiotherapy (9% x 0.067) 
0.169 
Esophagus Local In-patient surgery (62% x 0.077) + mild chemo (12% x 0.5) + moderate 
chemo (13% x 0.375) + radiotherapy (25% x 0.077) 
0.177 
 Regional In-patient surgery (40% x 0.077) + mild chemo (17% x 0.167) + moderate 
chemo (36% x 0.25) + radiotherapy (46% x 0.077) 
0.184 
 Distant In-patient surgery (10% x 0.077) + mild chemo (14% x 0.5) + moderate 
chemo (31% x 0.375) + palliative radiotherapy (25% x 0.064) 
0.210 
Middle Ear, Nasal, & 
Larynx 
Local In-patient surgery (70% x 0.077) + mild chemo (3% x 0.5) + moderate 
chemo (13% x 0.346) + radiotherapy (4% x 0.096) 
0.118 
 Regional In-patient surgery (70% x 0.077) + mild chemo (18% x 0.5) + moderate 
chemo (22% x 0.346) + radiotherapy (2% x 0.077) 
0.221 
 Distant In-patient surgery (41% x 0.077) + moderate chemo (15% x 0.5) + severe 
chemo (28% x 0.192) + palliative radiotherapy (9% x 0.067) 
0.167 
Lung, Bronchus, & 
Trachea 
Local In-patient surgery (65% x 0.077) + moderate chemo (8% x 0.25) + 
radiotherapy (23% x 0.096) 
0.092 
 Regional In-patient surgery (16% x 0.077) + moderate chemo (56% x 0.25) + 
radiotherapy (59% x 0.096) 
0.210 
 Distant Chemo (49% x 0.25) + palliative radiotherapy (47% x 0.058) 0.150 
Lymphomas & 
Multiple Myeloma2
Local NHL: Inpatient surgery (13% x 0.096) + moderate chemo (39% x 0.346) 
+ radiotherapy (13% x 0.096) 
HL: Inpatient surgery (33% x 0.077) + outpatient surgery (42% x 0.077) + 
moderate chemo (12% x 0.417) + radiotherapy (29% x 0.089) 
MM: Inpatient surgery (62% x 0.077) + mild chemo (12% x 0.5) + 
moderate chemo (13% x 0.375) + radiotherapy (25% x 0.077) 
0.158 
 Regional NHL: in/out-patient surgery (21% x 0.077) + moderate chemo (65% x 
0.346) + radiotherapy (3% x 0.096) 
HL: inpatient surgery (54% x 0.077) + outpatient surgery (54% x 0.077) + 
moderate chemo (28% x 0.417) + radiotherapy (33% x 0.089) 
MM: inpatient surgery (40% x 0.077) + mild chemo (17% x 0.5) + 
moderate chemo (36% x 0.375) + radiotherapy (46% x 0.077) 
0.245 
 Distant NHL: inpatient surgery (15% x 0.077) + severe chemo (61% x 0.346) + 
palliative radiotherapy (4% x 0.096) 
HL: inpatient surgery (20% x 0.077) + outpatient surgery (19% x 0.077) + 
moderate chemo (28% x 0.417) + curative radiotherapy (16% x 0.115) + 
palliative radiotherapy (15% x 0.077) 
MM: inpatient surgery (10% x 0.077) + mild chemo (14% x 0.5) + 
moderate chemo (31% x 0.375) + palliative radiotherapy (25% x 0.064) 
0.204 
Leukemias Local In-patient surgery (10% x 0.077) + mild chemo (100% x 0.5)  0.5077 
 Regional In-patient surgery (10% x 0.077) + mild chemo (100% x 0.5) 0.5077 
 Distant No cases diagnosed at this stage 0 
1 Treatment regime is assumed to progress from: (in, out patient) surgery, (mild, moderate, severe) chemotherapy, (curative, 
palliative) radiotherapy.  
2 Lyphomas and Multiple Myelomas: considered different treatment regimes for Non-hodgkins (NHL), Hodgkins (HL), and 
Multiple Myeloma (MM). Duration of primary therapy by severity is an average of the three cancers treatment progressions.  
Local: NHL/HL/MM averaged = (0.164+0.133+0.176/3) 0.158 
Regional: NHL/HL/MM averaged = (0.244+0.205+0.286/3) 0.245 





Derivation of Average Duration of Primary Therapy considering age distribution of stage 
at diagnosis 
 
 Males Females 
Disease Age Local Regional Distant Local Regional Distant 
ICD 140-149 0-4 31.8 56.5 11.8 45.9 45.9 8.2 
 5-14 31.8 56.5 11.8 45.9 45.9 8.2 
 15-29 31.8 56.5 11.8 45.9 45.9 8.2 
 30-44 31.8 56.5 11.8 45.9 45.9 8.2 
 45-59 30.5 57.5 12.1 41.2 49.8 9.1 
 60-69 29.9 58 12.2 38.8 51.7 9.5 
 70-79 36.8 51.2 12 44.8 45.1 10.1 
 80+ 36.8 51.2 12 44.8 45.1 10.1 
ICD 150 0-4 23.2 33 43.8 14 38 48 
 5-14 23.2 33 43.8 14 38 48 
 15-29 23.2 33 43.8 14 38 48 
 30-44 23.2 33 43.8 14 38 48 
 45-59 24.6 35.3 40.1 24 37.3 38.7 
 60-69 25.3 36.4 38.3 29 37 34 
 70-79 34.5 33.7 31.8 39.7 33.6 26.8 
 80+ 34.5 33.7 31.8 39.7 33.6 26.8 
ICD 160-161 0-4 43.4 52.9 3.7 36.6 57.4 5.9 
 5-14 43.4 52.9 3.7 36.6 57.4 5.9 
 15-29 43.4 52.9 3.7 36.6 57.4 5.9 
 30-44 43.4 52.9 3.7 36.6 57.4 5.9 
 45-59 44.6 51.2 4.4 38.7 57.9 3.3 
 60-69 45.2 50.4 4.4 39.8 58.2 2 
 70-79 51.8 45.2 2.9 43.9 51.9 4.2 
 80+ 51.8 45.2 2.9 43.9 51.9 4.2 
ICD 162-165 0-4 11.9 35.7 52.5 16.1 35.1 48.8 
 5-14 11.9 35.7 52.5 16.1 35.1 48.8 
 15-29 11.9 35.7 52.5 16.1 35.1 48.8 
 30-44 11.9 35.7 52.5 16.1 35.1 48.8 
 45-59 13.3 38.7 48 18 36.8 45.1 
 60-69 14 40.2 45.8 18.9 37.7 43.3 
 70-79 18.2 44.1 37.8 20.9 43 36.1 
 80+ 18.2 44.1 37.8 20.9 43 36.1 
ICD 200-203 0-4 23.7 17.9 58.4 21.5 24 54.5 
 5-14 23.7 17.9 58.4 21.5 24 54.5 
 15-29 23.7 17.9 58.4 21.5 24 54.5 
 30-44 23.7 17.9 58.4 21.5 24 54.5 
 45-59 22 13.7 64.2 22.8 18.4 58.8 
 60-69 21.2 11.7 66.1 23.5 15.6 61 
 70-79 20.2 13.8 66.1 21.6 15 63.5 
 80+ 20.2 13.8 66.1 21.6 15 63.5 
ICD 204-208 0-4 44 56 0 44 56 0 
 5-14 44 56 0 44 56 0 
 15-29 44 56 0 44 56 0 
 30-44 44 56 0 44 56 0 
 45-59 44 56 0 44 56 0 
 60-69 44 56 0 44 56 0 
 70-79 44 56 0 44 56 0 


















0-4 0.182 0.169 0-4 0.165 0.163 
5-14 0.182 0.169 5-14 0.165 0.163 
15-29 0.182 0.169 15-29 0.165 0.163 
30-44 0.182 0.169 30-44 0.165 0.163 
45-59 0.183 0.174 45-59 0.166 0.162 
60-69 0.184 0.176 60-69 0.166 0.162 
70-79 0.176 0.170 70-79 0.160 0.164 
140-149 
Oral Cavity & 
Pharynx 




80+ 0.160 0.164 
0-4 0.194 0.196 0-4 0.200 0.204 
5-14 0.194 0.196 5-14 0.200 0.204 
15-29 0.194 0.196 15-29 0.200 0.204 
30-44 0.194 0.196 30-44 0.200 0.204 
45-59 0.193 0.192 45-59 0.199 0.201 
60-69 0.192 0.191 60-69 0.197 0.199 
70-79 0.190 0.188 70-79 0.201 0.201 
150 
Esophagus 





80+ 0.201 0.201 
0-4 0.174 0.180 0-4 0.508 0.508 
5-14 0.174 0.180 5-14 0.508 0.508 
15-29 0.174 0.180 15-29 0.508 0.508 
30-44 0.174 0.180 30-44 0.508 0.508 
45-59 0.173 0.179 45-59 0.508 0.508 
60-69 0.172 0.179 60-69 0.508 0.508 
70-79 0.166 0.174 70-79 0.508 0.508 
160-161 
Middle Ear, 
Nasal, & Larynx 
80+ 0.166 0.174 
204-208 
Leukemias 
80+ 0.508 0.508 




















1, 3, 10 Year Relative Survival Rates for Site-specific Cancer, disaggregated by sex 
 
Oral Cavity & Pharynx (ICD9 codes 140-149) 
 Males Females 
Age 1-yr 3-yr 5-yr 10-yr 1-yr 3-yr 5-yr 10-yr 
0-4 85.6 60.1 54.6 43.7 87.8 75.3 69.1 69.1 
5-14 97.2 91.1 89.7 82.0 95.3 82.9 76.9 76.9 
15-29 92.2 83.5 81.6 78.3 95.4 90.0 86.4 86.4 
30-44 89.9 77.3 73.8 68.1 93.3 82.5 72.7 72.7 
45-59 83.6 64.8 58.7 49.1 86.6 70.8 57.0 57.0 
60-69 80.0 62.4 55.5 46.4 82.6 65.8 49.2 49.2 
70-79 79.5 64.7 59.0 52.7 77.4 92.6 47.4 47.4 
80+ 75.4 64.8 59.9 52.9 69.7 56.9 51.4 51.4 
 
Esophagus (ICD9 code 150) 
 Males Females 
Age 1-yr 3-yr 5-yr 10-yr 1-yr 3-yr 5-yr 10-yr 
0-4 n/a n/a n/a n/a 100 100 100 100 
5-14 n/a n/a n/a n/a 50.0 50.0 50.0 50.0 
15-29 52.7 47.4 47.4 47.4 66.7 66.7 66.7 66.7 
30-44 44.9 20.0 16.6 14.0 48.2 44.7 44.7 42.2 
45-59 40.1 16.3 12.9 9.6 25.5 22.6 22.6 19.6 
60-69 36.7 15.5 12.0 9.0 20.0 16.3 16.3 11.7 
70-79 35.1 15.2 11.6 9.4 19.6 16.6 16.6 13.1 
80+ 25.7 11.4 9.1 9.0 11.2 10.1 10.1 8.2 
 
Middle Ear, Nasal, & Larynx (ICD9 codes 160-161) 
 Males Females 
Age 1-yr 3-yr 5-yr 10-yr 1-yr 3-yr 5-yr 10-yr 
0-4 87.6 43.9 43.9 43.9 75.1 50.1 50.1 25.1 
5-14 69.2 69.2 61.1 61.1 85.7 85.7 85.7 85.7 
15-29 91.4 81.2 78.2 76.8 93.7 82.9 80.6 80.6 
30-44 90.9 77.7 72.4 65.5 94.5 85.9 84.3 79.1 
45-59 88.4 73.4 67.3 59.5 88.7 76.9 70.7 59.8 
60-69 87.6 71.1 65.8 55.2 86.5 73.1 65.6 57.0 
70-79 82.7 66.3 59.9 46.6 80.1 66.1 59.4 48.6 
80+ 75.0 59.2 54.1 53.7 69.8 59.7 57.6 50.7 
 
Lung, Bronchus, & Trachea (ICD9 codes 162-165) 
 Males Females 
Age 1-yr 3-yr 5-yr 10-yr 1-yr 3-yr 5-yr 10-yr 
0-4 86.5 81.2 79.5 79.5 100 98.0 92.9 92.9 
5-14 85.2 69.0 64.8 64.8 87.9 81.1 74.4 74.4 
15-29 66.7 53.5 51.0 49.7 75.5 62.3 60.6 58.1 
30-44 43.2 24.8 22.1 20.0 49.8 29.2 26.3 22.7 
45-59 40.3 20.4 16.9 13.5 47.5 26.1 21.8 17.5 
60-69 37.8 18.4 14.6 10.7 43.9 23.2 18.4 13.6 
70-79 32.3 14.8 11.3 8.8 36.5 18.9 14.5 11.2 






Appendix F continued:  
1, 3, 10 Year Relative Survival Rates for Site-specific Cancer, disaggregated by sex 
 
Lymphoma’s and Multiple Myeloma (ICD9 codes 200-203) 
 Males Females 
Age 1-yr 3-yr 5-yr 10-yr 1-yr 3-yr 5-yr 10-yr 
0-4 79.1 70.2 68.3 66.1 75.1 62.9 55.9 55.9 
5-14 87.8 78.9 76.3 71.3 89.5 81.3 79.0 75.7 
15-29 90.0 81.8 78.2 73.6 95.2 89.9 87.3 83.4 
30-44 83.3 72.1 67.2 59.1 90.7 81.4 76.2 67.8 
45-59 80.3 65.1 56.1 42.4 85.0 71.0 62.4 49.8 
60-69 73.0 54.3 43.8 30.1 78.0 59.7 50.2 37.3 
70-79 62.3 43.9 33.7 23.5 67.2 48.1 38.2 27.8 
80+ 49.6 34.4 26.6 23.1 52.1 35.8 27.9 22.4 
 
Leukemia’s (ICD9 codes 204-208) 
 Males Females 
Age 1-yr 3-yr 5-yr 10-yr 1-yr 3-yr 5-yr 10-yr 
0-4 84.2 64.1 56.1 51.4 80.1 63.3 59.4 56.5 
5-14 80.6 60.8 52.5 47.2 83.1 62.5 55.8 51.0 
15-29 69.0 45.1 36.2 32.1 73.3 48.6 43.5 36.8 
30-44 70.7 51.3 43.8 33.3 69.5 51.5 45.0 35.7 
45-59 73.4 58.1 50.2 35.3 68.1 52.0 45.8 35.9 
60-69 64.7 49.9 41.5 29.0 66.7 52.7 46.0 33.0 
70-79 53.4 40.0 33.1 23.5 56.7 43.1 35.4 25.7 












































Males       
0-4 4.52 n/a n/a 2.1 2.54 4.37 
5-14 8.78 n/a n/a 2.95 4.73 4.43 
15-29 4.16 n/a 3.60 2.04 5.50 3.62 
30-44 4.59 2.09 5.50 1.76 5.96 4.89 
45-59 5.09 2.03 5.49 1.94 7.86 7.34 
60-69 5.19 1.87 5.93 1.93 6.61 5.94 
70-79 4.55 1.74 6.62 1.59 5.02 3.73 
80+ 4.74 1.79 2.75 1.13 2.55 1.77 
Females       
0-4 3.73 n/a 5.69 n/a 3.08 3.24 
5-14 4.04 n/a n/a 4.74 4.15 4.08 
15-29 4.07 n/a 3.03 2.48 6.72 3.58 
30-44 5.44 2.81 5.02 2.15 7.81 4.48 
45-59 5.25 2.14 7.75 2.33 8.07 4.64 
60-69 5.61 2.14 6.57 2.32 6.55 5.93 
70-79 5.30 1.81 6.47 1.82 5.24 4.24 
80+ 2.45 1.29 3.18 1.11 3.04 1.71 


























Average Duration of Remission Stage for Survivors for Site-specific Cancer (disaggregated 












0-4 4.818 4.831 0-4 4.835 4.837 
5-14 4.818 4.831 5-14 4.835 4.837 
15-29 4.818 4.831 15-29 4.835 4.837 
30-44 4.818 4.831 30-44 4.835 4.837 
45-59 4.817 4.826 45-59 4.834 4.838 
60-69 4.816 4.824 60-69 4.834 4.838 
70-79 4.824 4.830 70-79 4.840 4.836 
140-149 
Oral Cavity & 
Pharynx 




80+ 4.840 4.836 
0-4 4.806 4.804 0-4 4.800 4.796 
5-14 4.806 4.804 5-14 4.800 4.796 
15-29 4.806 4.804 15-29 4.800 4.796 
30-44 4.806 4.804 30-44 4.800 4.796 
45-59 4.807 4.808 45-59 4.801 4.799 
60-69 4.808 4.809 60-69 4.803 4.801 
70-79 4.810 4.812 70-79 4.799 4.799 
150 
Esophagus 





80+ 4.799 4.799 
0-4 4.826 4.820 0-4 4.492 4.492 
5-14 4.826 4.820 5-14 4.492 4.492 
15-29 4.826 4.820 15-29 4.492 4.492 
30-44 4.826 4.820 30-44 4.492 4.492 
45-59 4.827 4.821 45-59 4.492 4.492 
60-69 4.828 4.821 60-69 4.492 4.492 
70-79 4.834 4.826 70-79 4.492 4.492 
160-161 
Middle Ear, 
Nasal, & Larynx 
80+ 4.834 4.826 
204-208 
Leukemia’s 
80+ 4.492 4.492 

















Average Duration Remission Stage of Site-specific Cancer for Non-survivors 













0-4 3.834 3.060 0-4 1.435 4.810 
5-14 8.094 3.366 5-14 2.284 4.180 
15-29 3.482 3.397 15-29 1.379 1.837 
30-44 3.904 4.770 30-44 1.092 1.500 
45-59 4.406 4.580 45-59 1.270 1.667 
60-69 4.509 4.934 60-69 1.265 1.655 
70-79 3.869 4.633 70-79 0.934 1.156 
140-149 
Oral Cavity & 
Pharynx 




80+ 0.469 0.446 
0-4 n/a n/a 0-4 1.835 2.371 
5-14 n/a n/a 5-14 4.035 3.446 
15-29 n/a n/a 15-29 4.810 6.012 
30-44 1.398 2.110 30-44 5.295 7.107 
45-59 1.341 1.450 45-59 7.156 7.369 
60-69 1.181 1.450 60-69 5.917 5.834 
70-79 1.049 1.122 70-79 4.316 4.534 
150 
Esophagus 





80+ 1.848 2.334 
0-4 n/a 5.010 0-4 3.361 2.229 
5-14 n/a 5.010 5-14 3.425 3.068 
15-29 2.930 2.346 15-29 2.616 2.568 
30-44 4.827 4.336 30-44 3.885 3.474 
45-59 4.822 7.068 45-59 6.326 3.636 
60-69 5.262 5.893 60-69 4.934 4.919 
70-79 5.955 5.797 70-79 2.720 3.229 
160-161 
Middle Ear, 
Nasal, & Larynx 
80+ 2.085 2.510 
204-208 
Leukemia’s 
80+ 0.762 0.706 
1 Median survival time Non-survivors = LNS - DTR - DM - DT; where LNS = average survival time for non-
















Estimates of DALY’s / 100,000 with Alternative Value Choices by Age-Distribution 
 
Oral Cavity & Pharynx Cancers (DALY’s per 100,000) 
 K=0, r=0 K=1, r=0 K=0, r=0.03 K=1, r=0.03 
S.W.O     
0-4 0 0 0 0 
5-14 0 0 0 0 
15-29 0.83 1.26 0.77 1.18 
30-44 38.80 36.11 21.76 22.61 
45-59 119.49 100.02 84.59 75.11 
60-69 396.50 252.05 302.25 206.28 
70-79 162.63 90.72 137.68 77.72 
80+ 161.14 69.96 144.04 62.76 
Toronto     
0-4 0 0 0 0 
5-14 0.16 0.20 0.15 0.19 
15-29 5.77 6.24 3.09 3.77 
30-44 19.03 18.01 11.10 11.89 
45-59 101.09 80.16 69.83 58.77 
60-69 241.37 152.01 186.06 122.53 
70-79 207.16 110.71 174.09 94.08 
80+ 215.21 91.67 193.02 82.46 
 
 
Esophagus Cancers (DALY’s per 100,000) 
 K=0, r=0 K=1, r=0 K=0, r=0.03 K=1, r=0.03 
S.W.O     
0-4 0 0 0 0 
5-14 0 0 0 0 
15-29 0 0 0 0 
30-44 0 0 0 0 
45-59 70.26 55.90 45.64 38.96 
60-69 330.93 211.95 251.38 174.27 
70-79 394.38 207.57 328.82 175.01 
80+ 268.38 116.10 238.73 103.65 
Toronto     
0-4 0 0 0 0 
5-14 0 0 0 0 
15-29 0 0 0 0 
30-44 21.82 19.83 12.27 12.34 
45-59 96.77 72.16 63.90 50.41 
60-69 241.03 151.97 181.44 125.47 
70-79 256.56 136.97 214.93 115.96 











Appendix I continued: 
Estimates of DALY’s / 100,000 with Alternative Value Choices by Age-Distribution 
 
 
Middle Ear, Nasal, & Larynx Cancers (DALY’s per 100,000) 
 K=0, r=0 K=1, r=0 K=0, r=0.03 K=1, r=0.03 
S.W.O     
0-4 0 0 0 0 
5-14 0 0 0 0 
15-29 0.48 0.73 0.45 0.68 
30-44 2.37 3.18 2.21 2.97 
45-59 76.93 59.21 53.35 42.84 
60-69 228.86 149.53 177.17 136.05 
70-79 108.95 60.14 93.27 51.90 
80+ 12.74 5.67 12.02 5.36 
Toronto     
0-4 0 0 0 0 
5-14 0.07 0.09 0.07 0.08 
15-29 0 0 0 0 
30-44 10.19 9.34 6.04 6.06 
45-59 41.52 32.44 28.93 23.63 
60-69 81.53 53.91 64.32 52.41 
70-79 74.94 41.03 64.31 35.50 
80+ 52.51 22.42 47.16 20.19 
 
 
Lung, Bronchus, & Trachea Cancers (DALY’s per 100,000) 
 K=0, r=0 K=1, r=0 K=0, r=0.03 K=1, r=0.03 
S.W.O     
0-4 1.66 1.08 1.55 1.00 
5-14 0 0 0 0 
15-29 1.53 2.33 1.45 2.20 
30-44 167.97 150.82 99.12 97.66 
45-59 1646.94 1243.88 1137.00 902.33 
60-69 4759.18 3031.41 3681.77 2613.48 
70-79 5615.65 3020.53 4732.04 2571.88 
80+ 3316.34 1426.34 2953.23 1275.06 
Toronto     
0-4 0.22 0.14 0.21 0.13 
5-14 0.13 0.16 0.12 0.15 
15-29 6.04 6.19 3.01 3.55 
30-44 96.23 87.83 56.33 56.66 
45-59 1000.02 764.89 685.21 550.77 
60-69 2784.13 1770.67 2159.15 1539.86 
70-79 3337.43 1789.05 2821.21 1527.89 














Appendix I continued: 
Estimates of DALY’s / 100,000 with Alternative Value Choices by Age-Distribution 
 
 
Lymphomas & Multiple Myeloma’s (DALY’s per 100,000) 
 K=0, r=0 K=1, r=0 K=0, r=0.03 K=1, r=0.03 
S.W.O     
0-4 0 0 0 0 
5-14 1.95 2.42 1.82 2.25 
15-29 2.11 3.21 1.97 2.99 
30-44 48.09 48.96 27.65 31.78 
45-59 299.39 226.31 204.13 162.75 
60-69 514.82 331.97 409.03 287.60 
70-79 1115.56 600.70 942.42 512.73 
80+ 608.14 262.52 544.75 235.92 
Toronto     
0-4 0.71 0.43 0.66 0.41 
5-14 35.52 38.07 15.52 18.53 
15-29 15.89 18.19 8.38 11.09 
30-44 74.54 71.48 43.87 46.61 
45-59 276.73 213.48 190.90 155.76 
60-69 676.73 433.84 525.45 367.85 
70-79 891.93 477.37 756.71 409.12 
80+ 934.82 400.44 839.44 360.73 
 
 
Leukemia (DALY’s per 100,000) 
 K=0, r=0 K=1, r=0 K=0, r=0.03 K=1, r=0.03 
S.W.O     
0-4 7.73 4.95 7.24 4.59 
5-14 4.63 5.72 4.34 5.35 
15-29 97.53 103.49 50.50 60.21 
30-44 143.73 132.06 81.01 82.31 
45-59 143.96 108.21 102.88 81.22 
60-69 443.89 280.71 338.96 229.02 
70-79 545.17 290.20 460.29 247.53 
80+ 559.32 236.92 503.35 213.80 
Toronto     
0-4 5.44 3.44 5.10 3.20 
5-14 47.80 54.71 22.05 27.96 
15-29 33.05 35.75 16.46 20.49 
30-44 79.05 74.75 45.10 47.20 
45-59 105.82 81.77 72.09 58.90 
60-69 310.63 197.73 239.22 161.97 
70-79 424.93 244.71 359.52 192.11 
80+ 413.60 174.38 374.27 158.21 
 
 
 
150 
